# Amino Desk > Independent, evidence-graded guide to peptides and GLP-1 medications for US readers: what each compound is, what human evidence exists, its legal status, reported dosing with sources, safety and cost. Each compound carries an evidence grade from A (strongest human evidence) to D (weakest). A grade is not a statement about safety or legality. Dose figures are reported with their source and are not recommendations. Health pages show a clinical-review status. Please cite the page URL when you use this content. ===== # BPC-157 vs TB-500 Source: https://aminodesk.com/compare/bpc-157-vs-tb-500 Publisher: Amino Desk Updated: 2026-11-14 Clinical review: completed 2026-11-14 These are the two "healing" peptides, usually sold together. They are different molecules with different amounts of evidence, and neither has been through a proper human trial for injury recovery. - **More human data:** BPC-157, though it is three tiny studies - **More ways to take it legally:** BPC-157 (injection, oral or topical). TB-500 is injection only. - **More certainty about what is in the vial:** BPC-157 - **Tested together in people:** never ## Side by side | | [BPC-157](https://aminodesk.com/library/bpc-157) | [TB-500](https://aminodesk.com/library/tb-500) | | --- | --- | --- | | **What it is** | A synthetic 15-amino-acid chain based on a protein fragment from stomach fluid | A short synthetic piece of thymosin beta-4, a 43-amino-acid repair protein | | **Human studies of the compound itself** | Three, with fewer than 20 participants in total. No randomized trials. | None completed. One early trial registered in 2026. | | **Where the rest comes from** | Rodent studies, much of it from one laboratory | Cells and animals, plus human trials of the full-length protein, which is a different molecule | | **Evidence grade** | C | D | | **Legal status** | Compoundable on prescription under the October 2026 policy | Same | | **Forms the policy covers** | Injection, oral, topical | Injection only | | **Advisory committee vote** | 8 to 6 in favor | 8 to 6 in favor | | **Established human dose** | None | None | | **Sport** | Prohibited | Prohibited | ## The difference that matters most With BPC-157, the molecule is well defined and the argument is about whether animal results carry over to people. With TB-500 there is an earlier problem: sources do not agree on exactly which fragment the name refers to, and reviewers note that products sold as TB-500 do not always contain the same sequence. The human studies quoted in its marketing used the full-length protein, in eye drops and on leg ulcers, not the fragment injected for a sore tendon. That is why TB-500 sits a grade lower. It is not that it has been shown to work less well. It is that less is known, including what is in the vial. ## Reported dosing **No dose has been established in human trials for either.** - **BPC-157:** the figure most often cited is 250 to 500 micrograms a day under the skin. It is extrapolated from animal work and prescriber habit. - **TB-500:** the pattern repeated online is 2 to 2.5 mg twice a week for four to six weeks. The source we found for it labels it anecdotal. Each compound's own page shows where those figures come from. ## Taking both Pairing them is sold as the Wolverine stack. No trial has tested the combination, and a single vial holding both falls outside the 2026 compounding policy, which allows one active ingredient per product. A clinician can prescribe them separately. The [stacks page](https://aminodesk.com/stacks) covers this in detail. If you are going to try one, trying one at a time is the only way to learn which, if either, does anything for you. ## Sources - [Narrative review of BPC-157 for musculoskeletal healing (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/) - [Lee and Burgess, 2025: BPC-157 intravenous safety pilot (PubMed)](https://pubmed.ncbi.nlm.nih.gov/40131143/) - [Scoping review of thymosin beta-4 and TB-500 in tissue healing (preprint)](https://www.preprints.org/manuscript/202605.1124/v1) - [HHS: 503A peptide enforcement discretion policy](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [GoodRx: forms and routes covered, and committee votes](https://www.goodrx.com/health-topic/peptides/what-peptides-are-fda-approved) Want a different pair? [Compare any compounds side by side](https://aminodesk.com/compare). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Semaglutide vs tirzepatide Source: https://aminodesk.com/compare/semaglutide-vs-tirzepatide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 These are the two approved weight-loss drugs most people are choosing between. They have been tested against each other directly, and tirzepatide produced more weight loss. That is not the whole decision. - **More weight loss on average:** tirzepatide - **Available as a pill:** semaglutide only - **Proven to cut heart attacks and strokes in people with heart disease:** semaglutide - **Lowest starting price:** semaglutide pill, $149 a month ## The head-to-head trial SURMOUNT-5 put the two drugs in the same trial: 751 adults with obesity and without type 2 diabetes, each drug taken up to its maximum tolerated dose for 72 weeks. Results were published in the New England Journal of Medicine in May 2025. | Result at 72 weeks | Tirzepatide | Semaglutide | | --- | --- | --- | | Average weight loss | 20.2% | 13.7% | | Lost at least 10% | 81.6% | 60.5% | | Lost at least 15% | 64.6% | 40.1% | | Lost at least 25% | 31.6% | 16.1% | | Waist reduction | 18.4 cm | 13.0 cm | Three things to know before leaning on those numbers: - **Eli Lilly, which makes tirzepatide, paid for the trial.** The figures match what each drug achieved in its own earlier blinded trials, which is reassuring. - **It was not blinded.** Participants knew which drug they were on. - **Semaglutide topped out at 2.4 mg.** The Wegovy label has since added a 7.2 mg weekly dose, which this trial did not test. Side effects in both groups were mostly in the gut. The tirzepatide group had more injection-site reactions. ## Where they differ beyond the scale | | [Semaglutide](https://aminodesk.com/library/semaglutide) | [Tirzepatide](https://aminodesk.com/library/tirzepatide) | | --- | --- | --- | | **Brands** | Wegovy, Ozempic, Rybelsus | Zepbound, Mounjaro | | **How it works** | Acts on one receptor, GLP-1 | Acts on two, GIP and GLP-1 | | **Forms** | Weekly injection or daily pill | Weekly injection only | | **Heart outcomes** | The SELECT trial showed fewer major cardiovascular events in people with established heart disease | No equivalent result in people without diabetes yet | | **Other approved uses** | Licensed for adolescents | Approved for obstructive sleep apnea | | **Top label dose** | 7.2 mg injection, 25 mg pill | 15 mg | | **Evidence grade** | A | A | ## What each costs without insurance | | Semaglutide (NovoCare) | Tirzepatide (LillyDirect) | | --- | --- | --- | | Starting dose | $149 pill, or $199 pen for the first two fills | $299 | | Maintenance | $299 pill, $349 pen | $449 with on-time refills, up to $699 without | Prices were checked in late October and early November 2026. The details, including the 45-day refill rule on Zepbound, are on the [costs page](https://aminodesk.com/costs). ## How people actually choose - **If you want the most weight loss and can inject:** the head-to-head data favors tirzepatide. - **If you will not inject:** semaglutide is the only one with a pill. - **If you have heart disease:** semaglutide has the outcome trial. Raise this with your prescriber. - **If you have sleep apnea:** tirzepatide carries that approval. - **If cost decides:** the Wegovy pill is the cheapest brand-name route at every stage. - **If insurance covers one and not the other:** that usually settles it. A covered drug at a $25 copay beats a better drug at $449. Both carry the same boxed warning about thyroid C-cell tumors, and with both, weight tends to return when treatment stops. A 13.7% average loss is still a large result; the weaker drug in this comparison is not a weak drug. ## Sources - [Aronne et al., 2025: SURMOUNT-5, tirzepatide compared with semaglutide, New England Journal of Medicine (PubMed)](https://pubmed.ncbi.nlm.nih.gov/40353578/) - [Lincoff et al., 2023: SELECT trial, semaglutide and cardiovascular outcomes, New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2307563) - [Eli Lilly: SURMOUNT-5 detailed results, May 2025](https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy) - [Diabetes on the Net: open-label design, SELECT and other approved uses](https://diabetesonthenet.com/?p=236892) - [American Pharmacists Association: injection-site reactions and limitations](https://www.pharmacist.com/Blogs/CEO-Blog/Article/tirzepatide-outperforms-semaglutide-for-weight-loss) - [GLP Chart: Wegovy cash prices](https://glpchart.com/wegovy-cost/) and [Zepbound cash prices](https://glpchart.com/zepbound-cost/), November 2026 Want a different pair? [Compare any compounds side by side](https://aminodesk.com/compare). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # What it costs Source: https://aminodesk.com/costs Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending What a GLP-1 actually costs depends almost entirely on which door you walk through. The same molecule ranges from under $100 to over $1,300 a month. Here is the map, with the date each price was checked. **Prices move constantly.** Every figure below was checked in late October or November 2026 and several have changed more than once this year. Confirm on the seller's own site before you sign up for anything. ## The four legitimate routes 1. **Insurance.** If your plan covers it, this is almost always cheapest. Copay cards can bring brand drugs to $0 to $25 a month for commercially insured patients. 2. **Manufacturer direct.** Eli Lilly sells Zepbound through LillyDirect; Novo Nordisk sells Wegovy through NovoCare. Cash prices, no insurance involved. 3. **Telehealth platforms.** A membership fee plus medication, which may be brand or compounded. 4. **In-person care.** A primary care or obesity medicine visit, then a normal pharmacy fill. ## Brand-name, direct from the manufacturer This is the benchmark to compare everything else against. | Product | Cash price per month | Conditions | | --- | --- | --- | | **Zepbound** (tirzepatide) 2.5 mg LillyDirect | $299 | Vial or KwikPen. Starting dose. | | **Zepbound** 5 mg | $399 | Vial or KwikPen. | | **Zepbound** 7.5 mg | $449, or $499 | $449 requires a refill within 45 days of your last delivery. | | **Zepbound** 10 to 15 mg | $449, or $699 | Same 45-day rule. Miss the window and the price jumps by $250. | | **Mounjaro** (tirzepatide) LillyDirect | $499 | Single-dose pen, same price at every dose. | | **Wegovy pill** 1.5 mg NovoCare | $149 | Starter dose. | | **Wegovy pill** 4 mg | $199 | An earlier $149 price on this dose ended 31 August 2026. | | **Wegovy pill** 9 mg and 25 mg | $299 | Maintenance doses. | | **Wegovy injection** 0.25 to 2.4 mg | $349, or $199 | $199 for the first two fills at the two starter doses, for new patients through 31 December 2026. | | **Wegovy HD pen** 7.2 mg | $399 | Highest-dose pen. | LillyDirect prices checked 27 to 30 October 2026. NovoCare prices checked 30 October to 2 November 2026. **The 45-day trap.** Lilly's best Zepbound price on higher doses depends on refilling within 45 days of your last delivery. A delayed shipment, a dose change or a vacation can cost you $250 in a month. Put the refill date in your calendar. ## What retail costs without any program Zepbound's list price runs to roughly $1,086 per fill, and Wegovy's published list price is $1,349.02 per package, the same at every dose. Almost nobody needs to pay these. If a pharmacy quotes you four figures, you are on the wrong route, not out of options. ## Compounded versions Compounded semaglutide and tirzepatide are pharmacy-made. They are not Wegovy, Ozempic, Zepbound or Mounjaro, they are not FDA-approved, and the formulation, including the salt form, can differ from the approved drug. In exchange, the price is usually much lower. | Molecule | Typical cash range | Notes | | --- | --- | --- | | Compounded semaglutide | Roughly $59 to $348 a month | The lowest prices usually require an annual prepayment or carry a separate membership fee. Some programs exclude certain states. | | Compounded tirzepatide | Roughly $69 to $349 a month | Same pattern. Ask which pharmacy compounds it and in what form. | Ranges from provider price checks dated 30 October to 13 November 2026. ## The teaser price problem This is the single most common way people misjudge the cost. Many platforms advertise a low first-month price that bears little relation to what you pay from month two onward, and several step the price up as your dose increases. Independent tracking through August 2026 found platforms advertising around $188 for a first month against roughly $448 a month ongoing. Three questions that cut through it: - What will I pay in month six, at a maintenance dose? - Is the membership fee separate from the medication? - Am I being charged monthly, or prepaying a year? ## Everything that is not a GLP-1 Peptides outside the GLP-1 class are priced differently and far less transparently. A compounded prescription peptide from a licensed pharmacy typically runs from the low tens to a few hundred dollars a month depending on the compound and dose. Research-chemical sellers undercut that substantially, and what arrives has no verified identity, purity or sterility. Price comparison across those two categories is not meaningful, because you are not buying the same thing. ## Sources - [LillyDirect: Zepbound self-pay pricing](https://www.lilly.com/lillydirect/zepbound) - [GLP Chart: Zepbound and Mounjaro cash prices, checked November 2026](https://glpchart.com/zepbound-cost/) - [GLP Chart: Wegovy cash prices by dose and form, checked November 2026](https://glpchart.com/wegovy-cost/) - [GLP Chart: 2026 telehealth price report, teaser versus ongoing pricing](https://glpchart.com/glp1-price-report-2026/) - [FormBlends: Wegovy list price and retail cash comparison](https://formblends.com/articles/cost-access/how-much-does-wegovy-cost) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # How to mix and inject a peptide safely Source: https://aminodesk.com/guides/mixing-and-injecting Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Some prescriptions arrive as a vial of freeze-dried powder that has to be mixed with sterile liquid and drawn into a syringe. This guide covers the steps that keep that process clean and accurate. **Your pharmacy's instructions come first.** Products differ in which liquid to use, how long a mixed vial keeps and where to inject. Where this page and the label on your prescription disagree, follow the label and ask the pharmacist. This page does not tell you what dose to take. If your medication comes in a prefilled pen, such as Wegovy or Zepbound pens, none of the mixing steps apply. Follow the instructions in the box. ## What you need - The vial, with a pharmacy label showing the drug, the amount in the vial and an expiration or beyond-use date. - The mixing liquid (diluent) named in the instructions for that product. - Alcohol swabs, individually wrapped. - A new sterile syringe and needle for mixing, and a new one for every dose. - A sharps container. Not sure which syringe size to get? See [syringes, needles and supplies](https://aminodesk.com/guides/supplies). ## The mixing liquid Use the diluent your pharmacy or the product label specifies, and nothing else. Never use tap water, bottled water or anything not labeled sterile for injection. - **Bacteriostatic water for injection** is sterile water with benzyl alcohol added as a preservative, usually 0.9%. It is made for vials that will be entered more than once. Its label carries a warning that it must not be used in newborns. - **Sterile water for injection** has no preservative. Some products must be mixed with it and used straight away. The tesamorelin (Egrifta) label, for example, says to use only the supplied sterile water and to inject immediately after mixing. A preservative slows the growth of bacteria. The CDC notes that it has no effect on viruses and does not fully protect a vial from contamination, so clean technique still matters on every entry. ## Mixing the vial 1. **Wash your hands** with soap and water and work on a clean, clear surface. 2. **Check the vial.** Confirm the name, the amount and the date. Do not use it if the seal is missing, the glass is cracked or the date has passed. 3. **Wipe both rubber stoppers** with a fresh alcohol swab and let them dry. Do not touch them afterward. 4. **Draw up the diluent.** Use the volume in your instructions. If you need to work out what a given volume does to the concentration, use the [reconstitution calculator](https://aminodesk.com/calculator). 5. **Add it slowly.** Push the needle through the stopper of the powder vial and let the liquid run down the inside wall of the glass. Manufacturer instructions describe this as the way to avoid foaming. 6. **Swirl or roll gently. Do not shake.** Drug labels for peptide products say this in plain terms. Give the powder time to dissolve. 7. **Look at it.** Use it only if the liquid is clear and free of particles, unless your product's label describes a different normal appearance. Do not use it if it is cloudy, discolored or has specks. 8. **Write on the vial:** the date you mixed it and the strength you made (for example, 2.5 mg per mL). 9. **Put the used syringe and needle in the sharps container.** Do not recap the needle. ## Drawing up a dose 1. Wash your hands. Wipe the stopper with a fresh alcohol swab and let it dry. 2. Use a new sterile syringe and needle. Every time. 3. Pull the plunger back to draw in air equal to your dose volume, push the needle through the stopper and push that air into the vial. 4. Turn the vial upside down with the needle tip in the liquid. Pull the plunger a little past your dose line. 5. If you see air bubbles, tap the syringe gently so they rise, then push the plunger back to your dose line. 6. Check the number against your instructions before you take the needle out. Syringe units measure volume, not dose; see [the calculator](https://aminodesk.com/calculator) for how the two relate. Never leave a needle sitting in the stopper between doses. The CDC warns that this gives germs a direct route into the vial. Do not mix two medications in one syringe unless a pharmacist has told you to. ## Injecting under the skin These steps describe a subcutaneous injection, which goes into the fat layer under the skin. They do not apply to injections into a muscle or a vein. 1. **Choose a site.** Labels for under-the-skin medications commonly list the abdomen and the thigh. The back of the upper arm is usually listed for when another person gives the injection. Use the sites your product's instructions name. 2. **Avoid damaged skin.** Skip any spot that is lumpy, thickened, bruised, tender, scarred or broken. 3. **Rotate.** Move each injection at least 1 cm (about a finger's width) from the last one. Repeated injections into the same spot cause fatty lumps under the skin that make absorption unpredictable. 4. **Clean the skin** with an alcohol swab and let it dry. 5. **Insert the needle.** Follow your prescriber's or pharmacist's instructions on the angle and on whether to pinch the skin. Expert recommendations for insulin favor short needles, 4 mm on pens and 6 mm on syringes, because longer ones are more likely to reach muscle. 6. **Push the plunger all the way down** and keep the needle in place for a few seconds before pulling it out. One manufacturer's vial instructions specify at least 5 seconds. 7. **Do not rub the spot.** If there is a drop of blood, press gently with gauze. 8. **Do not recap, reuse or share** the needle or syringe. Put it straight into the sharps container. ## Storage - **Follow the label on your prescription.** A compounding pharmacy assigns a beyond-use date to what it dispenses, and that date governs. - **How long a mixed vial keeps depends on the product.** Some must be used immediately and the remainder thrown away. For multi-dose vials in general, the CDC's rule is to discard within 28 days of first opening unless the manufacturer gives a different date, and never to use a vial past its expiration date. - **Many injectable peptide medications are kept refrigerated and away from light.** As one example, the Zepbound vial instructions give 36 to 46 degrees F (2 to 8 degrees C), in the original carton. - **Do not freeze a liquid medication** unless its label says you can. The Zepbound instructions, for example, say never to freeze it and not to use it if it has been frozen. - **Bacteriostatic water** is labeled for storage at room temperature, 68 to 77 degrees F (20 to 25 degrees C). ## When to throw a vial away - The liquid is cloudy, discolored or has particles in it. - It has passed its expiration or beyond-use date, or 28 days since first opening where no other date is given. - It was frozen, or left warm for longer than its label allows. - The stopper was touched by anything not sterile, or a used needle went back into it. - You are not sure what is in it or when it was mixed. ## Getting rid of needles The FDA's guidance for home users: - Put every used needle and syringe into a sharps disposal container straight away. FDA-cleared containers are sold at pharmacies and online. - If you do not have one, a heavy-duty plastic household container with a tight, puncture-resistant lid, such as a laundry detergent bottle, can be used. - Never put loose needles in the trash or recycling, and never flush them. - Follow your community's rules for disposing of the full container. Your pharmacist or local health department can tell you where to take it. ## When to get help - **Call 911** for trouble breathing, swelling of the face, lips or throat, or widespread hives after an injection. - **See a clinician promptly** if an injection site becomes increasingly red, hot, swollen or painful, drains pus, or you develop a fever. - **If you think you took the wrong amount,** call Poison Help at 1-800-222-1222, or 911 if symptoms are severe. ## What clean technique cannot fix Everything above reduces the germs and errors that you might add. It does nothing about what was in the vial to begin with. A product bought outside a licensed pharmacy has no verified identity, strength or sterility, and careful mixing does not change that. Contamination at the source has put patients in hospital even with pharmacy-made injections; see our page on [injectable glutathione](https://aminodesk.com/library/glutathione) for a 2026 example. If you are choosing where to get a prescription, start with [how to vet a provider](https://aminodesk.com/providers). ## Sources - [CDC: Preventing unsafe injection practices (multi-dose vials, the 28-day rule, needles left in stoppers)](https://www.cdc.gov/injection-safety/hcp/clinical-safety) - [FDA: Safely using sharps (needles and syringes) at home, at work and on travel](https://www.fda.gov/medical-devices/consumer-products/safely-using-sharps-needles-and-syringes-home-work-and-travel) - [Bacteriostatic Water for Injection, USP: product label (Hospira)](https://labeling.pfizer.com/ShowLabeling.aspx?id=4666) - [Zepbound single-dose vial: Instructions for Use (drawing a dose, injection steps, storage)](https://pi.lilly.com/us/zepbound-vial-us-ifu.pdf) - [Egrifta (tesamorelin) prescribing information, 2025: reconstitution and inspection](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf) - [PDR summary of the tesamorelin instructions: adding diluent down the vial wall to avoid foaming](https://pdr.net/drug-summary/Egrifta-tesamorelin-3656) - [Summary of the FITTER insulin delivery recommendations (Mayo Clinic Proceedings, 2016): needle length, site rotation, needle reuse](https://diatribe.org/diabetes-medications/optimizing-insulin-injection-expert-recommendations-fitter) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Protein and muscle on GLP-1 medications Source: https://aminodesk.com/guides/protein-on-glp-1 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending GLP-1 medications cut appetite, and people on them eat much less. Some of the weight that comes off is muscle. Eating enough protein and doing strength training are the two things medical societies recommend to limit that. - **Protein during active weight loss:** 1.2 to 1.6 grams per kilogram of body weight a day has been proposed, or simply 80 to 120 grams a day - **Strength training:** at least 3 times a week - **Aerobic activity:** at least 150 minutes a week at moderate effort - **Source:** a 2025 joint advisory from four US medical and nutrition societies The figures on this page come from that advisory unless noted. It was written for clinicians. It is general guidance, and your own targets are a question for your prescriber or a dietitian, especially if you have kidney disease. ## How much of the weight lost is muscle Body scans in the main trials measured "lean mass", which is everything that is not fat: muscle, but also water, organs and bone. - **Semaglutide:** in the body-scan group of the STEP 1 trial, about 62% of the weight lost was fat and about 38% was lean mass. - **Tirzepatide:** in the body-scan group of the SURMOUNT-1 trial, 160 people, roughly three quarters of the weight lost was fat and one quarter was lean mass. Lean mass is not the same as muscle. The advisory notes that muscle is about half of lean mass, which puts muscle loss at roughly 20% of the total in the semaglutide trial. Its modeling estimates muscle at 10% to 15% of weight lost in women and 20% to 25% in men when people do no structured strength training. Some lean mass is lost with any large weight loss, whatever the method. The aim is to keep the muscle share as small as possible. ## How much protein - The standard adult allowance is 0.8 grams per kilogram of body weight a day. - During active weight loss, 1.2 to 1.6 grams per kilogram a day has been proposed. - A simpler target the advisory offers is 80 to 120 grams a day. - It advises against staying at or above 2 grams per kilogram a day for long periods. The advisory says it is not settled which body weight to use for the per-kilogram math, and that using current weight can overestimate what a person with obesity needs. That is one reason the flat 80 to 120 gram range is practical. **Worked example:** at 80 kg (176 lb), 1.2 to 1.6 grams per kilogram is 96 to 128 grams a day. ## Getting there with a small appetite - **Eat the protein first.** The advisory suggests starting each meal with the protein-rich food, before you feel full. - **Eat small meals every 3 to 4 hours** instead of a few large ones. Large meals make nausea and vomiting more likely. - **Do not go long stretches without eating.** - **Watch the total.** The advisory warns that intake of essential nutrients may fall short below about 1,200 calories a day for women and 1,800 for men. If you can barely eat at all, tell your prescriber. That is a side effect to report, not a result to push through. ### Roughly how much protein is in common foods | Food | Amount | Protein, approximate | | --- | --- | --- | | Chicken breast, cooked | 3 oz | 26 g | | Canned tuna in water | 3 oz | 20 g | | Plain nonfat Greek yogurt | 6 oz | 17 g | | Low-fat cottage cheese | 1/2 cup | 13 g | | Lentils, cooked | 1/2 cup | 9 g | | Egg | 1 large | 6 g | These are typical values from the USDA food database. Brands vary, so check the label. Protein powders and ready-made shakes list their own amount per serving. ## Strength training The advisory recommends strength training at least 3 times a week, plus at least 150 minutes a week of moderate aerobic activity. Protein alone does not preserve muscle; the muscle has to be used. ## Vitamins, minerals and fluids - Eating much less food means fewer nutrients. The advisory lists iron, calcium, magnesium, zinc and vitamins A, D, E, K, B1, B12 and C as the ones at risk. - It says a multivitamin-mineral supplement may be considered, along with specific supplements such as vitamin D, calcium or B12 where needed. Ask your clinician which apply to you. - Drink enough fluid. Dehydration is a particular concern for the kidneys. - For constipation, the advisory suggests raising fluids and fiber from food gradually. ## When treatment stops The advisory reports that up to two thirds of the lost weight may return within a year of stopping. Whether structured nutrition and exercise programs prevent that has not been tested in controlled trials. Muscle built or kept during treatment is one thing a person carries forward either way. ## Sources - [Mozaffarian and colleagues, 2025: Nutritional priorities to support GLP-1 therapy for obesity, joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society (PubMed)](https://pubmed.ncbi.nlm.nih.gov/40450457/) - [The Obesity Society: summary of the joint advisory](https://obesity.org/nutritional-priorities-to-support-glp-1-therapy-for-obesity) - [Secondary summary of the STEP 1 and SURMOUNT-1 body-scan substudies (the tirzepatide data is from Look and colleagues, Diabetes, Obesity and Metabolism, 2025)](https://mitohealth.com/guide/glp-1-muscle-loss-dexa-scan) - [USDA FoodData Central](https://fdc.nal.usda.gov/) Related: [semaglutide](https://aminodesk.com/library/semaglutide), [tirzepatide](https://aminodesk.com/library/tirzepatide), [semaglutide vs tirzepatide](https://aminodesk.com/compare/semaglutide-vs-tirzepatide). Taking a prescribed GLP-1? Keep a private record of shots, weight and protein with the [GLP-1 log](https://aminodesk.com/glp1-log). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # GLP-3, GLP1-R, reta: what seller code names mean Source: https://aminodesk.com/guides/seller-code-names Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Online sellers of unapproved peptides often list weight-loss drugs under short codes instead of their real names. "GLP-3" is the best known. None of these codes is an official drug name, and none tells you what is in a vial. **There is no GLP-3 hormone and no GLP-3 drug class.** The term is slang for retatrutide, Eli Lilly's experimental drug, which is not approved and cannot legally be sold for human use. ## What the codes usually mean | Name on a listing or in a post | Usually refers to | Where it is documented | | --- | --- | --- | | GLP-3, "reta", "r3ta", "ratatouille" | Retatrutide | Public Citizen report, June 2026 | | GLP1-R, GLP-1-R | Retatrutide | FDA warning letters, March 31, 2026 | | Triple G | Retatrutide | Eli Lilly lawsuit, August 2026 | | GLP1-T | Tirzepatide | FDA warning letter, March 31, 2026 | | GLP-2 | Tirzepatide | FDA warning letter, March 31, 2026 | | GLP1-S | Semaglutide | FDA warning letter, March 31, 2026 | The codes are not standardized. The two FDA letters above show two sellers using different codes for the same drug in the same month, and sellers change them when a name gets blocked. Treat the table as a guide to what people mean, not as proof of what a product contains. ## Where the numbers come from The numbering counts hormone receptors. Semaglutide acts on one (GLP-1). Tirzepatide acts on two (GLP-1 and GIP). Retatrutide acts on three (GLP-1, GIP and glucagon). Sellers turned that into "GLP-1", "GLP-2" and "GLP-3". It is misleading. GLP-2 is a real and entirely different gut hormone that tirzepatide does not act on. And there is no hormone called GLP-3. ## Why sellers and influencers use codes - **To get past filters.** Public Citizen's 2026 investigation found that slang such as "GLP-3" and "r3ta" helps posts evade social media filters that block the drug's real name. - **To avoid naming a drug they cannot legally sell.** Retatrutide is still in clinical trials. The FDA has said it cannot be used in compounding, and Lilly says it has flagged more than 14,000 websites, ads and listings offering it. ## "Research use only" does not make it legal Listings that use these codes usually carry a line such as "for laboratory research only, not for human consumption". The FDA has rejected that defense in writing. In a March 2026 warning letter, it said the disclaimer was contradicted by the seller's own website, which described weight loss, blood sugar and appetite effects in people. It also treated the bacteriostatic water the seller offered in a kit with a syringe as an unapproved drug. Enforcement has not cleared the market. Public Citizen counted 14 FDA warning letters to retatrutide sellers since December 2024 and found that, as of May 2026, 11 of those sellers were still advertising retatrutide or other unapproved peptides. ## What is known about the products - **Contents vary.** Public Citizen cites a testing company that analyzed 2,759 samples sold as retatrutide. It rated 71 of 179 vendors as poor, bad or fraud. Many samples were impure, and others were stronger or weaker than labeled. - **People have been hospitalized.** The same report found 26 adverse event reports for retatrutide in the FDA's database from January to May 2026, 11 of them involving hospitalization and three described as life-threatening. - **Injection raises the stakes.** The FDA's letters note that an injected product bypasses the body's natural defenses against toxins and microorganisms. - **The drug itself is unfinished.** Even the genuine molecule has no approved dose and an incomplete safety record. See our [retatrutide page](https://aminodesk.com/library/retatrutide) for the trial data. In Lilly's words, what is sold on the black market "is not a medicine". ## If you see one of these codes - A code name on a product is a sign it is being sold outside the legal system. No licensed pharmacy dispenses "GLP-3". - Semaglutide and tirzepatide are available legally by prescription. See [semaglutide](https://aminodesk.com/library/semaglutide), [tirzepatide](https://aminodesk.com/library/tirzepatide) and [what they cost](https://aminodesk.com/costs). - To check a telehealth company before paying, use [how to vet a provider](https://aminodesk.com/providers). - If you have already used a product like this and feel unwell, seek medical care and tell the clinician exactly what you took. ## Sources - [FDA warning letter to Prime Sciences, March 31, 2026 (GLP1-R, GLP1-S, GLP1-T; research-use-only labeling)](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026) - [FDA warning letter to Gram Peptides, March 31, 2026, as archived by a third party ("GLP-1-R peptide", "GLP-2 peptide")](https://www.globalkeysolutions.net/records/warning_letter/gram-peptides/b2b56fcd-c361-476d-9ef2-3b5b5d5267b2) - [Public Citizen, June 16, 2026: The "miracle drug" and the peptide craze breaking the FDA](https://www.citizen.org/article/the-miracle-drug-and-the-peptide-craze-breaking-the-fda/) - [Healio, August 14, 2026: Eli Lilly files lawsuits against six companies for allegedly selling retatrutide](https://www.healio.com/news/endocrinology/20260814/eli-lilly-files-lawsuits-against-six-companies-for-allegedly-selling-retatrutide) - [Frier Levitt: analysis of Lilly's retatrutide lawsuits ("Triple G", 14,000 listings, FDA compounding statement)](https://www.frierlevitt.com/articles/lilly-retatrutide-lawsuits-ruo-peptide-sellers/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Syringes, needles and supplies: a plain guide Source: https://aminodesk.com/guides/supplies Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending If your prescription arrives as a vial, you need a few inexpensive supplies to measure and inject it safely. This page explains what each one is and how to pick the right size. **Ask your pharmacy first.** Many pharmacies include syringes and alcohol swabs with an injectable prescription, or will tell you exactly which ones to buy. Their instructions come before anything here. ## Insulin syringes Most under-the-skin injections drawn from a vial use a U-100 insulin syringe. On a U-100 syringe, 100 units equal 1 mL, so each unit is 0.01 mL. They come in three sizes. | Size | Holds | Typical markings | | --- | --- | --- | | 0.3 mL | 30 units | Every unit, and some versions every half unit | | 0.5 mL | 50 units | Every unit | | 1 mL | 100 units | Usually every 2 units | - **Use the smallest syringe that holds your dose.** The lines on a smaller syringe are farther apart and easier to read. - **A 1 mL syringe cannot show odd numbers of units precisely,** because most are marked in steps of two. If your dose is 7 units, a 0.3 mL or 0.5 mL syringe measures it more accurately. - **Check that the box says U-100.** Other syringes are marked differently, and the numbers will not match. To turn a prescribed dose into syringe units, use the [reconstitution calculator](https://aminodesk.com/calculator). ## Needle gauge and length - **Gauge is the thickness, and the scale runs backward.** A higher number is a thinner needle, so a 31-gauge needle is thinner than a 29-gauge one. - **Length:** insulin syringe needles commonly come in 6 mm, 8 mm and 12.7 mm. Expert recommendations for insulin favor the shortest, 6 mm on syringes, because longer needles are more likely to reach muscle. - **One use only.** A needle dulls after a single use, and reuse is linked to pain, bleeding and lumps under the skin. ## Adding the mixing liquid An insulin syringe holds at most 1 mL. If your instructions call for more diluent than that, it takes more than one draw or a larger sterile syringe. Use what your pharmacy supplies or recommends, and a new sterile one each time. The mixing liquid itself, usually bacteriostatic water, is a prescription product that should come from the pharmacy with your medication. We do not link to sellers of it. ## Alcohol prep pads - Buy pads that are sterile and individually wrapped. - Use a fresh one for each vial stopper and for your skin, and let the alcohol dry before the needle goes in. ## A sharps container - The FDA recommends putting every used needle and syringe straight into a sharps disposal container. FDA-cleared containers are sold at pharmacies and online. - If you do not have one, the FDA says a heavy-duty plastic household container, such as a laundry detergent bottle, can be used. - Never put loose needles in the trash or recycling. ## Buying syringes Rules on buying syringes without a prescription vary by state. A pharmacist can tell you what applies where you live, and a pharmacy counter is often the simplest place to buy them. ## Where to find them Affiliate links These links go to Amazon. We have not tested the products. Read each listing before you order: several are sold as lab or general-purpose supplies, not as medical devices, and we say so where that applies. For anything that touches a medication, your pharmacist's recommendation comes first. **Insulin syringes** - UltiCare U-100 insulin syringes, 1 mL, 31G x 8 mm, box of 100 - BD Ultra-Fine insulin syringes, 1 mL, 31G x 8 mm, box of 90 - 1 mL syringes, 31G x 8 mm, box of 100. Listed on Amazon as a lab sample syringe, not as an insulin syringe. - 0.5 mL insulin syringes (search results) - 0.3 mL insulin syringes with half-unit markings (search results) **For adding the mixing liquid** - BH Supplies 3 mL Luer Lock syringes, sterile, individually wrapped, box of 100. These come without a needle. - 3 mL syringes with a 25G x 5/8 inch needle attached, pack of 50. Listed on Amazon for lab and industrial use. - 30G x 1/2 inch Luer Lock needles, pack of 100. Listed on Amazon as a lab supply. **Reusable pens and pen supplies** Some people move a mixed medication into a cartridge and dose it with a reusable pen. We do not publish a method for filling cartridges, because we have not found one from a source we can cite. Ask your pharmacist before using a pen with a medication that was not dispensed in one. - Gansulin reusable all-metal pen, 1 to 60 unit dial, takes 3 mL cartridges - Reusable injection pen with adjustable dose dial, takes 3 mL cartridges - 3 mL pen cartridges, pack of 40. Check that they fit your pen. - Pen needles, 33G x 4 mm, two boxes of 100 - iHome pen needles, 32G x 4 mm, box of 100 - 3 mL cartridge holder with purge tower - Magnetic two-pen travel case. It does not keep anything cold. **Cleaning and disposal** - Care Touch alcohol prep pads, 70% isopropyl, sterile, individually wrapped, 400 count - Sharps containers (search results) **Organizing vials** Store every medication the way its label says. Do not freeze one unless the label tells you to. - Hydrapeak 32 oz insulated stainless steel food jar - Silicone insert set that holds 3 mL vials inside a Hydrapeak jar As an Amazon Associate, Amino Desk earns from qualifying purchases. It does not change what you pay. ## What we do not link to We do not link to peptides, to bacteriostatic water, or to "reconstitution kits" sold alongside research-use-only vials. The FDA has treated those kits as unapproved drugs in warning letters to sellers. See [what seller code names mean](https://aminodesk.com/guides/seller-code-names). ## Keep reading - [How to mix and inject a peptide safely](https://aminodesk.com/guides/mixing-and-injecting) - [Reconstitution calculator](https://aminodesk.com/calculator) - [How to vet a provider](https://aminodesk.com/providers) ## Sources - [HealthLink BC: insulin syringes (sizes, and using the smallest that fits the dose)](https://www.healthlinkbc.ca/healthwise/insulin-syringes) - [Healthline: insulin syringe sizes and markings](https://www.healthline.com/health/diabetes/insulin-syringes-sizes) - [Summary of the FITTER insulin delivery recommendations (Mayo Clinic Proceedings, 2016): needle length and reuse](https://diatribe.org/diabetes-medications/optimizing-insulin-injection-expert-recommendations-fitter) - [FDA: Safely using sharps (needles and syringes) at home, at work and on travel](https://www.fda.gov/medical-devices/consumer-products/safely-using-sharps-needles-and-syringes-home-work-and-travel) - [FDA warning letter to Prime Sciences, March 31, 2026 (reconstitution kit treated as a drug)](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # 5-amino-1MQ Source: https://aminodesk.com/library/5-amino-1mq Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 5-amino-1MQ is not a peptide. It is a small molecule that blocks an enzyme involved in NAD+ metabolism. The mouse data is genuinely interesting and there are no human trials at all. - **Legal lane:** not FDA-approved. Sold as a research chemical. - **Evidence grade:** D (no human data) - **Form:** oral capsule, and sold as an injection - **Sport:** prohibited, in the category for substances no regulator has approved ## What it is NNMT, nicotinamide N-methyltransferase, consumes nicotinamide (a form of vitamin B3) and a methyl donor called SAM. 5-amino-1MQ blocks it. The theory is that blocking NNMT leaves more nicotinamide available to make NAD+, and more SAM for everything else that needs methyl groups. Because it acts on an enzyme rather than a receptor, it is dosed in milligrams rather than the micrograms typical of peptides. ## What the evidence shows - The foundational 2018 study by Neelakantan and colleagues characterized it as a selective NNMT inhibitor and showed fat loss in diet-induced obese mice. - In those mice, body weight and fat mass fell without a change in how much they ate, and glucose tolerance improved. - Muscle findings appeared only in aged or injured animals, not healthy ones. - ClinicalTrials.gov lists no registered trial of 5-amino-1MQ, or of any NNMT inhibitor, in humans. Nothing has been published. Worth contrasting: NMN and NR, the other NAD+-pathway compounds people take, have completed early-phase human trials with published pharmacokinetics. This one has not. ## Legal status Not FDA-approved for anything. It is not a peptide, so some of the 2026 peptide compounding changes do not apply to it. Sources disagree about whether pharmacies are dispensing it; some clinic sites advertise it as compounded while the independent reviews say it is not available by prescription. Verify directly rather than trusting either. ## Reported dosing **No dose has been established in human trials.** The figures in circulation are 50 to 150 mg a day orally, commonly from 50 mg capsules. For the injectable version the reported range spans roughly 150 micrograms to 100 mg a day, a 40-fold spread, which tells you how little agreement exists. None of it comes from a study in people. ## Safety - No human safety data exists. Reproductive and developmental toxicology has not been done. - NNMT's byproduct, 1-methylnicotinamide, has biological activity of its own, so suppressing its production is not necessarily neutral. - Stacking it with NMN or NR changes the balance between NAD+ and methyl groups in ways nobody has characterized in humans. ## Common questions ### Is 5-amino-1MQ a peptide? No. It is a small molecule that blocks NNMT, an enzyme involved in NAD+ metabolism. ### Has 5-amino-1MQ been tested in humans? No. ClinicalTrials.gov lists no registered human trial of it, and nothing has been published. ### What is the usual 5-amino-1MQ dose? No dose has been established in human trials. The figures in circulation vary widely, and none comes from a study in people. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Neelakantan et al. 2018: NNMT inhibitors reverse high fat diet-induced obesity in mice (Biochem Pharmacol)](https://pubmed.ncbi.nlm.nih.gov/29155147/) - [Superpower: 5-amino-1MQ mechanism and evidence](https://superpower.com/guides/5-amino-1mq) - [FormBlends: the human clinical trial question](https://formblends.com/articles/peptide-hub/directory-5-amino-1mq-human-clinical-trial) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Adamax Source: https://aminodesk.com/library/adamax Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Adamax is a derivative of [Semax](https://aminodesk.com/library/semax) with two additions: a cap on one end and a cage-shaped carbon group called adamantane on the other. It is sold as the most potent Semax variant. It is also the least studied. - **Legal lane:** not FDA-approved. Sold as a research chemical. - **Evidence grade:** D for this modified version - **Form:** nasal spray as sold - **Established human dose:** none ## What it is The adamantane group makes the peptide more fat-soluble, which is meant to help it cross into the brain and last longer. The same trick is used in [P21](https://aminodesk.com/library/p21). ## What the evidence shows No human trial of Adamax has been published. The reference sources we read agree that the evidence is animal and cell work at best, and that almost every claim about Adamax is extrapolated from Semax data. A longer-lasting, more brain-penetrating version of a peptide is a different drug. It needs its own evidence. ## Legal status - Not FDA-approved for any use. - The October 2026 compounding policy names Semax. We have found nothing that extends it to a chemically modified version. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established for this modified version. Dosing on seller pages is borrowed from the parent peptide or invented. ## Safety - A modification made to change how long a peptide lasts and how much reaches the brain also changes its risks. Those have not been measured. - No human safety data exists for the modified version. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### What is Adamax? A Semax derivative with an acetyl cap and an adamantane group, sold as a nootropic. ### Has Adamax been tested in humans? No published human trial exists. ### Is Adamax better than Semax? That is the marketing claim. It has not been tested. ## Sources - [Pep IQ: Adamax, no published human trials](https://complete-peptide-reference.netlify.app/adamax-peptide-entry) - [WhatPeptide: Adamax, human clinical data absent](https://whatpeptide.pages.dev/peptides/adamax) - [Protein Parade: Adamax, evidence graded limited](https://protein-parade.lovable.app/peptide/adamax) - [Superpower: Semax and Selank, quality of the human evidence](https://superpower.com/guides/semax) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Adipotide Source: https://aminodesk.com/library/adipotide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 Adipotide produced dramatic fat loss in monkeys and damaged their kidneys at the same doses. That is the whole story, and it is why development stopped. This page covers status and risk only. - **Legal lane:** not approved anywhere. No compounding route. Sold as a research chemical. - **Evidence grade:** D - **Human trials:** no published results - **Key finding:** dose-dependent kidney toxicity in primates ## What it is Adipotide is a two-part engineered peptide. One part homes in on prohibitin, a protein concentrated on the blood vessels that feed white fat. The other part kills whatever cell it is delivered into. The design starves fat tissue of its blood supply, and the fat cells die behind it. ## What the evidence shows - In obese rhesus monkeys, 28 days of treatment produced roughly 11% body weight loss, with reductions in waist circumference and abdominal fat. - The same study documented dose-dependent kidney toxicity: raised creatinine and BUN, protein in the urine, and changes visible on kidney tissue under a microscope. - Kidney function recovered at least partly after treatment stopped in those animals. Whether that holds in people, and over what timeframe, is unknown. - No dose has been identified that separates the fat loss from the kidney damage. That is the unsolved problem, not a detail. The reason for the kidney effect is built into the mechanism: prohibitin is also present on kidney blood vessels, so the targeting is not as selective as the design intends. ## Human status A Phase 1 oncology trial was announced in 2012. No results were ever published, and there is no active development program, no IND and no registered trial. Adipotide has never been shown to be safe in a human being. ## Dosing **We do not publish a protocol for this compound.** There is no human dose, and the animal doses that produced fat loss are the same ones that damaged kidneys. The mechanism also destroys tissue permanently, so an adverse outcome cannot be undone by stopping. ## Common questions ### Is adipotide safe? It has never been shown to be safe in a human being. In rhesus monkeys, the doses that produced fat loss also caused dose-dependent kidney toxicity. ### Has adipotide been tested in humans? A Phase 1 oncology trial was announced in 2012. No results were ever published, and there is no active development program. ### Is there a dose for adipotide? No. We do not publish a protocol for this compound. No dose has been identified that separates the fat loss from the kidney damage. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Kolonin et al. 2004: reversal of obesity by targeted ablation of adipose tissue (Nat Med)](https://pubmed.ncbi.nlm.nih.gov/15133506/) - [Kim et al. 2010: proapoptotic peptide targeting adipose endothelium reduces food intake and body weight](https://pubmed.ncbi.nlm.nih.gov/20103704/) - [Superpower: adipotide mechanism, primate data and toxicity signal](https://superpower.com/guides/peptides/adipotide) - [Peptide Protocol Wiki: adipotide risks and regulatory status](https://www.peptideprotocolwiki.com/peptides/adipotide/risks) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # AHK-Cu (copper tripeptide) Source: https://aminodesk.com/library/ahk-cu Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending AHK-Cu is a copper-carrying peptide sold in hair serums and as research vials. It differs from the better-known [GHK-Cu](https://aminodesk.com/library/ghk-cu) by one amino acid. Its hair-growth claim rests on a single laboratory study from 2007. - **Legal lane:** legal as a cosmetic ingredient. Not a drug and not FDA-approved to treat anything. - **Evidence grade:** D - **Form:** scalp or skin serum - **What it is:** alanine, histidine and lysine with a copper ion ## What it is A three-amino-acid peptide bound to copper. On ingredient labels it may appear as Copper Tripeptide-3. GHK-Cu, its cousin, is Copper Tripeptide-1 and has a much larger body of research. ## What the evidence shows In the 2007 study, AHK-Cu lengthened human hair follicles kept alive outside the body and increased the growth of the follicle cells that drive hair production. That is the whole of the direct evidence. It has not been repeated, and no trial has tested it on people's scalps. Articles often count GHK-Cu studies as AHK-Cu evidence. They are different molecules. ## Legal status - Sold legally as a cosmetic ingredient. - Not approved as a drug for hair loss or anything else. - Injecting it is not an approved use and has not been studied. ## Reported dosing There is no medical dose and no established concentration. It is a cosmetic ingredient. Follow the product label. ## Safety - No specific safety problems are reported for cosmetic use, but it has barely been studied. - Hair loss has treatable causes and approved treatments. One assessment points out that minoxidil is the approved topical option. - Vials sold for injection are research chemicals with no verified contents. ## Common questions ### Does AHK-Cu regrow hair? It stimulated hair follicles in one 2007 laboratory study. No human trial has tested it. ### Is AHK-Cu the same as GHK-Cu? No. They differ by one amino acid, and GHK-Cu has far more research behind it. ### Is AHK-Cu FDA-approved? No. It is a cosmetic ingredient. ## Sources - [Pyo et al., 2007: tripeptide-copper complex and human hair growth in vitro](https://agris.fao.org/search/en/records/65de423b63b8185d9ca7d5b9) - [Outliyr: AHK-Cu evidence assessment](https://outliyr.com/reports/ahk-cu) - [Superpower: peptides for hair loss, evidence by compound](https://superpower.com/guides/peptides-for-hair-loss) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # AOD-9604 Source: https://aminodesk.com/library/aod-9604 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 AOD-9604 is unusual in this library: it was tested properly in humans for weight loss, and it did not work. The trial record is the most useful thing about it. - **Legal lane:** not FDA-approved. Compounding status has moved repeatedly; check before assuming availability. - **Evidence grade:** B for evidence quality, with a negative result - **Form:** oral in the trials; sold as an injection - **Also called:** hGH fragment 176-191 ## What it is AOD-9604 is a modified fragment of the tail end of the human growth hormone molecule, developed by Metabolic Pharmaceuticals in Melbourne. It was designed to trigger the fat-burning part of growth hormone's activity without the rest of it. Notably, it does not bind the growth hormone receptor and does not raise IGF-1, which the trials confirmed. ## What the evidence shows This is the part that matters, and the part marketing tends to skip. - An earlier, shorter trial reported about 2.6 to 2.8 kg of weight loss on the 1 mg dose against roughly 0.8 kg on placebo. That result is the one quoted on sales pages. - The pivotal trial was a 24-week, placebo-controlled study in 536 participants, adequately powered to detect weight loss. It did not meet its primary endpoint. There was no significant weight loss against placebo. - Metabolic Pharmaceuticals ceased development in 2007. The Australian regulator rejected an obesity indication. - Across the human trials, tolerability was indistinguishable from placebo, with no serious adverse events attributed to the compound. So: good safety record, well-run trial, negative result. The rodent mechanism did not translate, which researchers attribute to differences between mouse and human fat tissue. ## About the GRAS designation AOD-9604 received GRAS status ("generally recognized as safe") from the FDA for use as an ingredient in certain oral products at specified levels. This is a food-ingredient pathway. It is not a drug approval, it says nothing about whether the compound works, and it does not cover injection. It is the single most misused fact in AOD-9604 marketing. ## Legal status AOD-9604 has never held an FDA-approved indication. Its compounding status has changed several times as nominations were filed and withdrawn and the advisory committee reviewed it. Because this keeps moving, check the FDA's current bulk substances list rather than trusting a vendor's claim about availability. ## Reported dosing The human trials used **oral** doses of 1 mg, 5 mg, 10 mg and 30 mg daily. The 1 mg dose was the one that performed best in the earlier study. Note that the product sold today is an injection, which these trials did not test. ## Common questions ### Does AOD-9604 work for weight loss? The pivotal trial, a 24-week placebo-controlled study in 536 participants, did not meet its primary endpoint. There was no significant weight loss against placebo. ### Is AOD-9604 FDA-approved? No. Its GRAS status is a food-ingredient pathway for certain oral products. It is not a drug approval and does not cover injection. ### Is AOD-9604 safe? Across the human trials, tolerability was indistinguishable from placebo. Those trials used oral doses. The injection sold today was not what they tested. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Ng et al. 2000: metabolic studies of AOD9604 in obese rats (Horm Res)](https://pubmed.ncbi.nlm.nih.gov/11146367/) - [Heffernan et al. 2001: fat oxidation and weight loss in obese mice with hGH or AOD9604](https://pubmed.ncbi.nlm.nih.gov/11673763/) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [Superpower: AOD-9604 trial history and regulatory status](https://superpower.com/guides/peptides/aod-9604) - [FormBlends: Phase 2b results and safety record](https://www.formblends.com/peptides/aod-9604) - [FormBlends: what the AOD-9604 studies show, including GRAS](https://formblends.com/articles/peptide-hub/aod-9604-benefits-research) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # ARA-290 (cibinetide) Source: https://aminodesk.com/library/ara-290 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending ARA-290, also called cibinetide, is a short peptide modeled on part of erythropoietin, the hormone that drives red blood cell production. It was tested for nerve pain in people with sarcoidosis. The small trials were encouraging, but it never reached Phase 3 and its development is inactive. - **Legal lane:** not FDA-approved. Not one of the six peptides in the October 2026 policy. - **Evidence grade:** B. Small randomized trials in people; no large confirming trial. - **Form:** daily injection under the skin in the trials - **Established human dose:** none approved ## What it is An 11-amino-acid peptide copied from one surface of erythropoietin. It was designed to switch on a tissue-repair receptor without raising red blood cell counts, which is the effect that makes erythropoietin itself risky to use for repair. ## What the evidence shows - **Pilot trial:** a randomized, double-blind study in 22 people with sarcoidosis and small fiber neuropathy reported improved nerve symptoms. - **Dose-ranging trial:** a Phase 2 trial planned for up to 64 people compared three doses with placebo over 28 days. Reports from the program describe more small nerve fibers in the cornea and skin after treatment. - **Other uses:** Phase 2 work was also done in type 2 diabetes. These are small, short trials. No Phase 3 trial was started, and the company that developed it has shut down. One drug database lists its clinical status as inactive. ## Legal status - Not FDA-approved. It received an orphan drug designation for nerve damage in sarcoidosis, which is an incentive for development, not an approval. - It was never submitted for approval. - It is not one of the six peptides in the October 2026 compounding policy. What is sold online is a research chemical. ## Reported dosing **No approved dose exists.** The dose-ranging trial gave 1 mg, 4 mg or 8 mg under the skin once a day for 28 days. Those are trial doses in a monitored study, not a recommendation. ## Safety - The trials reported no safety concerns, but they were small and lasted about a month. - Long-term safety is unknown. - Nerve symptoms have many causes, some of them treatable. They need a diagnosis before any experiment. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### Is ARA-290 FDA-approved? No. It was never submitted for approval, and its development is inactive. ### What was ARA-290 tested for? Mainly nerve pain from small fiber neuropathy in people with sarcoidosis, and also type 2 diabetes. ### Does ARA-290 raise red blood cells like EPO? It was designed not to. It is a fragment of erythropoietin built to act on a repair receptor only. ## Sources - [Trial record NCT02039687: Phase 2 dose-ranging study of ARA 290 in sarcoidosis](https://ctv.veeva.com/study/study-of-efficacy-of-ara-290-on-corneal-nerve-fiber-density-and-neuropathic-symptoms-of-subjects-wit) - [EU Clinical Trials Register: the same trial, sponsor Araim Pharmaceuticals](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003016-45/NL) - [Superpower: regulatory status and research stage](https://superpower.com/guides/peptides/ara-290) - [Ozmosi drug profile: clinical status inactive](https://pryzm.ozmosi.com/product/14203) - [Summary of the 22-person pilot study and the follow-up study](https://www.peptideprotocolwiki.com/peptides/ara-290/research) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # BPC-157 Source: https://aminodesk.com/library/bpc-157 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 BPC-157 is the best-known "healing" peptide. It can now be compounded on prescription under an interim federal policy, but it is not FDA-approved and has almost no human trial data. - **Legal lane:** compounded on prescription under the October 2026 interim policy. Not FDA-approved. - **Evidence grade:** C - **Forms covered by the policy:** BPC-157 acetate as an injection under the skin or into muscle, oral, or topical - **Established human dose:** none ## What it is BPC-157 is a synthetic chain of 15 amino acids, based on a fragment of a protein found in stomach fluid. The name stands for "body protection compound". It is promoted for tendon, muscle and gut healing. ## What the evidence shows Almost all of the research is in rodents, much of it from one laboratory at the University of Zagreb. Those studies report faster healing of tendons, ligaments and gut tissue. In people, the published record is three small studies with fewer than 20 participants in total: - A look back at 12 patients given injections into the knee for pain. - A small pilot study in interstitial cystitis, a bladder condition. - A 2025 safety pilot in which two healthy adults received 10 mg and then 20 mg by intravenous infusion, with no side effects reported. There are no published randomized controlled trials for any use. A Phase 1 trial of an oral form was registered, but no results were published. When FDA scientists reviewed BPC-157 in July 2026, they recommended against allowing it to be compounded; the advisory committee voted 8 to 6 in favor. ## Legal status - **September 2023:** the FDA restricted compounding of BPC-157, citing possible immune reactions, impurities and a lack of safety data. - **April 2026:** it was removed from the restricted category. - **October 30, 2026:** HHS published an interim policy under which state-licensed pharmacies may compound it on an individual prescription. The policy is not approval and can be revised. Vials sold online as "research use only" are not covered by it. BPC-157 is also prohibited in sport under World Anti-Doping Agency rules. ## Reported dosing **No dose has been established in human trials.** Nobody has run the studies that would show how much works, how often, or for how long. The figure most often cited by clinics and online is 250 to 500 micrograms a day by injection under the skin. That range is extrapolated from animal studies and from prescriber habit. It did not come from a human dose-finding study. The only doses given in a published human safety study were far higher, 10 mg and 20 mg, as single intravenous infusions in a monitored research setting. That study had two participants and was not designed to show a benefit. If a clinician prescribes BPC-157, the dose on the prescription is the one to follow. Ask them what it is based on. ## Safety - The small human studies did not report serious side effects, but they are far too small to establish safety. - Long-term effects in people are unknown. - Quality is a separate risk. Products bought outside a pharmacy have no verified contents or sterility. ## What it costs Telehealth listings we have seen put a prescribed, compounded supply at roughly $80 to $150 a month. Prices are moving as more providers enter after the October policy. ## Common questions ### Is BPC-157 legal? State-licensed pharmacies may compound it on an individual prescription under an interim HHS policy published October 30, 2026. It is not FDA-approved, and vials sold online as research use only are not covered by the policy. ### Does BPC-157 work in humans? Nobody knows yet. Almost all of the research is in rodents. The published human record is three small studies with fewer than 20 participants in total, and there are no randomized controlled trials. ### What is the usual BPC-157 dose? No dose has been established in human trials. The figure most often cited, 250 to 500 micrograms a day by injection under the skin, is extrapolated from animal studies and prescriber habit. ### Is BPC-157 banned in sport? Yes. It is prohibited under World Anti-Doping Agency rules. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA briefing document: BPC-157-related bulk drug substances (July 2026)](https://www.fda.gov/media/193343/download) - [FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (agenda and briefing documents)](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [HHS: 503A peptide enforcement discretion policy (PDF)](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [Lee and Burgess, 2025: intravenous safety pilot (PubMed)](https://pubmed.ncbi.nlm.nih.gov/40131143/) - [Narrative review of BPC-157 for musculoskeletal healing (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/) - [Phase 1 trial registration, NCT02637284](https://clinicaltrials.gov/study/NCT02637284) - [GoodRx: FDA developments on peptides](https://www.goodrx.com/health-topic/peptides/what-peptides-are-fda-approved) - [Regulatory timeline and committee vote](https://nationwidecompounding.com/bpc-157-compounding-pharmacy-fda-vote/) - [BSCG: 2023 safety concerns and anti-doping status](https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026) - [Telehealth price listings](https://telehealthally.com/best/best-peptide-telehealth-providers) This compound is often sold inside a blend, such as Wolverine or KLOW. A vial holding more than one peptide falls outside the 2026 compounding policy; see [blends and stacks](https://aminodesk.com/stacks). See how the two repair peptides differ: [BPC-157 vs TB-500](https://aminodesk.com/compare/bpc-157-vs-tb-500). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # BPC-157 + KPV blend Source: https://aminodesk.com/library/bpc-157-kpv Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending This blend puts BPC-157 and KPV in one vial. It is sold for gut and tissue repair with an anti-inflammatory angle. No trial has tested the combination in people, and a mixed vial falls outside the 2026 compounding policy even though each ingredient alone is covered. - **Legal lane:** outside the October 2026 policy, which allows one active ingredient per product. Not FDA-approved. - **Evidence grade:** D for the combination - **What is in it:** BPC-157 and KPV - **Established human dose:** none ## What it is A premixed vial sold by peptide suppliers and some clinics. The ingredients: - **[BPC-157](https://aminodesk.com/library/bpc-157):** one of the six peptides in the October 2026 policy; almost all of its evidence is from animals. - **[KPV](https://aminodesk.com/library/kpv):** one of the six peptides in the October 2026 policy; graded D on its own page. ## What the evidence shows There is no trial of this blend. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown. The case for mixing them is that they act by different routes, so the effects should add up. That is a hypothesis. Nobody has measured whether the mixture does better than its parts, or whether it is as safe. ## Legal status In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it. Both ingredients here are on the list. A clinician can prescribe them as two separate vials within the policy. The premixed vial is outside it. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it. - The ratio is fixed by the seller. You cannot adjust one ingredient without moving the others. - No safety or absorption work exists on the mixture. - A product made outside the pharmacy system has no verified contents or sterility. ## Common questions ### What is in this blend? BPC-157 and KPV, mixed in one vial. ### Has this blend been tested in people? No. There is no human trial of the combination. ### Is this blend legal? Not as a mixed vial. Each ingredient can be compounded alone on prescription under the October 2026 policy. ## Sources - [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/) The repair blends are compared on [blends and stacks](https://aminodesk.com/stacks). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Cagrilintide (and CagriSema) Source: https://aminodesk.com/library/cagrilintide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Cagrilintide is an experimental weekly injection from Novo Nordisk that mimics amylin, a hormone released with insulin that helps signal fullness. Combined with semaglutide it is called CagriSema, which is under FDA review. Neither is approved. - **Legal lane:** investigational. Not approved; cannot be used in compounding. - **Evidence grade:** B - **Form:** weekly injection under the skin - **US status:** CagriSema application filed December 2025; decision expected late 2026 ## What it is Cagrilintide is a long-acting version of amylin. It works on different receptors from GLP-1 drugs, so the idea behind CagriSema is to add two appetite signals together. The first drugs of each kind, pramlintide and exenatide, were both approved in 2005. ## What the evidence shows - **REDEFINE 1** (New England Journal of Medicine, 2025): 3,417 adults with obesity or overweight and no diabetes, treated for 68 weeks. CagriSema produced an average weight loss of 20.4% counting everyone assigned to it, and 22.7% among people who stayed on treatment. The trial also had cagrilintide-alone and semaglutide-alone arms. - **REDEFINE 2** (same journal, 2025): 1,206 adults with type 2 diabetes. Weight loss was smaller, about 13.7%, as is usual in people with diabetes. The grade is B rather than A because the strong evidence is for the combination. Vials sold online are cagrilintide alone, which has much less data, and nothing is known about their content. ## Dosing used in the trials There is no approved dose. In REDEFINE 1 the target was 2.4 mg of cagrilintide plus 2.4 mg of semaglutide once a week, reached by gradual increases; about 75% of participants reached the full dose. Investigators could keep people on a lower dose if needed. ## Legal status Novo Nordisk filed for FDA approval of CagriSema in December 2025 and has said it expects a decision in the fourth quarter of 2026. The FDA states that cagrilintide cannot be used in compounding under federal law, so "compounded CagriSema" and research vials are unapproved and unverified. ## Common questions ### Is cagrilintide FDA-approved? No. Novo Nordisk filed for approval of CagriSema, the combination with semaglutide, in December 2025 and has said it expects a decision in the fourth quarter of 2026. ### How much weight did people lose on CagriSema? In REDEFINE 1, average weight loss over 68 weeks was 20.4% counting everyone assigned to it, and 22.7% among people who stayed on treatment. That evidence is for the combination, not cagrilintide alone. ### Can cagrilintide be compounded? No. The FDA states that cagrilintide cannot be used in compounding under federal law. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Garvey et al. 2025: REDEFINE 1, New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081) - [Davies et al. 2025: REDEFINE 2, New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2502082) - [FDA: Concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) - [Novo Nordisk: FDA application for CagriSema, December 2025](https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # CagriSema (cagrilintide + semaglutide) Source: https://aminodesk.com/library/cagrisema Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending CagriSema is Novo Nordisk's once-weekly injection that combines semaglutide with cagrilintide, an amylin drug. Its main trial showed about 20% weight loss. It is under FDA review and was not approved when we last checked, in November 2026. - **Legal lane:** investigational. Under FDA review; not approved. - **Evidence grade:** B. Large Phase 3 trials, not yet approved. - **Form:** weekly injection under the skin - **What is in it:** cagrilintide 2.4 mg and semaglutide 2.4 mg at the trial target dose ## What it is A fixed combination of two drugs made by the manufacturer: [semaglutide](https://aminodesk.com/library/semaglutide), the GLP-1 in Wegovy, and [cagrilintide](https://aminodesk.com/library/cagrilintide), which acts on the amylin receptor. Unlike the seller blends elsewhere in this library, this combination has been tested as a single product in large trials. ## What the evidence shows In REDEFINE 1, the main trial, average weight loss was 20.4%, or 22.7% counting only people who stayed on treatment. The trial included groups on cagrilintide alone and semaglutide alone, and the combination beat both. Two results temper that. The 20.4% figure was below what analysts had expected, and a head-to-head trial against tirzepatide, reported in February 2026, was described in coverage as a loss for CagriSema. ## Legal status - Novo Nordisk submitted its application to the FDA on December 18, 2025, based on REDEFINE 1 and REDEFINE 2. - The company said it expected a decision in the last quarter of 2026. As of early November 2026, no decision had been announced. - The company has said a US launch is planned for early 2027 if it is approved. - Until then it cannot be prescribed. The FDA has said cagrilintide cannot be compounded. This status changes on a single announcement. Check the date on this page. ## Reported dosing **No approved dose exists yet.** The Phase 3 trials worked up to a target of 2.4 mg of each drug once a week. If the FDA approves it, the label will set the schedule. ## Safety - Stomach side effects, the same kind seen with semaglutide, were the most common in trials. - Semaglutide carries a boxed warning about thyroid C-cell tumors seen in rodents. Whether and how that appears on a CagriSema label is for the FDA to decide. - Anything sold now as CagriSema or as cagrilintide has no regulated source. ## Common questions ### Is CagriSema FDA-approved? Not when we last checked, in early November 2026. It was under review, with a decision expected by the end of 2026. ### How much weight did people lose on CagriSema? 20.4% on average in the REDEFINE 1 trial, or 22.7% among people who stayed on treatment. ### What is in CagriSema? Cagrilintide and semaglutide, combined in one weekly injection. ### Can CagriSema be compounded? No. The FDA has said cagrilintide cannot be compounded. ## Sources - [Remy Research: CagriSema approval status, updated November 6, 2026](https://remyresearch.com/research/is-cagrisema-approved) - [PepGLP1: status as of November 3, 2026, and filing date](https://pepglp1.com/cagrisema-fda-approval/) - [Healthline: CagriSema results and FDA timeline](https://www.healthline.com/health/drugs/cagrisema-for-weight-loss) - [GLP Finders: REDEFINE results and the head-to-head trial against tirzepatide](https://glpfinders.com/medications/cagrisema) - [VialHelp: what the application is based on](https://vialhelp.com/2026/08/14/cagrisema-fda-review-decision-late-2026/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Cartalax Source: https://aminodesk.com/library/cartalax Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Cartalax is one of the Russian short peptides sold as bioregulators. It is marketed for cartilage and joint support. The evidence comes almost entirely from the group that developed it, and no independent trial has tested it in people. - **Legal lane:** not FDA-approved. Not eligible for pharmacy compounding. Sold as a research chemical. - **Evidence grade:** D - **What it is:** the tripeptide Ala-Glu-Asp - **Established human dose:** none ## What it is Cartalax is a peptide of three amino acids. It belongs to a family of peptides, two to four amino acids long, developed in St. Petersburg by Vladimir Khavinson's group. The idea behind them is that each organ makes its own short regulatory peptides, and that supplying them restores that organ. The group developed each target in two forms, a tissue extract and a short synthetic peptide. The synthetic ones are what research suppliers sell. ## What the evidence shows Cartalax has been tested on human cells taken from the mouth, in a study of cell aging and bone formation presented by the developers' network. That is cell work, not a clinical result. We found no controlled human trial of Cartalax in the sources we reviewed. For the family as a whole, the record is cell experiments, rodent studies, and small, often unblinded human studies run by the original group. Key findings have not been reproduced by independent teams. The most-cited human study, a 266-person cohort followed for six to eight years, tested thymus and pineal extracts, not this peptide, and was not blinded. ## Legal status - Not FDA-approved for any use. - Not eligible for pharmacy compounding, according to the research summary we read. - Not one of the six peptides in the October 2026 policy. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established in a controlled human trial. The course schedules that circulate come from the developers' own tradition and from sellers. ## Safety - No independent human safety data exists. - A peptide this small is often assumed to be harmless. That assumption has not been tested. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### What is Cartalax? A Russian short peptide, one of the Khavinson bioregulators, sold for cartilage and joint support. ### Is Cartalax FDA-approved? No. It is not approved and is not eligible for pharmacy compounding. ### Has Cartalax been tested in people? We found no controlled human trial. The evidence is cell and animal work from the group that developed it. ## Sources - [2019 conference abstract: Cartalax, Vesugen, Vilon and Epitalon on human oral-derived cells](https://khavinson.info/assets/files/pdf/2019-32_33.pdf) - [Overview of the Khavinson short peptides and the tiers of evidence behind them](https://ipsnews.net/business/?p=248484) - [The Peptide Column: bioregulator research summary and legal status](https://the-peptide-column.pages.dev/bioregulators) - [Khavinson and Morozov, 2003: the 266-person elderly cohort (PubMed)](https://pubmed.ncbi.nlm.nih.gov/14523363/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Cerebrolysin Source: https://aminodesk.com/library/cerebrolysin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Cerebrolysin is a mixture of peptides made from pig brain tissue. More than 50 countries have approved it for stroke and dementia. The US has not, and the independent reviews that pooled its trials did not find a convincing benefit. - **Legal lane:** approved in more than 50 countries. Not FDA-approved for any use. - **Evidence grade:** B. Many randomized trials; independent reviews find the benefit unproven. - **Form:** injection into a vein or muscle - **What it is:** a mixture, not a single peptide ## What it is A preparation derived from pig brain, first described in Austria in 1949 and made by an Austrian company. It is used in parts of Europe, Asia and Latin America for stroke, traumatic brain injury and dementia. Nootropic users import it for memory and brain recovery. ## What the evidence shows - **Stroke:** the 2023 Cochrane review pooled 7 randomized trials with 1,773 participants. It found no benefit on death from any cause, and a higher rate of serious adverse events that were not fatal. - **Vascular dementia:** an earlier Cochrane review could not reach a definite conclusion, and its 2019 update found no new trials. - **Pattern:** the positive results come mainly from trials sponsored by the manufacturer, without independent confirmation. This is one of the most thoroughly reviewed products in this library. Its wide use abroad does not reflect strong evidence that the FDA overlooked. ## Legal status - Not FDA-approved for any use. - A prescription medicine in the countries that have approved it. - Buying it abroad or online for personal use is importing an unapproved drug. ## Reported dosing **We do not publish a protocol for this compound.** Countries that approve it have their own labels, which we have not checked directly. It is given by infusion or injection under medical supervision. ## Safety - The Cochrane stroke review found more non-fatal serious adverse events with Cerebrolysin than without it. - It is an animal tissue product given by injection or infusion. - Stroke, head injury and dementia need medical care. An imported product is not a substitute. ## Common questions ### Is Cerebrolysin FDA-approved? No. It is approved in more than 50 other countries. ### Does Cerebrolysin work for stroke? The 2023 Cochrane review of 7 trials and 1,773 patients found no benefit on death and more serious adverse events. ### Is Cerebrolysin a peptide? It is a mixture of peptides and amino acids made from pig brain, not a single defined peptide. ## Sources - [Superpower: Cerebrolysin status and the 2023 Cochrane findings](https://superpower.com/guides/peptides/cerebrolysin) - [Cochrane: Cerebrolysin for vascular dementia](https://www.cochrane.org/evidence/CD008900_cerebrolysin-vascular-dementia) - [Cochrane review, 2019 update: Cerebrolysin for vascular dementia (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6844361) - [Empire Medical Training: how to read its use abroad](https://www.empiremedicaltraining.com/antiaging-regenerative-workshops/resources/peptide-therapy/cerebrolysin/) - [Peptide Journal: history and administration](https://peptidejournal.org/peptides/cerebrolysin-neuropeptide-research-overview) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # CJC-1295 Source: https://aminodesk.com/library/cjc-1295 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 CJC-1295 is a long-acting peptide that keeps growth hormone raised for days after one injection. Its human evidence is a small Phase 1 program from 2006 that measured hormone levels, not results people care about. - **Legal lane:** not FDA-approved. Not eligible for pharmacy compounding. - **Evidence grade:** C - **Form:** injection under the skin - **Sport:** prohibited ## What it is CJC-1295 is a synthetic version of growth-hormone-releasing hormone. Two different products go by the name: - **With DAC:** the original. An added chemical group binds it to a blood protein, giving a half-life of about six to eight days. - **Without DAC** (also called modified GRF 1-29): short-acting. This is the form usually paired with [ipamorelin](https://aminodesk.com/library/ipamorelin), and it is largely unstudied in controlled human trials. The two are not interchangeable, and labels do not always make clear which one is in the vial. ## What the evidence shows In two placebo-controlled trials in healthy adults published in 2006, a single injection of the DAC form raised average growth hormone two to ten times for six days or more, and raised IGF-1 for nine to eleven days. A follow-up study confirmed the body kept releasing growth hormone in pulses. That is the whole of the direct human evidence. No trial has shown a benefit for muscle, fat loss, recovery or aging. Development was halted after a death in a later trial that was never linked to the drug. ## Legal status CJC-1295 is not approved and is not on the list of substances pharmacies may compound. An FDA advisory committee recommended against adding it, and it was not part of the October 2026 policy. The FDA has also noted reports of raised heart rate and flushing reactions. ## Doses used in studies **No approved dose exists.** The 2006 studies gave single injections of the DAC form sized to body weight, for example 60 or 90 micrograms per kilogram in the follow-up study. These were one-off doses to measure hormone response. Online protocols for the no-DAC form do not come from human trials. ## Common questions ### What is the difference between CJC-1295 with DAC and without DAC? The DAC form binds to a blood protein and has a half-life of about six to eight days. The form without DAC, also called modified GRF 1-29, is short-acting and largely unstudied in controlled human trials. They are not interchangeable. ### Is CJC-1295 legal? It is not FDA-approved and is not on the list of substances pharmacies may compound. An FDA advisory committee recommended against adding it, and it was not part of the October 2026 policy. ### What does the human evidence show? Two placebo-controlled trials published in 2006 found that a single injection of the DAC form raised growth hormone for six days or more. No trial has shown a benefit for muscle, fat loss, recovery or aging. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA briefing document: CJC-1295-related bulk drug substances (December 2024)](https://www.fda.gov/media/183819/download) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [Teichman et al., 2006: CJC-1295 Phase 1 trials (PubMed)](https://pubmed.ncbi.nlm.nih.gov/16352683/) - [Superpower: CJC-1295 trial findings and FDA status](https://superpower.com/guides/cjc-1295-ipamorelin-stack) - [Superpower: CJC-1295 study doses and anti-doping status](https://wf.superpower.com/guides/cjc-1295) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # CJC-1295 + ipamorelin blend Source: https://aminodesk.com/library/cjc-1295-ipamorelin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending CJC-1295 with ipamorelin is the most widely sold growth-hormone peptide pairing. Each part raises growth hormone in short studies. No trial has tested them together, and neither can be legally compounded in the US. - **Legal lane:** not FDA-approved. Neither ingredient is eligible for pharmacy compounding. - **Evidence grade:** D for the combination. Each ingredient alone is graded C. - **Form:** injection under the skin, sold premixed or as two vials - **Sport:** both ingredients are prohibited ## What it is Two peptides that push the pituitary to release growth hormone by different routes. [CJC-1295](https://aminodesk.com/library/cjc-1295) is a synthetic version of growth-hormone-releasing hormone. [Ipamorelin](https://aminodesk.com/library/ipamorelin) imitates ghrelin at the receptor that triggers a growth hormone pulse. Sellers pair them on the theory that two signals produce a bigger release than one. "CJC-1295" covers two different products. The form with DAC lasts about six to eight days. The form without DAC is short-acting and largely unstudied. Blends rarely say clearly which one they contain. ## What the evidence shows No human trial has tested the combination. - **CJC-1295:** two placebo-controlled trials published in 2006 found that one injection of the DAC form kept growth hormone raised for six days or more. No trial has shown a benefit for muscle, fat loss, recovery or aging. - **Ipamorelin:** short studies show a brief growth hormone pulse. Its one Phase 2 trial, for bowel recovery after surgery, did not meet its main goal, and development stopped. So the pairing rests on hormone measurements from each part alone. Nobody has measured what people buy it for. ## Legal status - **CJC-1295:** not FDA-approved and not on the list of substances pharmacies may compound. An FDA advisory committee recommended against adding it. - **Ipamorelin:** in October 2024 an FDA advisory committee voted 0 to 12, with one abstention, against adding it to that list. - Neither was part of the October 2026 policy, which also allows only one active ingredient per product. Some clinic websites say ipamorelin was "reinstated" in 2026. We could not confirm that from FDA records. ## Reported dosing **No dose has been established for this combination.** No trial has tested the pair, and clinical development of both ingredients ended before an approved dose was set for either. The figures that circulate for each ingredient, and where they come from, are on the CJC-1295 and ipamorelin pages. ## Safety - Long-term effects of keeping growth hormone raised this way have not been studied for either ingredient, alone or together. - With a premixed vial you cannot tell which ingredient caused a reaction. - Products bought outside a pharmacy have no verified contents or sterility, and the form of CJC-1295 in the vial is often unclear. ## Common questions ### Has CJC-1295 with ipamorelin been tested together? No. No human trial has tested the combination. ### Is the CJC-1295 and ipamorelin blend legal? Neither ingredient is FDA-approved or eligible for pharmacy compounding, and neither was part of the October 2026 policy. ### Why are they sold together? They trigger growth hormone release by different routes, and sellers expect the two signals to add up. That expectation has not been tested in a trial. ## Sources - [Teichman et al., 2006: CJC-1295 Phase 1 trials (PubMed)](https://pubmed.ncbi.nlm.nih.gov/16352683/) - [Beck et al. 2014: randomized trial of ipamorelin for postoperative ileus (PubMed)](https://pubmed.ncbi.nlm.nih.gov/25331030/) - [FDA briefing document: CJC-1295-related bulk drug substances (December 2024)](https://www.fda.gov/media/183819/download) - [FDA briefing document: ipamorelin-related bulk drug substances (October 2024)](https://www.fda.gov/media/182088/download) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # CJC-1295 + ipamorelin + tesamorelin blend Source: https://aminodesk.com/library/cjc-1295-ipamorelin-tesamorelin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending This blend puts CJC-1295, ipamorelin and tesamorelin in one vial. It is sold for growth hormone support, fat loss and recovery. No trial has tested the combination in people, and two of the three ingredients cannot be legally compounded. - **Legal lane:** not FDA-approved as a blend. CJC-1295 and ipamorelin are not eligible for pharmacy compounding. - **Evidence grade:** D for the combination - **What is in it:** CJC-1295, ipamorelin and tesamorelin - **Established human dose:** none ## What it is A premixed vial sold by peptide suppliers and some clinics. The ingredients: - **[CJC-1295](https://aminodesk.com/library/cjc-1295):** not approved and not eligible for compounding; its human evidence is a 2006 hormone study. - **[ipamorelin](https://aminodesk.com/library/ipamorelin):** not approved; an FDA advisory committee voted 0 to 12 against allowing it to be compounded. - **[tesamorelin](https://aminodesk.com/library/tesamorelin):** FDA-approved as Egrifta, only to reduce excess abdominal fat in people with HIV and lipodystrophy. All three push the pituitary to release growth hormone. CJC-1295 and tesamorelin work through the same receptor, so the blend partly doubles up on one signal. ## What the evidence shows There is no trial of this blend. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown. The case for mixing them is that they act by different routes, so the effects should add up. That is a hypothesis. Nobody has measured whether the mixture does better than its parts, or whether it is as safe. ## Legal status - **CJC-1295:** not approved, and not on the list of substances pharmacies may compound. An FDA advisory committee recommended against adding it. - **Ipamorelin:** not approved, and an FDA advisory committee voted 0 to 12, with one abstention, against allowing it to be compounded. - **Tesamorelin:** a prescription drug approved for one use. - No approved product and no compounding route stands behind a vial of all three. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it. - The ratio is fixed by the seller. You cannot adjust one ingredient without moving the others. - No safety or absorption work exists on the mixture. - Three growth hormone releasers together have not been studied. Tesamorelin alone can worsen blood sugar. - A product made outside the pharmacy system has no verified contents or sterility. ## Common questions ### What is in this blend? CJC-1295, ipamorelin and tesamorelin, mixed in one vial. ### Has this blend been tested in people? No. There is no human trial of the combination. ### Is this blend legal? No. Two of the three ingredients are not eligible for pharmacy compounding, and no approved product combines them. ## Sources - [Teichman et al., 2006: CJC-1295 Phase 1 trials (PubMed)](https://pubmed.ncbi.nlm.nih.gov/16352683/) - [FDA briefing document: CJC-1295-related bulk drug substances (December 2024)](https://www.fda.gov/media/183819/download) - [Beck et al. 2014: randomized trial of ipamorelin for postoperative ileus (PubMed)](https://pubmed.ncbi.nlm.nih.gov/25331030/) - [FDA briefing document: ipamorelin-related bulk drug substances (October 2024)](https://www.fda.gov/media/182088/download) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) The repair blends are compared on [blends and stacks](https://aminodesk.com/stacks). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Cortagen Source: https://aminodesk.com/library/cortagen Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Cortagen is one of the Russian short peptides sold as bioregulators. It is marketed for brain and nerve support. The evidence comes almost entirely from the group that developed it, and no independent trial has tested it in people. - **Legal lane:** not FDA-approved. Not eligible for pharmacy compounding. Sold as a research chemical. - **Evidence grade:** D - **What it is:** the tetrapeptide Ala-Glu-Asp-Pro - **Established human dose:** none ## What it is Cortagen is a peptide of four amino acids. It belongs to a family of peptides, two to four amino acids long, developed in St. Petersburg by Vladimir Khavinson's group. The idea behind them is that each organ makes its own short regulatory peptides, and that supplying them restores that organ. The group developed each target in two forms, a tissue extract and a short synthetic peptide. The synthetic ones are what research suppliers sell. ## What the evidence shows In one published experiment, Cortagen switched on an immune gene in mouse spleen cells in a dish, less strongly than two sister peptides. That is a cell finding. We found no controlled human trial of Cortagen in the sources we reviewed. For the family as a whole, the record is cell experiments, rodent studies, and small, often unblinded human studies run by the original group. Key findings have not been reproduced by independent teams. The most-cited human study, a 266-person cohort followed for six to eight years, tested thymus and pineal extracts, not this peptide, and was not blinded. ## Legal status - Not FDA-approved for any use. - Not eligible for pharmacy compounding, according to the research summary we read. - Not one of the six peptides in the October 2026 policy. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established in a controlled human trial. The course schedules that circulate come from the developers' own tradition and from sellers. ## Safety - No independent human safety data exists. - A peptide this small is often assumed to be harmless. That assumption has not been tested. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### What is Cortagen? A Russian short peptide, one of the Khavinson bioregulators, sold for brain and nerve support. ### Is Cortagen FDA-approved? No. It is not approved and is not eligible for pharmacy compounding. ### Has Cortagen been tested in people? We found no controlled human trial. The evidence is cell and animal work from the group that developed it. ## Sources - [2002 cell study of Vilon, Epithalon and Cortagen in mouse spleen cells (PubMed)](https://pubmed.ncbi.nlm.nih.gov/12447482/) - [Overview of the Khavinson short peptides and the tiers of evidence behind them](https://ipsnews.net/business/?p=248484) - [The Peptide Column: bioregulator research summary and legal status](https://the-peptide-column.pages.dev/bioregulators) - [Khavinson and Morozov, 2003: the 266-person elderly cohort (PubMed)](https://pubmed.ncbi.nlm.nih.gov/14523363/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Dihexa Source: https://aminodesk.com/library/dihexa Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 Dihexa is sold as a memory and cognition peptide. It has no human trials, no human safety data, and the paper describing how it was supposed to work has been retracted. This page covers status and risk only. - **Legal lane:** not approved anywhere. Sold as a research chemical. - **Evidence grade:** D - **Human trials:** none, and none registered - **Also called:** PNB-0408 ## What it is Dihexa is a small modified peptide derived from angiotensin IV, developed at Washington State University. It was designed to be taken orally and to reach the brain, where it was proposed to promote the formation of new synapses. ## What the evidence shows - The published work is rodent studies: maze-based memory tasks and laboratory measures of synapse formation. - A key paper describing the mechanism, published by the originating group, has been retracted. A second study has drawn criticism. For a compound with so few papers, that is a significant share of the evidence base. - No human efficacy trial has been completed, and no trial is registered. - The FDA's own compounding review materials note that the agency has not identified human exposure data for dihexa and lacks important safety information about it. ## The specific unknown Dihexa is described as extraordinarily potent at promoting synapse formation. The pathway it is proposed to act on, HGF and its c-Met receptor, is also involved in cell growth and is implicated in some cancer biology. Whether that matters at the amounts people take is unknown, because the basic toxicology has never been done in any species over a long period. ## Dosing **We do not publish a protocol for this compound.** There is no human pharmacokinetic data, no established safe dose, and no long-term safety record in any species. ## Common questions ### Has dihexa been tested in humans? No. No human efficacy trial has been completed and none is registered. The FDA has noted that it has not identified human exposure data for dihexa. ### What is the evidence for dihexa? Rodent studies only. A key paper describing its mechanism has been retracted, and a second study has drawn criticism. ### Is dihexa legal? It is not approved anywhere and is sold as a research chemical. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [McCoy et al. 2013: metabolically stabilized angiotensin IV analogs as procognitive agents (rat study; journal has issued an expression of concern)](https://pubmed.ncbi.nlm.nih.gov/23055539/) - [Retraction notice (2025): Kawas et al. 2012, angiotensin IV analogs as hepatocyte growth factor/Met modifiers](https://pubmed.ncbi.nlm.nih.gov/40312092/) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [Superpower: dihexa evidence, retraction and legal status](https://superpower.com/guides/dihexa) - [Outliyr: dihexa report and FDA exposure-data note](https://outliyr.com/reports/dihexa) - [Peptide Protocol Wiki: dihexa research gaps](https://www.peptideprotocolwiki.com/peptides/dihexa/research) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # DSIP (delta sleep-inducing peptide) Source: https://aminodesk.com/library/dsip Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 DSIP is a nine-amino-acid peptide isolated in 1977 and sold today for sleep. In July 2026 it was the one compound of seven that an FDA advisory committee voted against allowing pharmacies to compound. - **Legal lane:** not FDA-approved. Advisory committee voted against adding it to the compounding list. - **Evidence grade:** C - **Form:** injection under the skin - **Also called:** emideltide ## What it is Delta sleep-inducing peptide was named for its apparent effect on slow-wave, or delta, sleep in early animal work. It is marketed for insomnia and, less often, for opioid withdrawal. ## What the evidence shows The human literature is old, small and inconsistent. Studies from the 1980s and 1990s in insomnia and withdrawal reported mixed results in small groups, and no modern controlled trial has settled the question. The FDA's own review concluded the evidence was not sufficient. ## Legal status At the July 24, 2026 advisory committee meeting, seven peptides were reviewed for the list that licensed pharmacies may compound. Six were recommended for inclusion. DSIP was the exception, voted down 6 to 7 with one abstention. It was not part of the October 2026 policy, so it remains unapproved and without a legal compounding route. ## Reported dosing **No dose has been established in human trials.** We do not publish figures for compounds where no trial, label or prescriber practice supports one. ## Safety - Long-term human safety has not been characterized. - Product sold outside a pharmacy has no verified identity, purity or sterility. - Persistent insomnia has treatments with real evidence behind them, starting with cognitive behavioral therapy for insomnia. A clinician is the better first stop. ## Common questions ### Does DSIP help with sleep? The human literature is old, small and inconsistent, and the FDA's own review concluded the evidence was not sufficient. ### Is DSIP legal? It is not FDA-approved. In July 2026 an FDA advisory committee voted 6 to 7, with one abstention, against allowing pharmacies to compound it, so it has no legal compounding route. ### What is the usual DSIP dose? No dose has been established in human trials, and we do not publish figures where no trial, label or prescriber practice supports one. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (agenda and briefing documents)](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [AmSpa: FDA advisory committee votes, July 2026](https://americanmedspa.org/news/fda-advisory-committee-recommends-adding-six-of-seven-peptides-to-compounding-list/) - [NPR via Michigan Public: FDA panel and the gray market](https://www.michiganpublic.org/2026-07-23/fda-panel-supports-broadening-access-to-peptides-popular-on-the-gray-market) - [Takeroon: what the DSIP research found](https://takeroon.com/blog/dsip-what-the-research-found) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Dulaglutide (Trulicity) Source: https://aminodesk.com/library/dulaglutide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Dulaglutide is the weekly GLP-1 injection sold as Trulicity. It is approved for type 2 diabetes and is not approved for weight loss. People on it do lose some weight, but far less than on the drugs built for that purpose. - **Legal lane:** FDA-approved for type 2 diabetes, prescription only. Not approved for weight loss. - **Evidence grade:** A for its approved use - **Form:** weekly injection under the skin, from a single-dose pen - **Brand:** Trulicity ## What it is Dulaglutide is a GLP-1 medication first approved in the US in 2014. It belongs to the same family as [semaglutide](https://aminodesk.com/library/semaglutide) and [liraglutide](https://aminodesk.com/library/liraglutide). It is prescribed to improve blood sugar in type 2 diabetes, and its label also covers lowering the risk of major heart events in adults with type 2 diabetes who have heart disease or several risk factors. ## What the evidence shows Its trials were diabetes trials. Weight was a secondary measure. In the trial that tested the higher doses, AWARD-11, 1,842 adults with type 2 diabetes took 1.5 mg, 3 mg or 4.5 mg a week. At 36 weeks, average weight change was about 6.6 lb on 1.5 mg, 8.4 lb on 3 mg and 10.1 lb on 4.5 mg, from a starting weight near 210 lb. The manufacturer notes that some patients did not lose weight. That is roughly 3% to 5% of body weight at the top doses, which is why dulaglutide is not marketed or approved as a weight-loss drug. ## Legal status - FDA-approved for type 2 diabetes. - **Not approved for weight loss.** The manufacturer states this on its own materials. - Prescribing it for weight alone would be off-label. ## Label dosing The label starts at 0.75 mg once a week. The dose can be raised to 1.5 mg for more blood sugar control, and then in 1.5 mg steps after at least four weeks on the current dose, to a maximum of 4.5 mg once a week. These steps are set by blood sugar response, not weight. The dose on your prescription is the one to follow. ## Safety - **Boxed warning:** thyroid C-cell tumors seen in rodents. It should not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. - **Stomach side effects:** nausea, diarrhea and vomiting were the most common in AWARD-11, at similar rates across the three doses. - **Severe stomach reactions:** reported more often on Trulicity than placebo in pooled trials. ## Common questions ### Is Trulicity approved for weight loss? No. It is approved for type 2 diabetes. Weight change was a secondary measure in its trials. ### How much weight do people lose on Trulicity? In the AWARD-11 trial, about 6.6 lb to 10.1 lb on average at 36 weeks, depending on dose, and some patients did not lose weight. ### What are the Trulicity doses? The label starts at 0.75 mg once a week and allows increases to 1.5 mg, 3 mg and a maximum of 4.5 mg. ## Sources - [FDA label: Trulicity (dulaglutide), 2020, including dose steps and boxed warning](https://www.accessdata.fda.gov/Drugsatfda_docs/Label/2020/125469s036lbl.Pdf) - [Lilly: Trulicity weight change by dose in AWARD-11, and the statement that it is not indicated for weight loss](https://trulicity.lilly.com/hcp/efficacy-weight/weight-loss-dosing) - [Lilly: Trulicity adult dosage](https://trulicity.lilly.com/hcp/efficacy-weight) - [The Medical Letter: two new doses of dulaglutide, AWARD-11 summary](https://secure.medicalletter.org/w1609f) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Eloralintide Source: https://aminodesk.com/library/eloralintide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Eloralintide is an experimental once-weekly injection from Eli Lilly that acts on the amylin receptor, a different target from the GLP-1 drugs. A mid-stage trial showed weight loss of up to about 20%. It is in Phase 3 trials and cannot be prescribed. - **Legal lane:** investigational. Not FDA-approved and not available by prescription. - **Evidence grade:** B. One strong mid-stage trial; Phase 3 results not yet in. - **Form:** weekly injection under the skin - **Developer:** Eli Lilly ## What it is Amylin is a hormone released with insulin that helps produce the feeling of fullness. Eloralintide is a selective amylin receptor agonist, formerly known as LY3841136. It belongs to the same new class as [cagrilintide](https://aminodesk.com/library/cagrilintide). ## What the evidence shows The Phase 2 trial enrolled 263 adults with obesity, or overweight with a related condition, and without type 2 diabetes. At 48 weeks, average weight loss ranged from 9.5% on the lowest dose to 20.1% on the highest, against 0.4% on placebo. Lilly presented the results in November 2025. In September 2026 Lilly reported that eloralintide combined with tirzepatide produced more weight loss than tirzepatide alone in a 48-week trial in adults with obesity and type 2 diabetes. These are company-reported mid-stage results. Phase 3 trials, which are larger and longer, decide whether the effect and the safety hold up. ## Legal status - Not FDA-approved. Phase 3 trials of eloralintide alone are under way. - Lilly said it would start Phase 3 trials of the combination with tirzepatide in the last quarter of 2026. - The only lawful way to receive it is as a participant in a trial. Anything sold online under this name has no regulated source. ## Reported dosing **No approved dose exists.** The Phase 2 trial tested 1 mg, 3 mg, 6 mg and 9 mg once a week, and two schedules that stepped up to 9 mg. Those are trial doses in a monitored study, not a recommendation. ## Safety - Lilly described the tolerability as favorable in Phase 2. Full safety data will come from Phase 3. - Long-term safety is unknown. - Products sold as eloralintide outside a trial have no verified contents. ## Common questions ### Is eloralintide FDA-approved? No. It is in Phase 3 trials. ### How much weight did people lose on eloralintide? Between 9.5% and 20.1% at 48 weeks in the Phase 2 trial, depending on dose, against 0.4% on placebo. ### How is eloralintide different from a GLP-1? It acts on the amylin receptor, a separate fullness signal. ### Can I get eloralintide now? Only by taking part in a clinical trial. ## Sources - [Lilly: Phase 2 results for eloralintide (November 6, 2025)](https://investor.lilly.com/node/53246) - [Lilly: eloralintide with tirzepatide Phase 2b results and Phase 3 plans (September 30, 2026)](https://investor.lilly.com/node/54991/pdf) - [BioSpace: trial population and analyst reaction](https://www.biospace.com/drug-development/lillys-amylin-agonist-headed-to-phase-iii-after-eliciting-up-to-20-weight-loss) - [Drug Topics: dose groups in the Phase 2 trial](https://www.drugtopics.com/view/eloralintide-reduces-weight-by-9-5-to-20-1-for-patients-with-obesity) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Epitalon Source: https://aminodesk.com/library/epitalon Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 Epitalon is a four-amino-acid peptide promoted for longevity, telomeres and sleep. Its best-known results are in cell cultures. Human evidence is limited to small studies, mostly from the research group that created it. - **Legal lane:** compounded on prescription under the October 2026 interim policy. Not FDA-approved. - **Evidence grade:** C - **Form covered by the policy:** Epitalon acetate as an injection under the skin or into muscle, in intermittent courses - **Established human dose:** none ## What it is Epitalon, also spelled Epithalon, is a synthetic chain of four amino acids. It was developed by the Russian researcher Vladimir Khavinson as a lab-made counterpart to epithalamin, an extract of the pineal gland. The two are chemically distinct. Much of the human "longevity" research people cite, including a long-running study in elderly patients, used epithalamin, not Epitalon. Evidence for one should not be treated as evidence for the other. ## What the evidence shows - **Cells:** Epitalon switched on telomerase and lengthened telomeres in human cell cultures. An independent lab reproduced that in 2025. - **Animals:** some studies report effects on lifespan and melatonin. - **People:** small studies of physiology and biomarkers, and an older report in the eye disease retinitis pigmentosa. Recent reviews found no randomized controlled trials, no studies of how the body processes the drug, and no dose-ranging studies. Nearly all of the research comes from one group, with little independent confirmation. The July 2026 FDA advisory committee reviewed Epitalon for insomnia and recommended it. ## Legal status Epitalon left the FDA's restricted category in April 2026 and is covered by the HHS interim policy published October 30, 2026, which allows state-licensed pharmacies to compound it on an individual prescription. The policy is not approval and can be revised. ## Reported dosing **No dose has been established in human trials.** Reviewers describe the missing dose-ranging and absorption data as a barrier to choosing any dose. The policy describes use in intermittent courses, not continuous daily use. We have not found a commonly quoted figure that traces to a published human dose-finding study, so we are not repeating one. If a clinician prescribes Epitalon, the prescription sets the dose and course length. ## Safety - No dedicated human safety studies have been published. - Because Epitalon acts on telomerase, which cancer cells also use, reviewers flag a theoretical long-term cancer question that has not been answered either way. ## Common questions ### Does Epitalon lengthen telomeres? In human cell cultures it switched on telomerase and lengthened telomeres, and an independent lab reproduced that in 2025. Recent reviews found no randomized controlled trials in people. ### Is Epitalon the same as epithalamin? No. They are chemically distinct. Much of the human longevity research people cite used epithalamin, a pineal gland extract, not Epitalon. ### Is Epitalon legal? State-licensed pharmacies may compound it on an individual prescription under the HHS interim policy published October 30, 2026. The policy is not approval and can be revised. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (agenda and briefing documents)](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [HHS: 503A peptide enforcement discretion policy (PDF)](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [Epitalon and epithalamin: mechanisms, evidence and gaps (review preprint, 2026)](https://www.preprints.org/manuscript/202609.0801/v1) - [Epitalon in regenerative and longevity medicine (review preprint, 2026)](https://www.preprints.org/manuscript/202607.2123/v1) - [GoodRx: FDA developments on peptides](https://www.goodrx.com/health-topic/peptides/what-peptides-are-fda-approved) (policy forms and routes; committee votes) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Epitalon + MOTS-c blend Source: https://aminodesk.com/library/epitalon-mots-c Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending This blend combines Epitalon and MOTS-c in one product. It is sold for longevity and energy. We found no trial of the two together, and a mixed vial falls outside the 2026 compounding policy even though each ingredient alone is covered. - **Legal lane:** outside the October 2026 policy, which allows one active ingredient per product. Not FDA-approved. - **Evidence grade:** D for the combination - **What is in it:** Epitalon and MOTS-c - **Established human dose:** none ## What it is A premixed product sold by peptide suppliers and some clinics. The ingredients: - **[Epitalon](https://aminodesk.com/library/epitalon):** one of the six peptides in the October 2026 policy; the best-known of the Russian bioregulators. - **[MOTS-c](https://aminodesk.com/library/mots-c):** one of the six peptides in the October 2026 policy; a mitochondrial peptide studied mainly in animals. ## What the evidence shows We found no trial of this combination. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown. The case for mixing them is that they act by different routes, so the effects should add up. That is a hypothesis. Nobody has measured whether the mixture does better than its parts, or whether it is as safe. ## Legal status In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it. Both ingredients here are on the list. A clinician can prescribe them as two separate vials within the policy. The premixed vial is outside it. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it. - The ratio is fixed by the seller. You cannot adjust one ingredient without moving the other. - No safety or absorption work exists on the mixture. - A product made outside the pharmacy system has no verified contents or sterility. ## Common questions ### What is in this blend? Epitalon and MOTS-c. ### Has this blend been tested in people? We found no human trial of the combination. ### Is this blend legal? Not as a mixed vial. Each ingredient can be compounded alone on prescription under the October 2026 policy. ## Sources - [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # FGL (FG loop peptide) Source: https://aminodesk.com/library/fgl Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending FGL is a peptide modeled on part of NCAM, a protein that helps nerve cells connect. It improved memory in rats and went through one human safety study as a nasal spray. No trial has shown that it works in people. - **Legal lane:** not FDA-approved. Sold as a research chemical. - **Evidence grade:** C. One human safety study; no efficacy trial. - **Form:** nasal spray in the human study - **Established human dose:** none ## What it is A synthetic peptide that copies a loop of the neural cell adhesion molecule. It activates a growth factor receptor on nerve cells. It was developed in Denmark as a possible treatment for Alzheimer's disease and other brain disorders. ## What the evidence shows - **Animals:** in rats it strengthened the connections between nerve cells and improved spatial memory, an effect that lasted up to two weeks after dosing. - **People:** a Phase 1 study gave single nasal doses to 24 healthy men. It was tolerated, and the peptide could be measured in blood for up to an hour. A European research program later reported it safe and well tolerated in human testing. Those studies measured safety. We found no published trial of whether it improves memory or any disease in people. ## Legal status - Not FDA-approved for any use. - Not one of the six peptides in the October 2026 compounding policy. - What is sold online is a research chemical. ## Reported dosing **No dose has been established.** The Phase 1 study tested single nasal doses of 25, 100 and 200 mg, once, to look at safety. That is not a treatment schedule, and it is very different from the microgram amounts seller sites describe. ## Safety - In the Phase 1 study some volunteers reported a burning sensation in the nose. - Safety with repeated use is not established. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### Has FGL been tested in humans? Yes, for safety only: single nasal doses in 24 healthy men. ### Does FGL improve memory? It did in rats. No human trial has tested that. ### Is FGL FDA-approved? No. ## Sources - [Anand et al., 2007: tolerability, safety and pharmacokinetics of FGL in healthy volunteers](https://www.springermedicine.com/tolerability-safety-and-pharmacokinetics-of-the-fgll-peptide-a-n/23071278) - [European Commission: NeuroFGL project report](https://cordis.europa.eu/project/rcn/102442/reporting/en) - [Alzforum: peptide sparks synaptic plasticity and improves memory in rodents](https://www2.slideshare.net/shiraknafo/alzforum-print-news) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # FOXO4-DRI Source: https://aminodesk.com/library/foxo4-dri Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending FOXO4-DRI is a designed peptide that kills senescent cells, the worn-out cells that build up with age. A 2017 mouse study made it famous. It has never been tested in a person. - **Legal lane:** not FDA-approved. Sold as a research chemical. - **Evidence grade:** D - **Form:** injection in animal studies - **Established human dose:** none ## What it is A peptide built from mirror-image amino acids in reverse order, which makes it resist breakdown. It works by separating two proteins, FOXO4 and p53, that keep senescent cells alive. With that bond broken, those cells die. Drugs that do this are called senolytics. ## What the evidence shows The case rests on one 2017 paper in the journal Cell. In aged mice the peptide restored fur density and kidney function. A few later papers have looked at specific tissues in animals. No human trial has been run or registered. There is no human data on dose, absorption or safety. ## Legal status - Not FDA-approved for any use. - Not one of the six peptides in the October 2026 compounding policy. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No human dose exists. Self-experiment write-ups scale from mouse doses, which is guesswork. ## Safety - It acts on p53, the body's main tumor-suppressor pathway. Interfering with it cuts both ways, and nobody has measured what happens in people. - No formal toxicology has been published. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### Has FOXO4-DRI been tested in humans? No. There are no completed or registered human trials. ### What did FOXO4-DRI do in mice? In a 2017 study it cleared senescent cells and restored fur density and kidney function in aged mice. ### Is FOXO4-DRI legal? It is not FDA-approved and is sold only as a research chemical. ## Sources - [Outliyr: FOXO4-DRI evidence assessment](https://outliyr.com/reports/fox04-dri) - [The Peptide Column: FOXO4-DRI, no human data](https://the-peptide-column.pages.dev/peptides/foxo4-dri) - [Peptide Protocol Wiki: research gaps](https://www.peptideprotocolwiki.com/peptides/foxo4-dri/research) - [Fight Aging!: no human data exists for FOXO4-DRI](https://www.fightaging.org/?p=27202) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # GHK-Cu and the Glow stack Source: https://aminodesk.com/library/ghk-cu Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending GHK-Cu is a copper-binding peptide found in skincare products and, increasingly, sold as an injection. The two forms are not equivalent. Topical use has modest human evidence. Injected use has almost none. - **Legal lane:** topical is a cosmetic ingredient. Injectable is not FDA-approved and awaits FDA review. - **Evidence grade:** C for topical skin use. D for injection. - **Forms:** creams and serums; injection under the skin - **Established injectable dose:** none ## What it is GHK is three amino acids (glycine, histidine, lysine) that bind a copper ion. It occurs naturally in human plasma and was first identified in 1973. On ingredient lists it appears as copper tripeptide-1. ## What the evidence shows - **Topical:** strong cell data and small, short human cosmetic studies suggesting improvements in skin texture and firmness. - **Wound healing:** supportive animal data, but no evidence yet that topical or injected GHK-Cu heals wounds in people. - **Hair:** some animal signals and limited human evidence. - **Injected, for skin, joints or recovery:** no controlled human trials. ## Legal status Topical GHK-Cu is a long-standing cosmetic ingredient. For compounding, the non-injectable form sits in the FDA's Category 1, which gives pharmacies some interim room to make it. The injectable form is different. It was removed from the FDA's restricted category in April 2026 but is not on the list of substances pharmacies may compound, and it was not covered by the October 2026 policy. An FDA advisory committee is due to consider it by the end of February 2027. Some clinics and websites describe injectable GHK-Cu as freely compoundable; the sources we trust most do not support that. ## Reported dosing **No injectable dose has been established in human trials.** Topical products are used as directed on the product. Injection protocols circulate in online communities. We have not found one that traces to a human study, so we are not repeating a figure. ## Safety - Injecting GHK-Cu puts copper directly into the body. Too much copper can build up and damage organs, and nobody knows what injected dose would cause that. - Injected products add risks that creams do not: sterility, impurities, immune reactions and dose accuracy. ## The Glow stack "Glow" is a marketing name for a blend of GHK-Cu with [BPC-157](https://aminodesk.com/library/bpc-157) and [TB-500](https://aminodesk.com/library/tb-500), sold as a single injection for skin and recovery. There are no human studies of the combination. It also sits outside the October 2026 policy on two counts. The policy requires each compounded product to contain a single active ingredient, and it does not cover injectable GHK-Cu at all. Read the pages for each component; a blend carries all of their unknowns at once. ## What it costs Listings we have seen put topical products at $40 to $100 a month and injectable programs at roughly $100 to $350 a month. ## Topical serums on Amazon Affiliate links These links go to Amazon. We have not tested the products. They are cosmetic serums for the skin, the form of GHK-Cu with some human evidence. None is an injection. Use them as the label directs. - The Ordinary Multi-Peptide + Copper Peptides 1% serum, 30 mL - Good Molecules Copper Peptide Serum with PDRN, 30 mL As an Amazon Associate, Amino Desk earns from qualifying purchases. [Affiliate disclosure](https://aminodesk.com/affiliate-disclosure). ## Common questions ### Is injectable GHK-Cu legal? It is not on the list of substances pharmacies may compound and was not covered by the October 2026 policy. An FDA advisory committee is due to consider it by the end of February 2027. Topical GHK-Cu is a long-standing cosmetic ingredient. ### Does GHK-Cu work? For topical skin use, small and short human cosmetic studies suggest improvements in texture and firmness. For injection, there are no controlled human trials. ### What is the Glow stack? A marketing name for a blend of GHK-Cu, BPC-157 and TB-500 sold as a single injection. There are no human studies of the combination, and it sits outside the October 2026 policy. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [HHS: 503A peptide enforcement discretion policy (PDF)](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [GoodRx: what is GHK-Cu](https://www.goodrx.com/health-topic/peptides/what-is-ghk-cu) - [BSCG: GHK-Cu evidence and legal status](https://www.bscg.org/blogs/single/ghk-cu-peptide-benefits-safety-legal-status-and-research) - [National Law Review: single-ingredient condition in the HHS policy](https://natlawreview.com/article/hhs-draws-new-lines-peptide-compounding-what-changes-503a-pharmacies) - [FormBlends: GHK-Cu history and cost](https://www.formblends.com/peptides/ghk-cu) Glow, and the four-peptide KLOW version of it, are covered in more detail on the [blends and stacks](https://aminodesk.com/stacks) page, including why a multi-peptide vial sits outside the 2026 compounding policy. --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # GHK-Cu + BPC-157 blend Source: https://aminodesk.com/library/ghk-cu-bpc-157 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending This blend puts GHK-Cu and BPC-157 in one vial. It is sold for skin and tissue repair. No trial has tested the combination in people, and a mixed vial falls outside the 2026 compounding policy. - **Legal lane:** outside the October 2026 policy. Not FDA-approved. - **Evidence grade:** D for the combination - **What is in it:** GHK-Cu and BPC-157 - **Established human dose:** none ## What it is A premixed vial sold by peptide suppliers and some clinics. The ingredients: - **[GHK-Cu](https://aminodesk.com/library/ghk-cu):** a copper peptide whose human evidence is for products applied to the skin; not one of the six policy peptides. - **[BPC-157](https://aminodesk.com/library/bpc-157):** one of the six peptides in the October 2026 policy; almost all of its evidence is from animals. ## What the evidence shows There is no trial of this blend. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown. The case for mixing them is that they act by different routes, so the effects should add up. That is a hypothesis. Nobody has measured whether the mixture does better than its parts, or whether it is as safe. ## Legal status In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it. This blend is outside the policy on two counts: it holds more than one active ingredient, and GHK-Cu is not one of the six peptides. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it. - The ratio is fixed by the seller. You cannot adjust one ingredient without moving the others. - No safety or absorption work exists on the mixture. - GHK-Cu delivers copper with every dose. Long courses are a reason to pay attention to copper and zinc balance, with a clinician. - A product made outside the pharmacy system has no verified contents or sterility. ## Common questions ### What is in this blend? GHK-Cu and BPC-157, mixed in one vial. ### Has this blend been tested in people? No. There is no human trial of the combination. ### Is this blend legal? Not under the October 2026 policy. It holds two active ingredients, and GHK-Cu is not one of the six peptides the policy covers. ## Sources - [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/) The repair blends are compared on [blends and stacks](https://aminodesk.com/stacks). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # GHK-Cu + KPV blend Source: https://aminodesk.com/library/ghk-cu-kpv Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending This blend puts GHK-Cu and KPV in one vial. It is sold for skin and inflammation. No trial has tested the combination in people, and a mixed vial falls outside the 2026 compounding policy. - **Legal lane:** outside the October 2026 policy. Not FDA-approved. - **Evidence grade:** D for the combination - **What is in it:** GHK-Cu and KPV - **Established human dose:** none ## What it is A premixed vial sold by peptide suppliers and some clinics. The ingredients: - **[GHK-Cu](https://aminodesk.com/library/ghk-cu):** a copper peptide whose human evidence is for products applied to the skin; not one of the six policy peptides. - **[KPV](https://aminodesk.com/library/kpv):** one of the six peptides in the October 2026 policy; graded D on its own page. ## What the evidence shows There is no trial of this blend. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown. The case for mixing them is that they act by different routes, so the effects should add up. That is a hypothesis. Nobody has measured whether the mixture does better than its parts, or whether it is as safe. ## Legal status In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it. This blend is outside the policy on two counts: it holds more than one active ingredient, and GHK-Cu is not one of the six peptides. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it. - The ratio is fixed by the seller. You cannot adjust one ingredient without moving the others. - No safety or absorption work exists on the mixture. - GHK-Cu delivers copper with every dose. Long courses are a reason to pay attention to copper and zinc balance, with a clinician. - A product made outside the pharmacy system has no verified contents or sterility. ## Common questions ### What is in this blend? GHK-Cu and KPV, mixed in one vial. ### Has this blend been tested in people? No. There is no human trial of the combination. ### Is this blend legal? Not under the October 2026 policy. It holds two active ingredients, and GHK-Cu is not one of the six peptides the policy covers. ## Sources - [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/) The repair blends are compared on [blends and stacks](https://aminodesk.com/stacks). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # GHRP-2 and GHRP-6 Source: https://aminodesk.com/library/ghrp-2-ghrp-6 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 GHRP-2 and GHRP-6 are older growth-hormone-releasing peptides. They do raise growth hormone, and they also raise cortisol, prolactin and appetite. Neither is approved in the US. - **Legal lane:** not FDA-approved. Sold as research chemicals; not eligible for compounding. - **Evidence grade:** C - **Form:** injection under the skin - **Sport:** prohibited ## What they are Both are six-amino-acid peptides that imitate ghrelin, the hunger hormone, to trigger a pulse of growth hormone. GHRP-6 came first. GHRP-2, also called pralmorelin, is the stronger of the two for growth hormone and causes less hunger. [Ipamorelin](https://aminodesk.com/library/ipamorelin) is a later, more selective member of the same family. ## What the evidence shows - Human studies show a growth hormone pulse within 15 to 30 minutes of an injection. - The same studies show rises in cortisol and prolactin. One summary puts these at roughly 25% to 35% and 15% to 25%, returning to baseline within a few hours. - In a study of healthy men, GHRP-2 increased food intake. GHRP-6 has the strongest appetite effect of the group. - GHRP-2's only regulatory approval anywhere is in Japan, as a one-time test for growth hormone deficiency. There are no controlled human trials showing either one improves muscle, fat, recovery or aging. ## Legal status Neither is FDA-approved, and neither is among the peptides opened up for compounding in 2026. They are sold online as research chemicals. Marketing them for human use is a red flag. ## Reported dosing **No approved dose exists.** Community sources commonly cite 100 to 200 micrograms, two or three times a day, in cycles of 6 to 12 weeks. That is a description of online practice, not a studied regimen. ## Safety - Repeated cortisol and prolactin rises are the main reason clinicians moved to ipamorelin. - Growth hormone works against insulin, so blood sugar can drift up. - Water retention and hunger are common complaints. ## Common questions ### What is the difference between GHRP-2 and GHRP-6? GHRP-6 came first. GHRP-2, also called pralmorelin, is the stronger of the two for growth hormone and causes less hunger. GHRP-6 has the strongest appetite effect. ### What are the side effects of GHRP-2 and GHRP-6? Both raise cortisol and prolactin as well as growth hormone. Blood sugar can drift up, and water retention and hunger are common complaints. ### Are GHRP-2 and GHRP-6 legal? Neither is FDA-approved, and neither is among the peptides opened up for compounding in 2026. They are sold online as research chemicals. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Laferrere et al. 2005: GHRP-2 increases food intake in healthy men (J Clin Endocrinol Metab)](https://pubmed.ncbi.nlm.nih.gov/15699539/) - [Bowers and Granda-Ayala 2001: GH and IGF-1 response to GHRP-2 in older adults (Endocrine)](https://pubmed.ncbi.nlm.nih.gov/11322505/) - [FDA warning letter: Tailor Made Compounding LLC (April 2020)](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020) - [Superpower: GHRP-2 (pralmorelin)](https://superpower.com/guides/peptides/ghrp-2) - [Superpower: GHRP-6 overview and safety](https://superpower.com/peptides/ghrp-6) - [FormBlends: GHRP-2 hormone effects and studies](https://www.formblends.com/peptides/ghrp-2) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # GLOW blend (GHK-Cu + BPC-157 + TB-500) Source: https://aminodesk.com/library/glow-blend Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending GLOW is a seller's name for three peptides mixed in one vial: GHK-Cu, BPC-157 and TB-500. It is sold for skin, hair and recovery together. No trial has tested the mixture, and a mixed vial falls outside the 2026 compounding policy. - **Legal lane:** outside the October 2026 policy, which allows one active ingredient per product. Not FDA-approved. - **Evidence grade:** D for the combination - **What is in it:** GHK-Cu, BPC-157 and TB-500 - **Established human dose:** none ## What it is A premixed vial that adds the copper peptide [GHK-Cu](https://aminodesk.com/library/ghk-cu) to the two repair peptides in the [Wolverine blend](https://aminodesk.com/library/wolverine-blend), [BPC-157](https://aminodesk.com/library/bpc-157) and [TB-500](https://aminodesk.com/library/tb-500). The name does not describe a tested product. ## What the evidence shows There is no trial of this blend. The evidence that exists applies to each ingredient studied separately. For BPC-157 and TB-500 it is almost entirely animal work with no completed controlled human trials. The human evidence for GHK-Cu is for products applied to the skin, which is a different thing from injecting it; see the GHK-Cu page for both. "Synergy" in blend marketing means the seller expects the combination to work better. It does not mean anyone measured it. ## Legal status In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it. GLOW has two problems under that policy. It holds more than one active ingredient, and GHK-Cu is not one of the six peptides the policy covers. A seller offering it is working outside the policy or is not a licensed compounding pharmacy. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - **You cannot tell what worked.** If you improve, you have learned nothing about which ingredient to keep. - **You cannot tell what went wrong.** A reaction means stopping everything, with no way to find the cause except starting over one at a time. - **The mixture itself is unstudied.** Reviews of compounded multi-peptide preparations note that no safety or absorption work exists on the combinations. - **Quality is a separate risk.** A pharmacy following the policy closely will not make a blend, so the product comes from outside that system. **Copper accumulates.** Anything based on GHK-Cu delivers copper with every dose. Long courses are a reason to pay attention to copper and zinc balance, which is a conversation for a clinician. ## Common questions ### What is in the GLOW blend? GHK-Cu, BPC-157 and TB-500, mixed in one vial. ### Is the GLOW blend legal? Not under the October 2026 policy. That policy allows one active ingredient per compounded product, and GHK-Cu is not among the six peptides it covers. ### Has the GLOW blend been tested in people? No. There is no human trial of the mixture. ## Sources - [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/) - [Buchanan Ingersoll & Rooney: single-active-ingredient formulations under the policy](https://www.bipc.com/compounding-peptides-what-compounding-pharmacies-need-to-know-about-the-hhs-interim-enforcement-discretion-policy-for-six-peptides) - [Healio: advisory committee discussion, including the combination-use concern raised on TB-500](https://www.healio.com/news/primary-care/20260724/fda-committee-recommends-looser-restrictions-for-several-peptides) All three repair blends are compared on [blends and stacks](https://aminodesk.com/stacks). To keep a private record of what you take, use the [dose and progress log](https://aminodesk.com/glp1-log). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Glutathione (injectable) Source: https://aminodesk.com/library/glutathione Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Glutathione is an antioxidant that every cell makes from three amino acids. It is sold as an oral supplement and, at clinics and wellness spas, as an injection or IV drip for skin brightening and "detox". No glutathione product is FDA-approved as a drug, and the FDA has issued repeated alerts about contaminated injectable batches. - **Legal lane:** compounded by pharmacies; not FDA-approved - **Evidence grade:** C - **Forms:** oral supplement; compounded injection and IV - **Current issue:** FDA alert and CDC investigation, 2026 ## What it is Glutathione is a tripeptide made of glutamate, cysteine and glycine, and the body's main internal antioxidant. Because the body makes its own, the question is whether giving more changes anything. ## What the evidence shows Human studies of injected glutathione are small and none has been large enough to support an approval. For skin lightening, the FDA has stated that it has not approved any injectable product, and regulators abroad have said there are no clinical trials establishing a dose or duration. ## Dosing **No dose established** for injected or IV glutathione for skin, energy or detox. ## The contamination problem - In 2019 the FDA reported patients who developed reactions after IV glutathione compounded from powder labeled "Caution: Dietary Supplement". FDA testing found endotoxin levels too high for an injection. - In August 2026 the FDA warned again after at least 30 patients had fever, chills, dizziness and sepsis-like symptoms after IV glutathione, some needing hospital care. The pharmacies involved had used supplement-grade ingredient from one supplier, and some issued recalls. - The CDC is investigating, and advises clinics not to give injectable glutathione unless the pharmacy can confirm the ingredient grade. If you are offered a glutathione injection, ask the clinic which pharmacy made it and whether the ingredient was pharmaceutical grade. ## Common questions ### Are glutathione injections FDA-approved? No. No glutathione product is FDA-approved as a drug. The injections are compounded by pharmacies. ### Are glutathione injections safe? The FDA has issued alerts about contaminated batches. In August 2026 it warned after at least 30 patients had fever, chills, dizziness and sepsis-like symptoms after IV glutathione, and the CDC is investigating. ### What should I ask before a glutathione injection? Ask the clinic which pharmacy made it and whether the ingredient was pharmaceutical grade. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA: reminder not to use dietary-supplement-grade glutathione for injectables (2026)](https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables) - [FDA compounding alert: dietary ingredient glutathione in sterile injectables (2019)](https://www.fda.gov/drugs/human-drug-compounding/fda-highlights-concerns-using-dietary-ingredient-glutathione-compound-sterile-injectables) - [CDC: current investigation and guidance for clinics](https://www.cdc.gov/healthcare-associated-infections/current-situation/index.html) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Gonadorelin Source: https://aminodesk.com/library/gonadorelin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Gonadorelin is a synthetic copy of GnRH, the brain signal that tells the pituitary to switch on the testes or ovaries. Clinics sell it alongside testosterone to protect fertility and testicle size. That specific use has not been tested in a controlled trial, and no FDA-approved gonadorelin product is sold in the US today. - **Legal lane:** no FDA-approved product is currently marketed. Supplied by compounding pharmacies on prescription. - **Evidence grade:** C for the way it is sold. Pump therapy for a rare hormone condition has better evidence. - **Form:** injection under the skin - **Established human dose:** none for use alongside testosterone ## What it is GnRH is released by the brain in pulses. Each pulse makes the pituitary release LH and FSH, which drive testosterone and sperm production in men. Gonadorelin is that hormone made synthetically. It works one step above [HCG](https://aminodesk.com/library/hcg), which acts on the testes directly. ## What the evidence shows - **Pump therapy:** given in timed pulses by a pump, GnRH is an established treatment for men born with a condition in which the brain does not send the signal. A meta-analysis of 420 such men found that pulsed GnRH started sperm production about 5.3 months sooner than gonadotropin injections, with no significant difference in sperm concentration or pregnancy rate. - **Alongside testosterone:** this is how it is mostly sold, as occasional injections and not as a pump. No published randomized trial has compared it with HCG for preserving testicle size or fertility in men on testosterone. The gap matters because the hormone's effect depends on pulses. An injection a few times a week is not what the pump studies tested. ## Legal status - The FDA once approved gonadorelin products for testing pituitary function and for fertility support in women, sold as Factrel and LutrePulse. Both have been discontinued in the US. - It is now supplied by compounding pharmacies on a patient-specific prescription. Compounded drugs are not FDA-approved. - Interest rose when regulatory changes limited the supply of compounded HCG. ## Reported dosing **No dose has been established for use alongside testosterone.** There is no current label and no controlled trial of this use. The schedules clinics use are prescriber practice, and we have not found a source for them that meets our standard. If a clinician prescribes it, ask what the dose is based on. ## Safety - The discontinued products were used under medical supervision for short tests and for monitored fertility treatment. Long-term use alongside testosterone has not been studied. - It may not do what it is prescribed for. If preserving fertility matters to you, ask about monitoring with semen analysis instead of assuming it is working. - Compounded products vary by pharmacy. Use a licensed one. ## Common questions ### Is gonadorelin FDA-approved? No approved product is marketed in the US today. The earlier brands, Factrel and LutrePulse, were discontinued, and it is now supplied by compounding pharmacies. ### Does gonadorelin work as a replacement for HCG? It has not been tested against HCG in a randomized trial for men on testosterone. ### What is gonadorelin proven to do? Given in pulses by a pump, it restores sperm production in men born without the brain's GnRH signal. ## Sources - [Superpower: compounded gonadorelin, including the 420-man meta-analysis and approval history](https://superpower.com/guides/peptides/compounded-gonadorelin) - [Superpower: gonadorelin as a testosterone therapy add-on and the limits of the evidence](https://superpower.com/guides/gonadorelin) - [Empower Pharmacy: discontinued brands and former approved uses (a compounding pharmacy's own article)](https://www.empowerpharmacy.com/compounded-gonadorelin-in-mens-health) - [FormBlends: no published randomized comparison with HCG (a seller's article)](https://formblends.com/articles/peptide-hub/compare-gonadorelin-vs-hcg) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Growth hormone (HGH) Source: https://aminodesk.com/library/growth-hormone Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Human growth hormone, sold as somatropin, is an FDA-approved prescription drug for specific medical conditions. It is also one of very few drugs that federal law restricts to its approved uses, which makes anti-aging and bodybuilding supply illegal. - **Legal lane:** FDA-approved, prescription only, for approved conditions - **Evidence grade:** A for approved uses. Not supported for anti-aging. - **Form:** injection under the skin, usually daily - **Sport:** prohibited ## What it is Somatropin is a lab-made copy of the 191-amino-acid hormone your pituitary gland produces. Brands include Omnitrope, Humatrope, Norditropin, Genotropin and Serostim. ## What it is approved for - Growth hormone deficiency in children and adults - Short stature linked to Turner syndrome, Prader-Willi syndrome, Noonan syndrome, SHOX deficiency and chronic kidney disease - HIV-related wasting and short bowel syndrome (specific brands) In adults, deficiency has to be confirmed by testing. An IGF-1 level that is low for a person's age is not, on its own, the diagnosis the approval is based on. ## The law is unusual here For most drugs, a doctor may prescribe for uses beyond the label. Growth hormone is an exception. A provision of the Food, Drug, and Cosmetic Act makes it a felony, punishable by up to five years in prison, to distribute growth hormone for a use that has not been authorized. Anti-aging, bodybuilding and athletic performance are not authorized uses. ## Dosing Dosing is set by the prescriber, depends on the brand and the condition, and is adjusted to response and blood IGF-1 levels. Current FDA labels start adults with growth hormone deficiency at about 0.2 mg a day (range 0.15 to 0.3 mg), or at no more than 0.04 mg per kilogram of body weight a week, and adjust every one to two months against response and IGF-1. For children with growth hormone deficiency, labels give roughly 0.16 to 0.24 mg per kilogram a week, split into daily injections. Individual product labels differ, so the label for the specific brand governs. ## Side effects and risks - In a trial in healthy older adults, 36% of those on growth hormone reported joint pain (versus 11% on placebo), 30% muscle pain (versus 12%) and 26% swelling (versus 3%). - Carpal tunnel syndrome and raised blood sugar are also reported. - Product bought outside a pharmacy is frequently diverted, smuggled or counterfeit. ## Related compounds Several peptides are marketed as ways to raise the body's own growth hormone instead of taking it directly. See [sermorelin](https://aminodesk.com/library/sermorelin). ## Common questions ### Is growth hormone legal for anti-aging? No. Federal law makes it a felony to distribute growth hormone for a use that has not been authorized. Anti-aging, bodybuilding and athletic performance are not authorized uses. ### What is growth hormone approved for? Growth hormone deficiency in children and adults, short stature linked to several named conditions, and, for specific brands, HIV-related wasting and short bowel syndrome. ### What are the side effects of growth hormone? In a trial in healthy older adults, 36% of those on growth hormone reported joint pain, 30% muscle pain and 26% swelling. Carpal tunnel syndrome and raised blood sugar are also reported. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA label: Norditropin (somatropin) injection, 2025](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf) - [DailyMed label: Genotropin (somatropin)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765) - [Drug Enforcement Administration: human growth hormone fact sheet](https://deadiversion.usdoj.gov/drug_chem_info/hgh.pdf) - [Perls, Reisman and Olshansky, JAMA 2005: growth hormone for "antiaging", clinical and legal issues](https://wwwapp.bumc.bu.edu/ocr/ClinicalResearchNewsletter/Attachments/AttachNov05/Perls%20article.pdf) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # HCG Source: https://aminodesk.com/library/hcg Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 HCG is an FDA-approved prescription hormone used in fertility care and for certain men with low testosterone. It is not a weight-loss drug, despite decades of marketing that says otherwise. - **Legal lane:** FDA-approved, prescription only - **Evidence grade:** A for approved uses. No evidence for weight loss. - **Form:** injection into muscle or under the skin - **Brands:** Pregnyl, Novarel, Ovidrel ## What it is Human chorionic gonadotropin is a hormone made by the placenta in early pregnancy. As a drug, it works by imitating luteinizing hormone (LH), the pituitary signal that triggers ovulation in women and testosterone production in the testes. ## What it is approved for - Triggering ovulation in fertility treatment - Hypogonadotropic hypogonadism in men, where the testes work but the pituitary signal is missing - Undescended testicles in boys ## Use alongside testosterone therapy Testosterone therapy shuts down the body's own LH signal, which shrinks the testes and can stop sperm production. Clinicians prescribe HCG off-label to keep the testes active. In one case series of 49 men whose sperm counts had collapsed on testosterone, an HCG-based regimen restored sperm production in 47. ## Not for weight loss The FDA requires HCG labels to state that it has not been shown to be effective for obesity, and that there is no substantial evidence it increases weight loss beyond what calorie restriction achieves. Over-the-counter "HCG diet" drops are not approved products. ## Reported dosing The prescriber sets the dose, and it varies widely by purpose. | Use | Reported dosing | Where it comes from | | --- | --- | --- | | Male hypogonadotropic hypogonadism | 1,500 to 5,000 IU, two or three times a week | Range used across clinical studies, per a published review | | Alongside or after testosterone therapy | About 1,000 to 3,000 IU a week in total, split into doses | Small published studies; practice varies | | Ovulation trigger | A single dose, often 5,000 to 10,000 IU | Fertility clinic practice, timed by the clinic | ## Side effects - **Men:** breast tissue growth, acne, fluid retention and mood changes. - **Women in fertility treatment:** ovarian hyperstimulation syndrome, which can be serious, and a higher chance of multiple pregnancy. ## Legal status and supply The FDA-approved brands are the clear legal route. HCG was reclassified as a biologic in March 2020, which sharply restricted compounding. Sources disagree on what compounding remains permitted, and some pharmacies still list it, so ask which product you are being dispensed. Many sports bodies prohibit HCG. ## Common questions ### Does HCG help with weight loss? No. The FDA requires HCG labels to state that it has not been shown to be effective for obesity. Over-the-counter HCG diet drops are not approved products. ### What is HCG approved for? Triggering ovulation in fertility treatment, hypogonadotropic hypogonadism in men, and undescended testicles in boys. ### Why is HCG prescribed with testosterone therapy? Testosterone therapy shuts down the body's own LH signal, which shrinks the testes and can stop sperm production. Clinicians prescribe HCG off-label to keep the testes active. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA label: Pregnyl (chorionic gonadotropin) for injection, 2023](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017692s028s036s043lbl.pdf) - [FDA label: Novarel (chorionic gonadotropin for injection)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017016s156lbl.pdf) - [Chorionic gonadotropin FDA label text](https://www.regdatalab.com/drug/chorionic-gonadotropin) - [Superpower: HCG guide, studies and compounding status](https://superpower.com/guides/hcg) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Hexarelin Source: https://aminodesk.com/library/hexarelin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Hexarelin is one of the strongest of the peptides that make the pituitary release growth hormone. Its human evidence is short hormone studies, and those studies found a problem: the response fades when it is used repeatedly. - **Legal lane:** not FDA-approved. Not on the list of substances pharmacies may compound. Sold as a research chemical. - **Evidence grade:** C - **Form:** injection under the skin - **Sport:** prohibited at all times ## What it is Hexarelin, also called examorelin, is a synthetic chain of six amino acids, closely related to [GHRP-6](https://aminodesk.com/library/ghrp-2-ghrp-6). It acts on the ghrelin receptor to trigger a pulse of growth hormone. It was developed in the 1990s and never reached approval in any country. ## What the evidence shows - Short studies in people confirm that a dose produces a growth hormone pulse. - The same studies show it also raises cortisol and prolactin. - **The response fades.** With continued use, the growth hormone released by a given dose falls substantially over a matter of weeks. - No controlled trial has measured muscle, fat loss, recovery or any other benefit over months. Claims that it protects the heart come from animal studies. No large human trial has tested them. ## Legal status - Not FDA-approved for any use, and not approved by any major regulator. - Not on the FDA's list of bulk substances that pharmacies may compound. - Prohibited by the World Anti-Doping Agency in and out of competition. ## Reported dosing **No dose has been established.** No approved product exists and development ended without one. The schedules that circulate, including the breaks intended to work around the fading response, come from sellers and forums and not from a trial. ## Safety - Raised cortisol and prolactin with each dose. - Long-term safety is unknown. The human studies were short. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### Does hexarelin stop working? Its effect weakens. Studies found that the growth hormone response to the same dose falls substantially over weeks of regular use. ### Is hexarelin legal? It is not FDA-approved and is not eligible for pharmacy compounding. It is sold as a research chemical. ### Is hexarelin proven to build muscle? No. No controlled human trial has measured muscle or body composition over months. ## Sources - [Superpower: hexarelin, human data and regulatory status](https://superpower.com/guides/peptides/hexarelin) - [Superpower: hexarelin is not on the FDA's list for routine compounding](https://wf.superpower.com/peptides/hexarelin) - [Empire Medical Training: desensitization with repeated use](https://www.empiremedicaltraining.com/antiaging-regenerative-workshops/resources/peptide-therapy/hexarelin/) - [Rite Aid: hexarelin status and anti-doping position](https://riteaid.com/peptides/hexarelin) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Humanin Source: https://aminodesk.com/library/humanin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Humanin is a small peptide made by mitochondria, the energy-producing parts of the cell. Natural levels fall with age, which is why it is sold as a longevity peptide. No trial has tested giving it to people. - **Legal lane:** not FDA-approved. Sold as a research chemical. - **Evidence grade:** D for the injected peptide - **Form:** injection - **Established human dose:** none ## What it is A peptide of 24 amino acids, discovered in 2001 and encoded in mitochondrial DNA. It was the first of a family that also includes [MOTS-c](https://aminodesk.com/library/mots-c). In cells and animals it protects against several kinds of stress. ## What the evidence shows The human evidence is observational. Circulating humanin declines with age, runs higher in the children of centenarians, and is lower in Alzheimer's disease. Those are associations with a natural marker. They do not show that adding humanin helps. Most animal work used a stronger laboratory analog, not the natural peptide. The Alzheimer's Drug Discovery Foundation's review says clinical testing in humans has not been conducted and no therapeutic dose has been established. ## Legal status - Not FDA-approved for any use. - Not on the FDA's lists of substances nominated for compounding, according to one clinical summary. - Not one of the six peptides in the October 2026 compounding policy. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established in people. ## Safety - The same review notes that humanin's effects depend on context and may differ by sex. - It promotes cell survival, which is the reason sources raise a theoretical caution for people with cancer. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### What is humanin? A 24-amino-acid peptide made by mitochondria that protects cells under stress. ### Has humanin been tested in people? Only by measuring natural levels. No trial has given it to people as a treatment. ### Is humanin related to MOTS-c? Yes. Both are mitochondrial-derived peptides. ## Sources - [Alzheimer's Drug Discovery Foundation: humanin and humanin analogs, evidence summary](https://www.AlzDiscovery.org/uploads/cognitive_vitality_media/Humanin-and-humanin-analogs.pdf) - [Yen et al., 2020: humanin, lifespan and healthspan (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7343442/) - [Superpower: humanin research stage](https://superpower.com/guides/peptides/humanin) - [Superpower: regulatory status](https://wf.superpower.com/guides/humanin) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # IGF-1 LR3 Source: https://aminodesk.com/library/igf-1-lr3 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 IGF-1 LR3 is a laboratory reagent sold to bodybuilders. It has never been tested in humans, is not approved anywhere, and the closest approved drug carries serious warnings. This page covers what it is and why we do not publish a protocol for it. - **Legal lane:** research reagent. Not approved anywhere; no compounding route. - **Evidence grade:** D - **Human trials:** none - **Sport:** prohibited at all times ## What it is IGF-1 LR3 is an engineered 83-amino-acid version of insulin-like growth factor 1, altered so that it binds poorly to the proteins that normally keep IGF-1 inactive in the blood. The practical effect is that more of it stays free and active for longer. It was made as a cell-culture reagent, and that is still its only legitimate use. ## What the evidence shows There are no human trials of IGF-1 LR3. None. There is no pharmacokinetic data in people, no dose-finding work, and no safety database. What exists instead is the label of mecasermin (Increlex), an approved IGF-1 product used in children with severe primary IGF-1 deficiency. It is a different molecule given under close medical supervision, so it is not a guide to using IGF-1 LR3. It does show what this hormone does when given to people: - Low blood sugar is the signature problem. The label reports hypoglycemia in a large share of treated patients, and seizures from it are documented. - The label carries a warning about malignant neoplasia. IGF-1 is a growth signal, and the concern about feeding undiagnosed cancers is on the approved label, not a rumor. - Enlarged tonsils, snoring and sleep apnea, and injection-site reactions are also listed. - Treatment requires eating before or after each dose, and a doctor monitoring blood sugar. ## Why there is no protocol here We publish dosing when it comes from an FDA label, a published human study, or documented prescriber practice. For IGF-1 LR3 there is none of the three. The numbers circulating in forums were not derived from any study, and the hypoglycemia and cancer warnings on the approved IGF-1 label are the reason we are not going to repeat them. If you are considering this compound, the honest summary is that nobody, including the people selling it, knows what a safe dose in a healthy adult is. ## Common questions ### Has IGF-1 LR3 been tested in humans? No. There are no human trials, no dose-finding work and no safety database. ### What are the risks of IGF-1 LR3? The label of mecasermin (Increlex), an approved IGF-1 product and a different molecule, reports low blood sugar, including seizures from it, and carries a warning about malignant neoplasia. ### Why is there no IGF-1 LR3 dose on this page? We publish dosing only when it comes from an FDA label, a published human study or documented prescriber practice. For IGF-1 LR3 there is none of the three. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA warning letter: Tailor Made Compounding LLC (April 2020)](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020) - [FDA label for Increlex (mecasermin), 2025](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021839s033lbl.pdf) - [Outliyr: IGF-1 LR3 evidence review](https://outliyr.com/reports/igf-1-lr3) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Ipamorelin Source: https://aminodesk.com/library/ipamorelin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Ipamorelin is the most popular of the "growth hormone secretagogue" peptides, usually sold paired with CJC-1295. It reliably raises growth hormone for a short time. None of the reasons people buy it have been tested in human trials. - **Legal lane:** not FDA-approved. Not eligible for routine pharmacy compounding, according to the sources we trust most. - **Evidence grade:** C - **Form:** injection under the skin - **Sport:** prohibited at all times ## What it is Ipamorelin imitates ghrelin, a gut hormone, at the receptor that triggers a pulse of growth hormone from the pituitary. It is described as more selective than older compounds in its class, meaning it raises growth hormone with less effect on cortisol, prolactin and appetite. ## What the evidence shows Human data is limited to short pharmacology studies showing that it produces a brief growth hormone pulse, plus one Phase 2 trial. That trial tested ipamorelin for bowel recovery after surgery, not for anything it is marketed for today, and it did not meet its main goal: patients tolerated a first solid meal at a median of 25.3 hours on ipamorelin and 32.6 hours on placebo, a difference that was not statistically significant. Development stopped. No human trial has measured fat loss, muscle gain, sleep or recovery with ipamorelin, and none has tested the CJC-1295 combination. ## Legal status This one is contested, so check anything you are told. Ipamorelin was restricted from compounding in 2023 and taken off that restricted list in 2024 when its nomination was withdrawn. In October 2024 an FDA advisory committee voted 0 to 12, with one abstention, against adding it to the list of substances pharmacies may compound. It was not part of the October 2026 policy. Some clinics and websites say ipamorelin was "reinstated" for compounding in 2026. We could not confirm that from FDA records or from the independent summaries we read. ## Reported dosing **No approved dose exists.** Clinical development was discontinued before one was set. The figures repeated across clinics and community sources are 100 to 300 micrograms per injection, one to three times a day, often before sleep, in cycles of 8 to 12 weeks. The source that catalogs these labels them anecdotal. They do not come from a trial of any outcome. ## Safety - The FDA has flagged possible immune reactions, impurities and limited safety information for compounded ipamorelin. - Raising growth hormone and IGF-1 over long periods carries theoretical concerns that short studies cannot rule out. ## Common questions ### Can pharmacies legally compound ipamorelin? This is contested. In October 2024 an FDA advisory committee voted 0 to 12, with one abstention, against adding it to the compounding list, and it was not part of the October 2026 policy. We could not confirm claims that it was reinstated in 2026. ### Does ipamorelin work? It raises growth hormone for a short time. Its one Phase 2 trial, for bowel recovery after surgery, did not meet its main goal. No human trial has measured fat loss, muscle gain, sleep or recovery. ### What is the usual ipamorelin dose? No approved dose exists. The figures repeated by clinics and community sources, 100 to 300 micrograms per injection one to three times a day, are labeled anecdotal by the source that catalogs them. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Beck et al. 2014: randomized proof-of-concept trial of ipamorelin for postoperative ileus (Int J Colorectal Dis)](https://pubmed.ncbi.nlm.nih.gov/25331030/) - [FDA briefing document: ipamorelin-related bulk drug substances (October 2024)](https://www.fda.gov/media/182088/download) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [Superpower: ipamorelin evidence and status](https://superpower.com/guides/ipamorelin) - [Project Biohacking: advisory committee votes, from the FDA minutes](https://projectbiohacking.beehiiv.com/p/cjc-1295-ipamorelin-pcac-vote-503a-status) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Khavinson short peptides: Bronchogen, Cardiogen and seven more Source: https://aminodesk.com/library/khavinson-bioregulators Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending This page covers nine Russian short peptides that are each sold for a single organ: Bronchogen, Cardiogen, Chonluten, Crystagen, Livagen, Ovagen, Pancragen, Prostamax and Testagen. They belong to the family known as Khavinson bioregulators. We found no controlled human trial of any of the nine, and none has a lawful route in the US. - **Legal lane:** not FDA-approved. Not eligible for pharmacy compounding. Sold as research chemicals. - **Evidence grade:** D for each of the nine - **What they are:** synthetic peptides two to four amino acids long - **Established human dose:** none ## What they are Beginning in the 1970s, Vladimir Khavinson's group in St. Petersburg extracted peptide mixtures from animal organs, then made short synthetic peptides meant to reproduce each extract's effect. The idea is that every organ makes its own short regulatory peptides, and that supplying them restores that organ. The synthetic versions are what research suppliers sell. Members of the family with more of a record have their own pages: [Epitalon](https://aminodesk.com/library/epitalon), [Pinealon](https://aminodesk.com/library/pinealon), [Vilon](https://aminodesk.com/library/vilon), [Cortagen](https://aminodesk.com/library/cortagen), [Cartalax](https://aminodesk.com/library/cartalax) and [Vesugen](https://aminodesk.com/library/vesugen), and the registered Russian drugs [Thymalin](https://aminodesk.com/library/thymalin) and [Thymogen](https://aminodesk.com/library/thymogen). ## The nine on this page | Peptide | Sold for | Human trial evidence | | --- | --- | --- | | **Bronchogen** | Bronchial and lung support. | None found. | | **Cardiogen** | Heart support. | None found. | | **Chonluten** | Lung and airway support. Also spelled Choluten. | None found. | | **Crystagen** | Immune support. | None found. | | **Livagen** | Liver support and anti-aging. | None found. | | **Ovagen** | Liver and digestive support. | None found. | | **Pancragen** | Pancreas and blood sugar support. | None found. | | **Prostamax** | Prostate support. | None found. | | **Testagen** | Testicular and hormone support. | None found. | The target organ in each case is the seller's and developer's description. It is not a tested medical use. ## What the evidence shows We found no controlled human trial of any of these nine peptides in the sources we reviewed. For the family as a whole, the record is cell experiments, rodent studies, and small, often unblinded human studies run by the original group. Key findings have not been reproduced by independent teams. The most-cited human study, a 266-person cohort followed for six to eight years, tested thymus and pineal extracts, not these peptides, and was not blinded. A result in a cell dish shows a possible pathway. It is the kind of evidence furthest from showing that a compound does anything in a living person. ## Legal status - None of the nine is FDA-approved for any use. - None is eligible for pharmacy compounding, according to the research summary we read. - None is among the six peptides in the October 2026 policy. Epitalon, a relative, is. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for these compounds.** No dose has been established in a controlled human trial for any of them. The course schedules that circulate come from the developers' own tradition and from sellers. ## Safety - No independent human safety data exists for any of the nine. - Peptides this small are often assumed to be harmless. That assumption has not been tested. - Each is sold for an organ that, if it is causing symptoms, needs a diagnosis. A research chemical is not a substitute for one. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### What are Khavinson bioregulators? A family of short peptides developed in Russia, each marketed for a particular organ. ### Are Bronchogen, Cardiogen or the others FDA-approved? No. None of the nine is approved, and none is eligible for pharmacy compounding. ### Have these peptides been tested in people? We found no controlled human trial of any of the nine. The family's evidence is cell and animal work and small unblinded studies from its developers. ### Which bioregulator has the most evidence? Epitalon is the most studied of the short peptides. Thymalin and Thymogen are registered drugs in Russia. ## Sources - [Overview of the Khavinson short peptides and the tiers of evidence behind them](https://ipsnews.net/business/?p=248484) - [The Peptide Column: bioregulator research summary and legal status](https://the-peptide-column.pages.dev/bioregulators) - [Khavinson and Morozov, 2003: the 266-person elderly cohort (PubMed)](https://pubmed.ncbi.nlm.nih.gov/14523363/) - [MedicalResearch.com: what four decades of bioregulator research does and does not show](https://medicalresearch.com/?p=75499) - [Paper (St. Petersburg), 2024: Khavinson's drugs and their critics in evidence-based medicine](https://papernews.online/en/he-promised-to-extend-the-lives/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Kisspeptin Source: https://aminodesk.com/library/kisspeptin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 Kisspeptin is a natural hormone that sits at the top of the reproductive axis. It has better controlled-trial evidence than most compounds in this library. The catch is that the form sold online is not the form most of those trials used. - **Legal lane:** investigational. No FDA-approved product. - **Evidence grade:** B - **Form:** injection; trials used intravenous and subcutaneous routes - **Two versions:** kisspeptin-10 (commonly sold) and kisspeptin-54 (used in the strongest trials) ## What it is Kisspeptin signals the hypothalamus to release GnRH, which in turn drives LH and FSH and the sex hormones downstream. It is the switch that starts puberty. Kisspeptin-10 is a short fragment with a half-life measured in minutes. Kisspeptin-54 is longer-acting and is what researchers used in the trials below. Vendors usually sell the -10 form; do not read trial results from one as evidence for the other. ## What the evidence shows - **Fertility:** teams at Imperial College London used kisspeptin as the trigger for egg maturation in IVF, reporting effective maturation with a lower risk of ovarian hyperstimulation syndrome than the standard trigger. - **Sexual desire:** two randomized placebo-controlled trials published in JAMA Network Open, one in men and one in 32 premenopausal women with low sexual desire, reported changes in brain activity and in some behavioral measures. - These are small, early-phase studies in clinical settings, not evidence for general use. ## Legal status Kisspeptin remains investigational. There is no approved product, and it was not included among the peptides opened to compounding in 2026. Material sold online is a research chemical. ## Dosing in studies **No approved dose exists.** Trials dosed by body weight, intravenously or by infusion, under direct supervision, using kisspeptin-54 in most cases. The round numbers circulating in forums for the -10 form do not come from any of this work. ## Safety - Trial participants tolerated it well over short exposures under supervision. - Nothing is known about repeated self-administration over months. - It acts on the hormonal axis that controls reproduction, so effects on fertility, cycles and testosterone are plausible and unstudied outside the trial settings above. ## Common questions ### What has kisspeptin been studied for? Fertility, as the trigger for egg maturation in IVF, and low sexual desire, in two small randomized placebo-controlled trials. These are early-phase studies in clinical settings. ### What is the difference between kisspeptin-10 and kisspeptin-54? Kisspeptin-10 is a short fragment with a half-life measured in minutes. Kisspeptin-54 is longer-acting and is what most of the trials used. Vendors usually sell the -10 form. ### Is kisspeptin legal? It remains investigational. There is no approved product, and it was not among the peptides opened to compounding in 2026. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Thurston et al. 2022: kisspeptin in women with hypoactive sexual desire disorder, randomized trial (JAMA Network Open)](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797718) - [Mills et al. 2023: kisspeptin in men with hypoactive sexual desire disorder, randomized trial (JAMA Network Open)](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800937) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [Superpower: kisspeptin trials and status](https://superpower.com/guides/kisspeptin) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # KLOW blend (GHK-Cu + BPC-157 + TB-500 + KPV) Source: https://aminodesk.com/library/klow-blend Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending KLOW is the GLOW blend with a fourth peptide, KPV, added. The usual vial has a fixed ratio that is mostly GHK-Cu by weight. The mixture has never been tested in people, and a mixed vial falls outside the 2026 compounding policy. - **Legal lane:** outside the October 2026 policy, which allows one active ingredient per product. Not FDA-approved. - **Evidence grade:** D for the combination - **What is in it:** GHK-Cu, BPC-157, TB-500 and KPV. The most common vial is 80 mg: 50 mg GHK-Cu and 10 mg each of the other three. - **Established human dose:** none ## What it is The [GLOW blend](https://aminodesk.com/library/glow-blend) ([GHK-Cu](https://aminodesk.com/library/ghk-cu), [BPC-157](https://aminodesk.com/library/bpc-157) and [TB-500](https://aminodesk.com/library/tb-500)) with the anti-inflammatory peptide [KPV](https://aminodesk.com/library/kpv) added. Some compounders add a fifth peptide, larazotide, which has been studied for intestinal permeability. Because the ratio is fixed in the vial, you cannot adjust one ingredient without moving all four. KLOW is 62.5% GHK-Cu by weight. If the ingredient you want is BPC-157, you are buying mostly something else. ## What the evidence shows There is no trial of this blend, and no study has shown that the combination does better than its ingredients taken separately. The evidence that exists applies to each ingredient on its own. For BPC-157 and TB-500 it is almost entirely animal work. Each ingredient's page has its grade and what has been shown. ## Legal status In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it. Three of KLOW's four ingredients are on that list, which is why 2026 looked like the year blends became legitimate. The single-ingredient condition means the mixed vial is still outside the policy, and GHK-Cu is not one of the six. A seller offering KLOW is working outside the policy or is not a licensed compounding pharmacy. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic applied to a product nobody has studied. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - **You cannot tell what worked.** If you improve, you have learned nothing about which ingredient to keep. - **You cannot tell what went wrong.** A reaction means stopping everything, with no way to find the cause except starting over one at a time. - **The mixture itself is unstudied.** Reviews of compounded multi-peptide preparations note that no safety or absorption work exists on the combinations. - **Quality is a separate risk.** A pharmacy following the policy closely will not make a blend, so the product comes from outside that system. **Copper accumulates.** Most of a KLOW vial is GHK-Cu, which delivers copper with every dose. Long courses are a reason to pay attention to copper and zinc balance, which is a conversation for a clinician. ## If you are considering it anyway - Ask the seller which pharmacy compounded it and whether that pharmacy is operating under the HHS policy. A blend cannot be, and a straight answer tells you what you are dealing with. - Ask for a certificate of analysis showing each ingredient's identity and purity separately, not one figure for the vial. - Consider one compound at a time. It is slower, and it is the only way to learn how you respond. - If a clinician is prescribing, ask why a blend and not separate vials, and whether the ratio can be adjusted for you. ## Common questions ### What is in KLOW? GHK-Cu, BPC-157, TB-500 and KPV. The most common vial holds 50 mg of GHK-Cu and 10 mg of each of the others. ### What is the difference between GLOW and KLOW? KLOW is the GLOW formula with KPV added as a fourth peptide. ### Is KLOW legal? Not under the October 2026 policy, which allows one active ingredient per compounded product. ## Sources - [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/) - [Buchanan Ingersoll & Rooney: single-active-ingredient formulations under the policy](https://www.bipc.com/compounding-peptides-what-compounding-pharmacies-need-to-know-about-the-hhs-interim-enforcement-discretion-policy-for-six-peptides) - [Healio: advisory committee discussion, including the combination-use concern raised on TB-500](https://www.healio.com/news/primary-care/20260724/fda-committee-recommends-looser-restrictions-for-several-peptides) All three repair blends are compared on [blends and stacks](https://aminodesk.com/stacks). To keep a private record of what you take, use the [dose and progress log](https://aminodesk.com/glp1-log). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # KPV Source: https://aminodesk.com/library/kpv Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 KPV is a tiny peptide promoted for gut and skin inflammation. Its evidence comes from cells and animals. Under the October 2026 policy it can be compounded for oral and topical use only. - **Legal lane:** compounded on prescription under the October 2026 interim policy. Not FDA-approved. - **Evidence grade:** D - **Forms covered by the policy:** KPV acetate, oral and topical. Injection is not covered. - **Established human dose:** none ## What it is KPV is three amino acids: lysine, proline and valine. It is the tail end of alpha-MSH, a 13-amino-acid hormone with known anti-inflammatory effects. Researchers study KPV because it appears to keep some of that activity without the hormone's effect on skin pigment. ## What the evidence shows In cell studies and in mouse models of colitis, KPV reduced inflammatory signals. Reviews we read found no published human efficacy trials. When FDA staff assessed KPV for the July 2026 advisory committee, they recommended against allowing it to be compounded, citing insufficient data and open questions about impurities and immune reactions. The committee considered KPV for wound healing and inflammatory conditions and voted 8 to 6 to recommend it. ## Legal status KPV left the FDA's restricted category in April 2026 and is covered by the HHS interim policy published October 30, 2026. The policy covers oral and topical KPV acetate. Products sold for injection, or sold online as "research use only", are outside it. ## Reported dosing **No dose has been established in human trials.** No dose, frequency or duration has been clinically validated. Animal studies have used oral, topical and injected routes at varying amounts. We have not found a commonly quoted human figure that traces back to a published human study, so we are not repeating one here. If a clinician prescribes KPV, the prescription sets the dose. ## Safety - There is no meaningful human safety record. - Route matters. The policy's limit to oral and topical forms reflects that injected products carry different risks. ## Common questions ### What is KPV used for? It is promoted for gut and skin inflammation. The evidence comes from cell studies and mouse models. Reviews we read found no published human efficacy trials. ### Can KPV be injected legally? The October 2026 policy covers oral and topical KPV acetate only. Products sold for injection, or sold online as research use only, are outside it. ### What is the usual KPV dose? No dose has been established in human trials. We have not found a commonly quoted figure that traces back to a published human study, so we do not repeat one. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA briefing document: KPV-related bulk drug substances (July 2026)](https://www.fda.gov/media/193346/download) - [FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (agenda and briefing documents)](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [HHS: 503A peptide enforcement discretion policy (PDF)](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [BSCG: KPV research and FDA staff recommendation](https://bscg.org/blogs/single/kpv-peptide-benefits-safety-legal-status-and-research) - [Superpower: KPV evidence summary](https://superpower.com/guides/peptides/kpv) - [Rite Aid: KPV status and FDA assessment](https://riteaid.com/peptides/kpv) - [HealingMaps: committee vote](https://healingmaps.com/kpv-peptide-anti-inflammatory-wound-healing/) - [GoodRx: FDA developments on peptides](https://www.goodrx.com/health-topic/peptides/what-peptides-are-fda-approved) (policy forms and routes; committee votes) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # L-carnitine (injectable) Source: https://aminodesk.com/library/l-carnitine Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending L-carnitine (levocarnitine) helps carry fat into cells to be burned. It is an FDA-approved drug, Carnitor, for people who are deficient in it, and a common supplement. Clinics and sellers now offer it as weight-loss shots, a use it is not approved for. - **Legal lane:** approved for carnitine deficiency; supplement; injections for weight loss are off-label or unregulated - **Evidence grade:** B for weight loss (many trials, small effect) - **Approved forms:** tablets, oral solution, IV injection - **Brand:** Carnitor ## What it is Carnitine is an amino-acid derivative the body makes and also gets from meat and dairy. Real deficiency is uncommon and mostly seen in inherited metabolic disorders and in people on dialysis. ## What the evidence shows for weight There are dozens of randomized trials, mostly of oral supplements. A 2020 analysis of 37 of them found people on L-carnitine lost about 1.2 kg (under 3 pounds) more than controls. A 2016 analysis found a similar difference and that the effect shrank the longer people took it. That is real but small, and it comes from oral use. The weight-loss injections sold today have no trials of their own. ## Dosing on the label The approved injection is for carnitine deficiency, not weight. For people on dialysis, the label starts at 10 to 20 mg per kg of dry body weight, given slowly into a vein after each session and adjusted by blood levels. The injection is labeled for intravenous use only. **No dose is established for weight-loss injections.** The intramuscular shots offered by clinics do not follow any label. ## Side effects and warnings - Serious allergic reactions, including anaphylaxis, have been reported after IV use, mostly in dialysis patients. - Seizures have been reported, including more frequent seizures in people who already have them. - Oral doses can upset the stomach. In people with kidney failure, high oral doses can build up a by-product that causes a fishy body odor. ## Common questions ### Do L-carnitine shots work for weight loss? The weight-loss injections sold today have no trials of their own. For oral supplements, a 2020 analysis of 37 trials found about 1.2 kg more weight loss than controls. ### Is L-carnitine FDA-approved? Yes, as Carnitor, for people who are deficient in carnitine. It is not approved for weight loss, and the approved injection is labeled for intravenous use only. ### What are the risks of L-carnitine injections? Serious allergic reactions, including anaphylaxis, and seizures have been reported after intravenous use. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Carnitor (levocarnitine) injection label (DrugCentral)](https://drugcentral.org/label/cf801cc4-775e-433d-9d32-e5d9a98981d3/view) - [2020 meta-analysis of 37 trials of L-carnitine and weight, Clinical Nutrition ESPEN (PubMed)](https://pubmed.ncbi.nlm.nih.gov/32359762/) - [Pooyandjoo et al. 2016: meta-analysis of L-carnitine and weight loss (PubMed)](https://pubmed.ncbi.nlm.nih.gov/27335245/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Larazotide Source: https://aminodesk.com/library/larazotide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Larazotide is an oral peptide that was tested as an add-on to the gluten-free diet in celiac disease. It is now sold as a "leaky gut" peptide and added to some blends. Its Phase 3 trial was stopped in 2022 because the interim results showed it was unlikely to succeed. - **Legal lane:** not FDA-approved. Not on the list of substances pharmacies may compound. - **Evidence grade:** B. Real trials in people; the largest was stopped for lack of effect. - **Form:** capsule by mouth in the trials - **Established human dose:** none ## What it is Larazotide acetate, also called AT-1001, is a chain of eight amino acids. It was designed to tighten the junctions between the cells that line the gut, so that less gluten slips through. It was the first celiac drug candidate to reach Phase 3. ## What the evidence shows - **Phase 2:** a trial in 342 adults with celiac disease who had been on a gluten-free diet for at least 12 months found that one of the doses tested reduced symptoms. - **Phase 3:** the CedLara trial enrolled people who still had symptoms on a gluten-free diet. In June 2022 an interim analysis found the difference from placebo was not statistically significant, and that the number of extra patients needed to show an effect was too large to continue. The company stopped the trial. No trial has tested it for the general gut, skin or inflammation claims it is sold for. ## Legal status - Not FDA-approved for any use. One summary reports no active development program as of 2026. - Not on the FDA's list of bulk substances pharmacies may compound. - It is not one of the six peptides in the October 2026 policy. ## Reported dosing **No dose has been established.** Development ended before an approved dose was set, and the positive Phase 2 result was at a single dose level that the larger trial did not confirm. The trials used capsules. No trial has tested it by injection, which is how blends deliver it. ## Safety - The trials did not raise major safety concerns, but they tested capsules, in celiac patients, for limited periods. - Injecting it, alone or in a blend, is untested. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### Is larazotide approved for celiac disease? No. Its Phase 3 trial was stopped in 2022 and it is not FDA-approved for anything. ### Why was the larazotide trial stopped? An interim analysis found no statistically significant benefit, and continuing would have needed far more patients than was feasible. ### Does larazotide fix leaky gut? No trial has tested that claim outside celiac disease. ## Sources - [BioSpace: interim results end the Phase 3 trial of larazotide](https://www.biospace.com/poor-results-end-9-meters-phase-iii-trial-for-larazotide) - [Beyond Celiac: Phase 3 study of larazotide discontinued](https://www.beyondceliac.org/research-news/phase-3-study-discontinued/) - [Beyond Celiac: the earlier Phase 2 trial in 342 adults](https://www.beyondceliac.org/?p=19290) - [Superpower: larazotide acetate status and evidence](https://superpower.com/guides/peptides/larazotide-acetate) - [PeptideGrids: compounding status and development status](https://peptidegrids.pages.dev/compound/larazotide/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Lipo-C and Lipo-C + B12 (MIC lipotropic injections) Source: https://aminodesk.com/library/lipo-c Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Lipo-C is a compounded injection of methionine, inositol and choline, usually with vitamin B12 and sometimes carnitine. Weight-loss clinics sell it as a fat-burning shot. It is not a peptide, and we found no controlled trial showing it causes weight loss. - **Legal lane:** compounded on prescription. Not an FDA-approved product. - **Evidence grade:** D for weight loss - **Form:** injection - **Also called:** MIC, Lipo-MIC, lipotropic injection, skinny shot ## What it is It is also sold as Lipo-C + B12 or MIC + B12. Most recipes already include B12, so that is usually the same product under a longer name. The three core ingredients are nutrients involved in how the liver handles fat. That role in normal metabolism is the basis for the name "lipotropic". The recipe is not standard. Each pharmacy chooses its own ingredients and strengths, so two products called Lipo-C can be quite different. ## What the evidence shows A nutrient being needed for fat metabolism does not mean that injecting more of it burns fat. We found no controlled trial of the injection for weight loss in the sources we reviewed. The numbers on clinic and seller pages are their own. The B12 in the shot is a real medicine for people who are deficient. Its label lists no use for energy or weight in people with normal levels. See [vitamin B12 injections](https://aminodesk.com/library/vitamin-b12). ## Legal status - Compounded by pharmacies on a prescription. - Compounded medications are not FDA-approved finished products. The combination has no label and has not been reviewed by the FDA. - It is not a controlled substance. ## Reported dosing **No dose has been established for this combination.** There is no label. Strength and schedule are set by the clinic and the pharmacy. ## Safety - The individual nutrients are familiar at ordinary doses. - Because formulations differ between pharmacies, ask exactly what is in the vial and at what strength. - Injection-site soreness is the commonly described side effect. ## Common questions ### Is Lipo-C a peptide? No. It is a mix of nutrients. ### Do lipotropic injections cause weight loss? We found no controlled trial showing that they do. ### What is in Lipo-C? Methionine, inositol and choline, usually with vitamin B12 and sometimes carnitine. Recipes vary by pharmacy. ## Sources - [The Peptide Column: Lipo-C contents and approval status](https://the-peptide-column.pages.dev/peptides/lipo-c) - [Review of a telehealth MIC + B12 product: compounded, not FDA-approved](https://www.newswire.com/news/readyrx-mic-b12-review-2026-what-the-ingredient-research-and-subscription-terms) - [Cyanocobalamin injection prescribing information](https://www.drugs.com/pro/cyanocobalamin.html) - [The Peptide Breakdown: how compounding pharmacies describe Lipo-C](https://thepeptidebreakdown.blogspot.com/2026/04/lipo-c-guide-benefits.html) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Liraglutide (Saxenda, Victoza) Source: https://aminodesk.com/library/liraglutide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Liraglutide is the older GLP-1 medication, injected every day and sold as Saxenda for weight and Victoza for type 2 diabetes. It produces less weight loss than the weekly drugs, and in 2025 it became the first GLP-1 with an FDA-approved generic for weight loss. - **Legal lane:** FDA-approved, prescription only - **Evidence grade:** A - **Form:** daily injection under the skin, from a prefilled pen - **Brands:** Saxenda (weight), Victoza (type 2 diabetes), and generics of both ## What it is Liraglutide acts on the same GLP-1 receptor as [semaglutide](https://aminodesk.com/library/semaglutide), but it is cleared faster and has to be injected daily. The FDA approved Saxenda for chronic weight management in adults in December 2014 and extended it to adolescents aged 12 to 17 in December 2020. ## What the evidence shows The main trial, SCALE Obesity and Prediabetes, followed 3,731 adults for 56 weeks. Average weight loss was 8.0% on liraglutide 3 mg against 2.6% on placebo. About 63% of people on liraglutide lost at least 5% of their weight, against 27% on placebo. That is a real effect and a smaller one than the weekly drugs produced in their own trials. The trials were separate, so the comparison is indirect. ## Legal status - FDA-approved as Saxenda for chronic weight management, with a reduced-calorie diet and more physical activity, in adults with obesity or with overweight and a weight-related condition, and in some adolescents. - FDA-approved as Victoza for type 2 diabetes. - **Generics:** a generic of Victoza launched in June 2024. On August 27, 2025, the FDA approved a generic of Saxenda, the first generic GLP-1 approved for weight loss in the US. ## Label dosing The Saxenda label starts at 0.6 mg a day for one week and raises the dose by 0.6 mg each week, through 1.2 mg, 1.8 mg and 2.4 mg, to 3 mg a day. The slow increase is there to reduce stomach side effects. The label says to check progress at 16 weeks and stop if a patient has not lost at least 4% of their starting weight. The dose on your prescription is the one to follow. ## Safety - **Boxed warning:** thyroid C-cell tumors seen in rodents. It should not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. - **Stomach side effects:** nausea is the most common, especially while the dose is rising. - **Gallbladder:** gallbladder disease was more common on Saxenda than placebo in trials. - **Injection sites:** the label says to rotate sites. On any GLP-1, some of the weight lost is muscle. See [protein and muscle on GLP-1s](https://aminodesk.com/guides/protein-on-glp-1). ## Common questions ### How is liraglutide different from semaglutide? It acts on the same receptor but is injected every day, not every week, and its main trial showed less weight loss. ### How much weight do people lose on Saxenda? In its main trial, an average of 8.0% of body weight over 56 weeks, against 2.6% on placebo. ### Is there a generic Saxenda? Yes. The FDA approved a generic of Saxenda on August 27, 2025. ### What is the Saxenda dose schedule? The label starts at 0.6 mg a day and rises by 0.6 mg each week to 3 mg a day. ## Sources - [Saxenda prescribing information (dose schedule, boxed warning, 16-week check)](https://www.drugs.com/pro/saxenda.html) - [Novo Nordisk: Saxenda dosing and the 16-week assessment](https://www.novomedlink.com/obesity-treatment/products/saxenda/dosing-administration/saxenda-dosing.html) - [Pi-Sunyer et al., 2015: SCALE Obesity and Prediabetes trial, NEJM (PubMed)](https://pubmed.ncbi.nlm.nih.gov/26132939/) - [Patient Care: first generic of Saxenda approved (August 2025)](https://www.patientcareonline.com/view/generic-liraglutide-approved-marking-first-generic-glp-1-ra-indicated-specifically-for-weight-management-in-the-us) - [Healio: generic Saxenda approval and the 2024 Victoza generic](https://www.healio.com/news/endocrinology/20251117/fda-approves-first-generic-glp1-indicated-for-weight-loss) Taking a prescribed GLP-1? Keep a private record of shots, weight and protein with the [dose and progress log](https://aminodesk.com/glp1-log). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # LL-37 (cathelicidin) Source: https://aminodesk.com/library/ll-37 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending LL-37 is an antimicrobial peptide the body makes itself, part of the skin's first line of defense. It has been tested in people only as a topical treatment for leg ulcers, with mixed results. It is sold online as an injection, which has never been studied. - **Legal lane:** no approved product; FDA compounding review due by February 2027 - **Evidence grade:** C - **Studied form:** applied to wounds - **Sold form:** injectable powder ## What it is LL-37 is the only human cathelicidin, a family of peptides that kill bacteria and help coordinate wound repair. Chronic wounds tend to have low levels of it, which is the reasoning behind applying it directly. ## What the evidence shows - A 2014 trial in 34 people with hard-to-heal venous leg ulcers found faster healing with the two lower strengths applied twice a week, and no benefit at the highest strength. - A larger 2021 trial in 148 people found no significant improvement in healing over placebo across the whole group. Both trials put LL-37 on the wound. No human trial has tested it as an injection, for immune support, or for anything else it is sold for. ## Dosing **No dose established.** The only human dosing is topical concentrations applied to ulcers in clinical trials. Nothing in that work tells you what an injected dose would do. ## Legal status In April 2026 the FDA took LL-37 off its list of substances flagged as significant safety risks for compounding. That is not permission to compound it. An FDA advisory committee is scheduled to review it, with GHK-Cu, dihexa, Melanotan II and PEG-MGF, before the end of February 2027. ## Common questions ### Has LL-37 been tested in people? Only as a topical treatment for leg ulcers, with mixed results. A 2014 trial in 34 people found faster healing at lower strengths. A larger 2021 trial in 148 people found no significant improvement over placebo. ### Can pharmacies compound LL-37? Not currently. Its April 2026 removal from the FDA's safety-risk list is not permission to compound it. An advisory committee is scheduled to review it before the end of February 2027. ### Is there a dose for injected LL-37? No. No human trial has tested LL-37 as an injection. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Grönberg et al. 2014: LL-37 for venous leg ulcers, randomized trial (PubMed)](https://pubmed.ncbi.nlm.nih.gov/25041740/) - [HEAL LL-37, 2021: Phase 2b trial in 148 patients (PubMed)](https://pubmed.ncbi.nlm.nih.gov/34687253/) - [FDA: upcoming Pharmacy Compounding Advisory Committee meeting](https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Mazdutide Source: https://aminodesk.com/library/mazdutide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Mazdutide is a weekly weight-loss injection approved in China in 2025. It is not FDA-approved and is not legally available in the United States. - **Legal lane:** not approved in the US. Approved in China for weight management and type 2 diabetes. - **Evidence grade:** B - **Form:** weekly injection under the skin - **US status:** in earlier-stage trials; no FDA filing yet ## What it is Mazdutide activates two hormone receptors, GLP-1 and glucagon. It was created at Eli Lilly and is developed in China by Innovent Biologics. Lilly holds the rights elsewhere. ## What the evidence shows The evidence comes from Phase 3 trials in Chinese adults. - **GLORY-1** (published in the New England Journal of Medicine, 2025): 11% average weight loss on 4 mg and 14% on 6 mg at 48 weeks. - **GLORY-2** (published in JAMA, 2026): on 9 mg, average weight loss of roughly 17% to 19% at 60 weeks, depending on how the analysis handles people who stopped treatment. These are solid, published trials, but in one population. Results in US patients are not yet known, which is why the grade is B. ## Dosing used in the trials There is no US dose. In GLORY-2, treatment started at 3 mg once a week and rose by 3 mg every four weeks, reaching the 9 mg maintenance dose at week 8. GLORY-1 tested 4 mg and 6 mg. ## Legal status China approved mazdutide for chronic weight management in June 2025 and for type 2 diabetes in September 2025. A Chinese approval does not make it legal to sell in the US. Products sold online as mazdutide are unapproved here, and the FDA named it in a 2026 warning letter to a research-peptide seller. ## Common questions ### Is mazdutide available in the US? No. China approved it in 2025 for weight management and type 2 diabetes. It is not FDA-approved, and products sold online as mazdutide are unapproved here. ### How much weight did people lose on mazdutide? In Phase 3 trials in Chinese adults, average weight loss was 11% on 4 mg and 14% on 6 mg at 48 weeks, and roughly 17% to 19% on 9 mg at 60 weeks. ### How does mazdutide work? It activates two hormone receptors, GLP-1 and glucagon. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA: Concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) - [Ji et al., 2025: GLORY-1 trial of mazdutide, New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2411528) - [Mazdutide: First Approval, 2025: summary of the China approvals (PubMed)](https://pubmed.ncbi.nlm.nih.gov/41028652/) - [Drug Topics: GLORY-2 results and dosing](https://www.drugtopics.com/view/mazdutide-shows-weight-reductions-for-patients-with-obesity) - [Pharmacally: GLORY-2 efficacy analysis](https://pharmacally.com/?p=16706) - [FDA warning letters naming mazdutide](https://glp1-us.com/news/2026-08-24-fda-warns-research-peptide-sellers/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Melanotan I (afamelanotide, Scenesse) Source: https://aminodesk.com/library/melanotan-i Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Melanotan I is the research name for afamelanotide. The FDA approved it in 2019 as Scenesse, a small implant placed under the skin by a trained clinician, for adults with a rare inherited disorder that makes sunlight painful. It is not approved for tanning. - **Legal lane:** FDA-approved for one rare condition, prescription only - **Evidence grade:** A for its approved use - **Form:** 16 mg dissolving implant inserted every 2 months - **Brand:** Scenesse ## What it is Afamelanotide is a synthetic copy of alpha-melanocyte-stimulating hormone, the signal that tells skin to make melanin. It is a different molecule from [Melanotan II](https://aminodesk.com/library/melanotan-ii), which acts on more receptors and also affects libido and appetite. ## What the evidence shows The approval rested on three placebo-controlled trials in 244 adults with erythropoietic protoporphyria (EPP), a condition where light exposure causes severe pain. People with the implant could spend more time in direct sunlight without pain than people with a dummy implant. No trial has tested afamelanotide for cosmetic tanning in people without EPP. ## Dosing on the label One 16 mg implant is inserted under the skin above the hip bone every 2 months by a healthcare professional trained in the procedure. Patients are watched for 30 minutes afterward. **No dose is established for injected Melanotan I.** The powder vials sold online are not the approved product. The implant releases the drug slowly over weeks; an injection of loose powder does not, and nobody has studied what it does. ## Side effects and warnings - Implant-site reactions were the most common, followed by nausea, throat pain, cough, fatigue, dizziness and sleepiness. - It darkens skin and existing moles. The label recommends a full-body skin check twice a year to monitor moles. ## Common questions ### Is Melanotan I approved for tanning? No. As Scenesse, it is FDA-approved only for adults with erythropoietic protoporphyria, a rare disorder that makes sunlight painful. ### Is Melanotan I the same as Melanotan II? No. They are different molecules. Melanotan II acts on more receptors and also affects libido and appetite. ### How is Scenesse given? One 16 mg implant is inserted under the skin every 2 months by a trained healthcare professional. No dose is established for injected Melanotan I powder. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA label: Scenesse (afamelanotide) implant](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210797s000lbl.pdf) - [FDA Drug Trials Snapshot: Scenesse](https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-scenesse) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Melanotan II Source: https://aminodesk.com/library/melanotan-ii Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 Melanotan II is an injectable or nasal peptide used for tanning and libido. It is not approved anywhere in the world, there is no legal way to get it in the US, and regulators in several countries have warned against it. - **Legal lane:** gray market. Not FDA-approved and not legally compounded. - **Evidence grade:** C, with serious safety signals - **Forms sold:** injection, nasal spray - **Established human dose:** none ## What it is Melanotan II is a synthetic peptide that switches on several melanocortin receptors at once. One of those receptors drives skin pigment, which produces the tan. Others affect appetite, blood pressure and sexual arousal, which is why its effects are not limited to skin. ## What the evidence shows Small human studies confirmed that it darkens skin and can cause erections, alongside nausea and flushing that limited the dose. It has never completed Phase 3 safety or effectiveness trials. What has accumulated since is case reports and regulator data: - Published case reports link use to melanoma, new and changing moles, prolonged erections, muscle breakdown and kidney injury. - Australia's drug regulator logged 89 adverse event reports and two melanoma diagnoses in 18 months, and in February 2026 placed it in the same legal schedule as heroin. - The UK regulator has warned of "serious health risks". Case reports do not prove Melanotan II causes melanoma. Skin cancer specialists still advise against it, because a changed mole or a melanoma cannot be undone when the tan fades. ## Legal status Melanotan II was removed from the FDA's restricted category in April 2026, but removal is not approval. It is not on the list of substances pharmacies may compound, and it was not part of the October 2026 policy. An FDA advisory committee is due to consider it by the end of February 2027. Until then, every product on sale is unapproved and unverified. ## Related approved drugs Two FDA-approved drugs act on the same receptor family and are sometimes confused with it. Afamelanotide (Scenesse) is approved for a rare light-sensitivity disorder. Bremelanotide (Vyleesi) is approved for low sexual desire in premenopausal women. They are different molecules, and their safety data cannot be applied to Melanotan II. ## Reported dosing **No dose has been established.** No approved dosing exists anywhere, and because there is no legal product, there is no prescriber-directed practice to report. We are not repeating forum protocols for a compound with these safety signals. ## If you have used it Have a dermatologist check your skin, and get any new or changing mole looked at promptly. ## Common questions ### Is Melanotan II legal? There is no legal way to get it in the US. It is not approved anywhere in the world and is not on the list of substances pharmacies may compound. ### Is Melanotan II safe? Published case reports link it to melanoma, new and changing moles, prolonged erections, muscle breakdown and kidney injury. Case reports do not prove it causes melanoma, but skin cancer specialists advise against it. ### Is Melanotan II the same as PT-141 or Scenesse? No. Bremelanotide (Vyleesi) and afamelanotide (Scenesse) are different, FDA-approved molecules, and their safety data cannot be applied to Melanotan II. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [GoodRx: what is Melanotan II](https://www.goodrx.com/health-topic/peptides/what-is-mt2) - [BeautyMatter: regulator reports from Australia and the UK](https://beautymatter.com/articles/fda-panel-backs-six-peptides-in-another-maha-win) - [Superpower: Melanotan II evidence and case reports](https://superpower.com/guides/peptides/melanotan-2) - [McDermott: advisory committee schedule](https://www.mcdermottlaw.com/insights/blogs/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Methylene blue Source: https://aminodesk.com/library/methylene-blue Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Methylene blue is a real prescription drug with a narrow approved use and a boxed warning. The version sold in dropper bottles for focus and energy is the same compound without the oversight. The drug interaction is the part to read. - **Legal lane:** FDA-approved for one condition, by injection. Products sold as supplements are not FDA-approved. - **Evidence grade:** A for its approved use, D for cognition and longevity - **Not a peptide:** a synthetic dye, first made in 1876 - **Boxed warning:** serotonin syndrome with serotonergic drugs and opioids ## What it is Methylene blue, or methylthioninium chloride, is a synthetic dye that became a medicine. Its FDA-approved use is intravenous treatment of methemoglobinemia, a life-threatening condition in which the blood cannot carry oxygen properly. That is the only approved indication. ## The interaction that matters most Methylene blue is a potent inhibitor of monoamine oxidase A, the enzyme that breaks down serotonin. The FDA label carries a boxed warning, the most serious warning level, stating that serious or fatal serotonin syndrome can occur when it is combined with serotonergic drugs and opioids. Named classes include SSRIs, SNRIs, MAOIs and opioids. - The documented cases and fatalities involve intravenous use, often during surgery, at doses of roughly 1 to 8 mg/kg. - Oral risk at supplement doses has not been documented, which is not the same as ruled out. Clinical references rate the interaction as high severity and possible occurrence, and advise screening before any use. - Serotonin syndrome presents as fever, muscle rigidity, tremor, confusion and rapid heart rate. It is a medical emergency. - The SSRIs named in the warning are among the most commonly prescribed drugs in the country. Someone tapering off an antidepressant still needs a washout period. Other contraindications on the clinical record: G6PD deficiency, kidney disease, liver disease and pregnancy. ## What the evidence shows for cognition - The human evidence most often cited in marketing is a single small randomized trial of about 26 participants testing one dose, which reported changes in brain activity and memory measures. - One small single-dose study does not establish that regular low-dose use improves cognition in healthy adults. - No randomized trial exists for the microdosing protocol promoted in biohacking circles. - Results in Alzheimer's disease, where related compounds have been tested more seriously, are mixed. Clinical reference services reviewing this in 2026 concluded the evidence for cognitive enhancement and anti-aging is weak and advised against these products. ## Product quality Most methylene blue sold online for cognitive use is not registered as a dietary supplement, and purity varies widely. Some is industrial grade. Aquarium-grade methylene blue, sold for fish tanks, should never be swallowed. ## Dosing The approved dose is an intravenous dose for a hospital emergency, given by clinicians. It is not a guide to anything else. No dose has been established for cognition or longevity. ## Products that publish their testing Affiliate links These links go to Amazon. We have not tested the products, and listing them is not a recommendation to take methylene blue. If you are going to buy it, a product that names its grade and publishes a certificate of analysis is a better starting point than an unlabeled dropper bottle. The testing claims below are the sellers' own. **Read the interaction section above first.** Talk to your doctor or pharmacist before use if you take an antidepressant (SSRI, SNRI or MAOI) or an opioid, have G6PD deficiency, kidney or liver disease, or are pregnant. - Nutricel methylene blue capsules, 12 mg, 60 count. Listed as USP grade. The seller says its products are tested by an outside lab and that certificates are on its website. - Bluesun methylene blue drops, 1% (10 mg per mL), 60 mL. Listed as USP grade, made in the USA and third-party tested. As an Amazon Associate, Amino Desk earns from qualifying purchases. [Affiliate disclosure](https://aminodesk.com/affiliate-disclosure). ## Common questions ### Can methylene blue be taken with antidepressants? The FDA label carries a boxed warning that serious or fatal serotonin syndrome can occur when it is combined with serotonergic drugs and opioids, including SSRIs, SNRIs and MAOIs. The documented cases involve intravenous use. Oral risk at supplement doses has not been documented, which is not the same as ruled out. ### What is methylene blue FDA-approved for? Intravenous treatment of methemoglobinemia. That is the only approved indication. ### Does methylene blue improve focus? The evidence most often cited is a single small randomized trial of about 26 participants testing one dose. That does not establish that regular low-dose use improves cognition in healthy adults. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA label: Provayblue (methylene blue) injection, 2024](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204630Orig1s023lbl.pdf) - [FDA Drug Safety Communication: serious CNS reactions when methylene blue is given with serotonergic psychiatric medications (2011)](https://www.fda.gov/Drugs/DrugSafety/ucm263190.htm) - [NatMed (Therapeutic Research): methylene blue and the nootropic trend, 2026](https://naturalmedicines.therapeuticresearch.com/Content/nm/Newsletters/August2026) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # MK-677 (ibutamoren) Source: https://aminodesk.com/library/mk-677 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending MK-677, or ibutamoren, is a pill that raises growth hormone. It is not a peptide. It has real human trials, and they are the reason for caution: a small gain in lean mass with no gain in strength, higher blood sugar, and one trial stopped early over heart failure. - **Legal lane:** not FDA-approved. On the FDA's list of substances that may present significant safety risks in compounding. - **Evidence grade:** B. Real human trials, with mixed and partly negative results. - **Form:** taken by mouth - **Sport:** prohibited at all times ## What it is Ibutamoren is a small molecule that imitates ghrelin at the receptor that triggers growth hormone release. Unlike the injectable growth hormone peptides, it works when swallowed. Merck developed it in the 1990s and stopped. Another company has since studied it for growth hormone deficiency in children. ## What the evidence shows - **Healthy older adults:** a two-year trial in 65 adults aged 60 to 81 found that 25 mg a day raised growth hormone and IGF-1 to young-adult levels. After 12 months, fat-free mass was up 1.1 kg against a 0.5 kg loss on placebo. Strength and physical function did not improve, and fasting blood sugar rose. - **Hip fracture recovery:** a trial in 123 older patients was stopped early because of a heart failure signal, reported as about 6.5% of patients on the drug against 1.7% on placebo. The authors concluded it had an unfavorable safety profile in that group, and most measures of function did not improve. - **Alzheimer's disease:** a large trial did not slow the disease. The pattern across the trials is consistent: the hormone numbers move, and the outcomes people care about mostly do not. ## Legal status - MK-677 is not FDA-approved for any use. - The FDA lists ibutamoren among bulk substances that may present significant safety risks in compounding, citing the heart failure finding. It is not eligible for routine pharmacy compounding. - It is not a dietary supplement ingredient, although it is sold online as one and as a "research chemical". ## Reported dosing **No approved dose exists.** The dose used in the main trials was 25 mg once a day by mouth, in monitored studies of older adults and patients. That is what was tested. It is not a recommendation, and the hip fracture trial at that dose was the one stopped for safety. ## Safety - **Heart failure:** the signal that stopped the hip fracture trial. Most relevant to older people and anyone with heart disease. - **Blood sugar:** fasting glucose rose in trials, and insulin sensitivity fell. - **Common effects in trials:** increased appetite, swelling in the legs and muscle aches. - **Long-term safety:** not established. - **Quality:** products sold online have no verified contents. ## Common questions ### Is MK-677 a peptide? No. It is a small-molecule drug taken by mouth. It is sold alongside peptides because it raises growth hormone. ### Is MK-677 legal? It is not FDA-approved, and the FDA lists it among substances that may present significant safety risks in compounding. ### Does MK-677 build muscle? In the main trial, fat-free mass rose by 1.1 kg over 12 months, but strength and physical function did not improve. ### Why was an MK-677 trial stopped? A trial in hip fracture patients was ended early because of a heart failure signal in patients taking the drug. ## Sources - [Nass et al., 2008: two-year trial of MK-677 in healthy older adults, Annals of Internal Medicine (PubMed)](https://pubmed.ncbi.nlm.nih.gov/18981485/) - [Adunsky et al., 2011: MK-0677 in patients recovering from hip fracture, Phase 2b (PubMed)](https://pubmed.ncbi.nlm.nih.gov/21067829/) - [Tel Aviv University record of the hip fracture trial: early termination for a heart failure signal](https://cris.tau.ac.il/en/publications/mk-0677-ibutamoren-mesylate-for-the-treatment-of-patients-recover/) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [Superpower: summary of the MK-677 trials, including the Alzheimer's trial and anti-doping status](https://superpower.com/guides/peptides/mk-677-ibutamoren) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # MOTS-c Source: https://aminodesk.com/library/mots-c Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 MOTS-c is a peptide your own mitochondria make. Synthetic versions are promoted for metabolism, exercise and longevity. As of 2026, no completed study had given the drug itself to people. - **Legal lane:** compounded on prescription under the October 2026 interim policy. Not FDA-approved. - **Evidence grade:** D - **Form covered by the policy:** MOTS-c acetate as an injection under the skin or into muscle - **Established human dose:** none ## What it is MOTS-c is a short peptide encoded in mitochondrial DNA, first described in 2015. Levels in the body rise with exercise and appear to fall with age. A manufactured MOTS-c product is not the same thing as the peptide your body makes: dose, purity and route all change how the body responds. ## What the evidence shows In cells and mice, MOTS-c changed how glucose is used and reduced fat gain. In people, the FDA's 2026 review found no completed studies in which anyone received a MOTS-c drug. The closest human data comes from a related but different molecule, CB4211, tested in a small early study of people with obesity and fatty liver disease. That program was discontinued. A first controlled trial of MOTS-c itself, in people with prediabetes, is reported to be recruiting. The July 2026 advisory committee considered MOTS-c for obesity and osteoporosis and recommended it. FDA scientists had recommended against, noting that no studies had examined how effects change with dose. ## Legal status MOTS-c left the FDA's restricted category in April 2026 and is covered by the HHS interim policy published October 30, 2026, which allows state-licensed pharmacies to compound it on an individual prescription. The policy is not approval and can be revised. ## Reported dosing **No dose has been established in human trials.** MOTS-c has no standardized clinical dose. Protocols shared online use different amounts, schedules and cycle lengths, usually without saying what they are based on. We have not found one that traces to a human study of MOTS-c, so we are not repeating a figure. The related compound CB4211 was given daily for four weeks in its early study, but it is a different molecule and that regimen is not a guide for MOTS-c. ## Safety - Human safety data is the largest gap. Long-term effects are unknown. - Reviewers have raised concerns about impurities, clumping of the peptide and unwanted immune reactions in compounded products. ## What it costs One listing we saw put cash prices at compounding pharmacies at $200 to $500 a month. That figure predates the October policy. ## Common questions ### Has MOTS-c been tested in humans? The FDA's 2026 review found no completed studies in which anyone received a MOTS-c drug. A first controlled trial, in people with prediabetes, is reported to be recruiting. ### Is MOTS-c legal? State-licensed pharmacies may compound it on an individual prescription under the HHS interim policy published October 30, 2026. The policy is not approval and can be revised. ### What is the usual MOTS-c dose? There is no standardized clinical dose. Protocols shared online differ from each other, and we have not found one that traces to a human study of MOTS-c. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (agenda and briefing documents)](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [HHS: 503A peptide enforcement discretion policy (PDF)](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [Public Citizen testimony to the FDA advisory committee, July 2026](https://www.citizen.org/article/testimony-before-the-food-and-drug-administrations-pharmacy-compounding-advisory-committee-regarding-placing-mots-c-on-the-503a-bulks-list-no-human-studies-or-proven-benefits-but-possible-r/) - [Rite Aid: MOTS-c status, FDA review and the recruiting trial](https://riteaid.com/peptides/mots-c) - [HealingMaps: uses under review and cost](https://healingmaps.com/mots-c-mitochondrial-peptide-obesity-osteoporosis/) - [GoodRx: FDA developments on peptides](https://www.goodrx.com/health-topic/peptides/what-peptides-are-fda-approved) (policy forms and routes; committee votes) This compound appears in widely promoted weight-loss stacks alongside the others. No trial has tested those combinations; see [blends and stacks](https://aminodesk.com/stacks). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # N-acetyl Selank amidate Source: https://aminodesk.com/library/n-acetyl-selank Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending N-acetyl Selank amidate is [Selank](https://aminodesk.com/library/selank) with a chemical cap on each end, added so the peptide resists breakdown. It is sold as a stronger anti-anxiety peptide. The modified version has not been studied in people. - **Legal lane:** not FDA-approved. Sold as a research chemical. - **Evidence grade:** D for this modified version - **Form:** nasal spray as sold - **Established human dose:** none ## What it is Selank is a seven-amino-acid peptide developed in Russia from a natural immune peptide. This version adds an acetyl group at one end and an amide at the other to slow its breakdown. ## What the evidence shows The claims on seller pages, that the modified version is more potent, lasts longer and reaches the brain better, are not backed by a human study. A clinical education source notes that the existing evidence is about Selank as studied and registered, not about this molecule. Selank's own human evidence is limited to small, mostly Russian studies, often run by the institutions that developed it. ## Legal status - Not FDA-approved for any use. - Not one of the six peptides in the October 2026 compounding policy. Our [Selank](https://aminodesk.com/library/selank) page covers the parent peptide's status. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established for this modified version. Dosing on seller pages is borrowed from the parent peptide or invented. ## Safety - A modification made to change how long a peptide lasts and how much reaches the brain also changes its risks. Those have not been measured. - No human safety data exists for the modified version. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### Is N-acetyl Selank amidate stronger than Selank? Sellers say so. No human study has tested it. ### Has N-acetyl Selank amidate been studied in humans? No. The human studies are of unmodified Selank. ### Is it FDA-approved? No. ## Sources - [Empire Medical Training: N-acetyl Semax and Selank amidate, what the modifications do](https://www.empiremedicaltraining.com/antiaging-regenerative-workshops/resources/peptide-therapy/n-acetyl-semax-selank-amidate/) - [Superpower: Semax and Selank, quality of the human evidence](https://superpower.com/guides/semax) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # N-acetyl Semax amidate Source: https://aminodesk.com/library/n-acetyl-semax Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending N-acetyl Semax amidate is [Semax](https://aminodesk.com/library/semax) with a chemical cap on each end, added so the peptide resists breakdown. It is sold as a stronger, longer-lasting Semax. The modified version has not been studied in people. - **Legal lane:** not FDA-approved. Sold as a research chemical. - **Evidence grade:** D for this modified version - **Form:** nasal spray as sold - **Established human dose:** none ## What it is Semax is a seven-amino-acid peptide registered in Russia. This version adds an acetyl group at one end and an amide at the other. Both changes block the enzymes that normally break the peptide down within minutes. ## What the evidence shows Whatever the Semax studies show, they are studies of unmodified Semax. A clinical education source puts the problem plainly: claiming the molecule behaves differently while claiming the original evidence applies unchanged is inconsistent. One guide reports that the modified version has no clinical studies, and that a laboratory study found acetylation removed one of Semax's protective mechanisms. Semax's own human evidence is small, mostly Russian studies that have not been independently repeated. ## Legal status - Not FDA-approved for any use. - The October 2026 compounding policy names Semax. We have found nothing that extends it to a chemically modified version. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established for this modified version. Dosing on seller pages is borrowed from the parent peptide or invented. ## Safety - A modification made to change how long a peptide lasts and how much reaches the brain also changes its risks. Those have not been measured. - No human safety data exists for the modified version. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### Is N-acetyl Semax amidate stronger than Semax? It is designed to last longer. Nobody has tested whether that makes it work better in people. ### Has N-acetyl Semax amidate been studied in humans? No. The human studies are of unmodified Semax. ### Is it covered by the 2026 compounding policy? The policy names Semax. We have found nothing that extends it to the modified version. ## Sources - [Empire Medical Training: N-acetyl Semax and Selank amidate, what the modifications do](https://www.empiremedicaltraining.com/antiaging-regenerative-workshops/resources/peptide-therapy/n-acetyl-semax-selank-amidate/) - [Peptide Playbook: no clinical studies of the modified version](https://peptideplaybook.pages.dev/blog/semax-complete-guide) - [Superpower: Semax and Selank, quality of the human evidence](https://superpower.com/guides/semax) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # NAD+ Source: https://aminodesk.com/library/nad Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending NAD+ is not a peptide, but it is sold alongside them as an injection or nasal spray for energy and aging. The human research is mostly on oral supplements that raise NAD+. For injected NAD+ itself, controlled outcome trials are missing. - **Legal lane:** long-standing compounded prescription. Not FDA-approved. - **Evidence grade:** D for injected NAD+ - **Forms sold:** injection under the skin, intravenous infusion, nasal spray - **Typical cost:** roughly $150 to $500 a month ## What it is NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that every cell uses to turn food into energy. That basic biology is not in dispute. The open question is whether adding more does anything useful. ## What the evidence shows Most human trials use oral precursors, mainly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). These reliably raise NAD+ in the blood. Whether that improves how people feel or function is another matter: a recent review found mixed results, with small benefits on some measures and no clear effect on physical performance, insulin sensitivity or sleep. Telehealth companies sell something different: NAD+ itself, by injection or nasal spray. The same review found no eligible controlled outcome trials of intravenous, intramuscular or under-the-skin NAD+ for anti-aging or wellness. The route with the most hype has the least evidence. ## Legal status There is no FDA-approved NAD+ drug. Injected and nasal NAD+ are compounded medications that require a prescription. NMN and NR are sold separately as dietary supplements. ## Reported dosing There is no standardized protocol for injected NAD+. Providers set their own doses and schedules, and we have not found one supported by a controlled human trial. The prescription sets the dose. ## Safety - Because every injected NAD+ product is compounded, quality varies by pharmacy. - In 2025 the FDA announced a Class I recall, its most serious category, of one manufacturer's NAD+ for injection after endotoxins were detected. ## What it costs Listings we have seen run from about $150 to $500 a month for injections, depending on the provider. Clinic infusions are priced per session, commonly $250 to $750. ## Oral products on Amazon Affiliate links These links go to Amazon. We have not tested the products ourselves. We chose ones where an outside party has checked what is in the bottle. They are dietary supplements taken by mouth, not the injected NAD+ described above, and as the evidence section says, results in people are mixed. - Tru Niagen, nicotinamide riboside (NR) 300 mg, 30 capsules. NR is one of the two precursors used in most human trials. The maker says it is NSF Certified for Sport. - Double Wood NAD+ 500 mg, 60 capsules. Contained its labeled amount of NAD+ in an independent 2025 test by SuppCo. - Rho Nutrition Liposomal NAD+ liquid. Passed the same SuppCo test, the only product labeled liposomal that did. In that test, half of the ten popular NAD+ products checked held little or none of what the label claimed ([SuppCo report](https://supp.co/articles/suppco-tested-nad-supplement-testing-report-failures-revealed)). One tested batch does not guarantee the next. Ask your doctor or pharmacist before adding a supplement if you take prescription medication. As an Amazon Associate, Amino Desk earns from qualifying purchases. [Affiliate disclosure](https://aminodesk.com/affiliate-disclosure). ## Common questions ### Do NAD+ injections work? A recent review found no eligible controlled outcome trials of intravenous, intramuscular or under-the-skin NAD+ for anti-aging or wellness. Most human trials use oral precursors, NR and NMN. ### Is NAD+ a peptide? No. It is a coenzyme that every cell uses to turn food into energy. It is sold alongside peptides. ### Is injectable NAD+ FDA-approved? No. There is no FDA-approved NAD+ drug. Injected and nasal NAD+ are compounded medications that require a prescription. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Reyna et al. 2026: intravenous NAD+ versus nicotinamide riboside, retrospective tolerability pilot study](https://pubmed.ncbi.nlm.nih.gov/41704678/) - [Trammell et al. 2016: nicotinamide riboside is orally bioavailable in mice and humans (oral precursor, not injected NAD+)](https://pubmed.ncbi.nlm.nih.gov/27721479/) - [Science-Based Medicine: the evidence for NAD+ infusions and the 2025 recall](https://sciencebasedmedicine.org/science-vs-hype-the-unproven-promise-of-nad-iv-therapy/) - [HealingMaps: what the NAD+ trials did and did not show](https://healingmaps.com/is-nad-therapy-legit/) - [Testing.com: NAD+ injections, evidence by claim](https://www.testing.com/?p=47220) - [FormBlends: NAD+ routes and cost](https://www.formblends.com/peptides/nad-plus) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Oxytocin Source: https://aminodesk.com/library/oxytocin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Oxytocin is a natural peptide hormone. As an injection it is an FDA-approved hospital drug for labor. As a nasal spray, the form sold for bonding, mood and sex, it is not approved for any use, and the largest trial of it found no benefit. - **Legal lane:** the injection is FDA-approved for use in labor. The nasal spray is not approved and is made by compounding pharmacies. - **Evidence grade:** B for the nasal spray: a large, well-run trial, and it was negative. A for the approved hospital use. - **Forms:** intravenous infusion in hospital; compounded nasal spray - **Established dose for nasal use:** none ## What it is Oxytocin is made in the brain and released during labor, breastfeeding and social contact. It is often called the bonding hormone. That reputation, built on animal studies and small human experiments, is what drives sales of the nasal spray. ## What the evidence shows The best test of the nasal spray was a trial in autism published in the New England Journal of Medicine in October 2021. It enrolled 290 children and adolescents aged 3 to 17 and gave daily nasal oxytocin or placebo for 24 weeks. There was no significant difference in social functioning, and the secondary measures generally did not differ either. Side effects were similar in the two groups. Earlier, smaller studies had been mixed, and some clinicians were already prescribing it off-label. The journal's accompanying editorial said the results did not support that use. For the adult uses it is sold for, such as bonding, anxiety and sexual function, we found no trial of comparable quality. ## Legal status - **Approved:** intravenous oxytocin for inducing labor, given in hospital. - **Not approved:** nasal oxytocin, for any use. It is not sold commercially in the US. It reaches patients when a pharmacy compounds it on prescription. ## Reported dosing **No dose has been established for nasal oxytocin.** The approved drug is given by infusion in hospital and adjusted minute by minute by staff. Nothing about that carries over to a nasal spray used at home, and no label exists for the spray. ## Safety - In the 24-week trial, side effects on nasal oxytocin were similar to placebo. - Long-term effects of regular use have not been established. - Oxytocin acts on the uterus. Anyone who is pregnant should not use it outside medical care. - Compounded sprays vary by pharmacy in strength and quality. ## Common questions ### Is oxytocin nasal spray FDA-approved? No. Only the intravenous form is approved, for inducing labor. The nasal spray is compounded and not approved for any use. ### Does oxytocin nasal spray work? In the largest trial, 290 children and adolescents with autism over 24 weeks, it did no better than placebo on social functioning. ### Is nasal oxytocin safe? Side effects matched placebo over 24 weeks in that trial. Long-term safety is not established. ## Sources - [Duke Center for Autism: largest study of its kind finds oxytocin safe but ineffective (NEJM, October 14, 2021)](https://autismcenter.duke.edu/news/largest-study-its-kind-finds-oxytocin-safe-ineffective) - [Sikich et al., 2021: trial abstract, design and conclusions](https://digitalcommons.fiu.edu/all_faculty/314) - [Reuters Health: 290-patient trial and the accompanying editorial](https://conferences.medicom-publishers.com/specialisation/neurology/nasal-oxytocin-fails-in-large-double-blind-test-as-treatment-for-autism/) - [The Hospitalist: approval status of intravenous and intranasal oxytocin](https://blogs.the-hospitalist.org/content/intranasal-oxytocin-autism-promising-then-came-data) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # P21 (P021) Source: https://aminodesk.com/library/p21 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending P21, also written P021, is a small designed compound based on a nerve growth factor called CNTF. It is sold as a brain-repair and memory peptide. All of its evidence is in mice. - **Legal lane:** not FDA-approved. Sold as a research chemical. - **Evidence grade:** D - **Form:** injection or nasal spray as sold - **Established human dose:** none ## What it is Researchers took the active fragment of CNTF, shortened it to four amino acids, and attached a carbon cage called adamantane to help it reach the brain. Sellers often describe it as a fragment of [Cerebrolysin](https://aminodesk.com/library/cerebrolysin). It is a separate designed compound. It is also unrelated to the cell-cycle protein called p21. ## What the evidence shows In mice, including models of Alzheimer's disease, it raised a brain growth factor, increased the birth of new neurons and reduced tau pathology. Those results come almost entirely from the inventor's group, whose lead scientist co-founded the company commercializing it. One independent assessment reports that the single outside attempt to reproduce the growth-factor effect in animals failed. No human trial exists. ## Legal status - Not FDA-approved for any use. - Not one of the six peptides in the October 2026 compounding policy. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established in people. ## Safety - No human safety data exists. - Earlier trials of full-length CNTF in people ran into side effects. Whether a fragment avoids them has not been tested in humans. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### Is P21 the same as Cerebrolysin? No. It is a designed fragment of the growth factor CNTF, often marketed alongside Cerebrolysin. ### Has P21 been tested in humans? No. All of the evidence is from mice and cells. ### Is P21 the same as the p21 protein? No. They share a label and nothing else. ## Sources - [Outliyr: P21 (P021) evidence assessment](https://outliyr.com/reports/p21/) - [Outliyr: Cerebrolysin and P21 compared](https://outliyr.com/comparisons/cerebrolysin-vs-p21) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # PE-22-28 Source: https://aminodesk.com/library/pe-22-28 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending PE-22-28 is a seven-amino-acid peptide sold as a mood and focus compound. It was designed by French researchers as an improved version of a natural peptide called spadin. All of the evidence is in rodents. - **Legal lane:** not FDA-approved. Sold as a research chemical. - **Evidence grade:** D - **Form:** nasal spray or injection as sold - **Established human dose:** none ## What it is A shortened analog of spadin. It blocks a potassium channel in nerve cells called TREK-1, which makes those cells more responsive. In laboratory tests it blocked the channel far more strongly than spadin and lasted longer in the body. ## What the evidence shows The 2017 paper that introduced it reported antidepressant-like behavior in mice and signs of new nerve cell growth. The authors called it a promising alternative to spadin for treating depression. No human trial of PE-22-28 or of spadin has been completed or registered, according to a clinical summary last updated in September 2026. ## Legal status - Not FDA-approved for any use. - Not one of the six peptides in the October 2026 compounding policy. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established in people. ## Safety - The channel it blocks is also found in the heart, pancreas and gut. The effects of blocking it throughout the body are uncharacterized. - Depression is treatable with therapies that have been tested. An untested research chemical is not a safe substitute, and stopping a prescribed antidepressant to try one is risky. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### Has PE-22-28 been tested in humans? No. The evidence is from rodents. ### What does PE-22-28 do? It blocks the TREK-1 potassium channel, which produced antidepressant-like effects in mice. ### Is PE-22-28 legal? It is not FDA-approved and is sold only as a research chemical. ## Sources - [Djillani et al., 2017: shortened spadin analogs, TREK-1 inhibition and antidepressant activity (PubMed)](https://pubmed.ncbi.nlm.nih.gov/28955242/) - [Superpower: PE-22-28 research stage and status](https://superpower.com/guides/peptide-science/pe-22-28) - [Outliyr: PE-22-28 assessment and off-target concerns](https://outliyr.com/health-optimization-index/pe-22-28) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # PEG-MGF (mechano growth factor) Source: https://aminodesk.com/library/peg-mgf Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending PEG-MGF is a modified, longer-lasting version of mechano growth factor, a form of IGF-1 that muscle makes after hard exercise. It is sold for muscle repair and growth. No human trial of the injected product has been published. - **Legal lane:** not FDA-approved. Not on the list of substances pharmacies may compound. Sold as a research chemical. - **Evidence grade:** D - **Form:** injection - **Sport:** prohibited at all times ## What it is Mechano growth factor, or MGF, is a variant of IGF-1 produced inside muscle in response to load and damage. The natural peptide breaks down within minutes. PEG-MGF has a polyethylene glycol chain attached to make it last longer. It is a growth factor analog, in the same family as [IGF-1 LR3](https://aminodesk.com/library/igf-1-lr3). ## What the evidence shows The evidence is from cells and animals. In human muscle-cell cultures, the MGF peptide increased the activation of muscle stem cells. The strongest human finding is an observation, not a treatment trial: a 2003 biopsy study found that one bout of leg exercise raised MGF activity in eight men aged 25 to 36 but not in seven men aged 70 to 82. That shows the body makes it. It says nothing about injecting a synthetic version. No controlled human trial has tested injected MGF or PEG-MGF for muscle, repair or anything else, and no human dose, absorption or safety data exists. ## Legal status - Not FDA-approved for any use. - Not on the FDA's list of bulk substances pharmacies may compound, according to the summaries we read. - Some clinics describe a regulatory change in April 2026 as FDA clearance. One medical training organization that reviewed it calls that description inaccurate. - Prohibited by the World Anti-Doping Agency in and out of competition. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established in people, because no human study of the injected product exists. The schedules that circulate come from bodybuilding forums and sellers. ## Safety - It acts on growth-factor pathways. The approved IGF-1 drug carries warnings about low blood sugar and about use in people with cancer, and nobody has checked whether those apply here. - The attached PEG chain makes exposure long-lasting, and its effects with repeated injection are unstudied. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### Has PEG-MGF been tested in people? No. There are no published human trials of the injected product. ### Is PEG-MGF legal? It is not FDA-approved and is not eligible for pharmacy compounding. It is sold as a research chemical. ### Does PEG-MGF build muscle? That has only been studied in cells and animals. ## Sources - [Superpower: mechano growth factor, including the 2003 biopsy study](https://superpower.com/guides/mgf-mechano-growth-factor) - [Superpower: cell studies and the limits of the evidence](https://superpower.com/guides/peptides/mechano-growth-factor) - [PeptideGrids: no human trials, compounding status](https://peptidegrids.pages.dev/compound/peg-mgf/) - [Empire Medical Training: the April 2026 change and why it is not FDA clearance](https://www.empiremedicaltraining.com/antiaging-regenerative-workshops/resources/peptide-therapy/peg-mgf/) - [Rite Aid: PEG-MGF status and anti-doping position](https://riteaid.com/peptides/peg-mgf) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Pentosan polysulfate (Elmiron) Source: https://aminodesk.com/library/pentosan-polysulfate Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Pentosan polysulfate is a heparin-like drug, not a peptide. As a capsule it is FDA-approved for one thing, bladder pain from interstitial cystitis. Some clinics sell it as an injection for joints. No injectable form is approved in the US. - **Legal lane:** the capsule is FDA-approved, prescription only. Injections are not approved. - **Evidence grade:** A for the approved bladder use. We have not graded the joint injections. - **Form:** capsule by mouth - **Brand:** Elmiron ## What it is Pentosan polysulfate sodium is a semi-synthetic compound related to heparin, with mild blood-thinning effects. How it eases bladder pain is not known. One idea is that it coats the bladder lining. Only about 6% of a dose taken by mouth reaches the bloodstream. ## What the evidence shows The approval rests on two studies in interstitial cystitis: a three-month placebo-controlled trial of 100 mg three times a day, and a long-term study of 2,499 patients without a comparison group. For joint pain, the use that puts it on peptide clinic menus, we have not reviewed the trial evidence and do not grade it here. What we can say is that no injectable product has been approved for it in the US. ## Legal status - FDA-approved as Elmiron capsules for the relief of bladder pain or discomfort associated with interstitial cystitis. - No injectable pentosan polysulfate is FDA-approved. An injection offered by a clinic is a compounded or imported product. ## Label dosing The label dose is 100 mg by mouth three times a day, taken with water at least an hour before or two hours after meals. Patients are reassessed after three months and may continue for another three if there is no improvement and no limiting side effect. There is no label dose for injection. ## Safety - **Eyes:** the label warns of pigment changes in the retina, called pigmentary maculopathy, found with long-term use. It can affect vision. Anyone taking it for a long period should ask about eye checks. - **Bleeding:** it is a weak blood thinner. The label advises care in people with conditions or medicines that raise bleeding risk. - **Injections:** an unapproved injectable has no label, so the dose, purity and sterility depend on the supplier. ## Common questions ### Is pentosan polysulfate a peptide? No. It is a heparin-like compound. ### What is it approved for? Bladder pain or discomfort from interstitial cystitis, as a capsule. ### Are pentosan injections approved? No. No injectable form is FDA-approved. ### What is the eye warning? The label warns of pigment changes in the retina with long-term use, which can affect vision. ## Sources - [Elmiron prescribing information](https://www.drugs.com/pro/elmiron.html) - [PrescriberPoint: Elmiron dosage and trial populations](https://prescriberpoint.com/therapies/elmiron-f0ba651) - [Elmiron label: indication and retinal pigmentary changes warning](https://www.regdatalab.com/drug/pentosan-polysulfate-sodium) - [Australian TGA safety alert: pigmentary maculopathy](https://www.tga.gov.au/news/safety-alerts/pentosan-polysulfate-sodium-elmiron) - [Drugs.com monograph: three-month reassessment and bleeding precautions](https://www.drugs.com/monograph/elmiron.html) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Pinealon Source: https://aminodesk.com/library/pinealon Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Pinealon is a synthetic three-amino-acid peptide (glutamate, aspartate, arginine, often written EDR) from Vladimir Khavinson's institute in St. Petersburg. It is sold for brain health and memory. There are no controlled human trials of it. - **Legal lane:** research chemical. No approval and no US compounding route. - **Evidence grade:** D - **Human trials:** no randomized controlled trials - **Related to:** [Epitalon](https://aminodesk.com/library/epitalon), from the same research group ## What it is Pinealon belongs to the "peptide bioregulators" developed by Khavinson's group, who propose that very short peptides enter cells and adjust which genes are switched on. That idea comes almost entirely from their own laboratory and has not been taken up by mainstream pharmacology. ## What the evidence shows The published work is in cell cultures and rodents, where the group reports less oxidative stress and better survival in nerve cells. Reviews by the same group describe Russian studies in elderly people and in people recovering from brain injury, but those were small, uncontrolled and not independently replicated. ## Dosing **No dose established.** There is no controlled human study to take a dose from, and the injectable regimens sold online did not come from one. ## Safety Unknown. No safety study in people has been published, and research-grade vials carry the usual risks of unverified content and sterility. ## Common questions ### Has Pinealon been tested in humans? There are no randomized controlled trials. The Russian studies described by its developers were small, uncontrolled and not independently replicated. ### Is Pinealon related to Epitalon? Yes. Both come from the same research group, Vladimir Khavinson's institute in St. Petersburg. ### What is the usual Pinealon dose? No dose has been established. There is no controlled human study to take one from. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Khavinson et al. 2020: EDR peptide and gene expression, review in Molecules (PubMed)](https://pubmed.ncbi.nlm.nih.gov/33396470/) - [Ilina et al. 2022: proposed mechanisms of ultrashort peptides (PubMed)](https://pubmed.ncbi.nlm.nih.gov/35457077/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # PNC-27 Source: https://aminodesk.com/library/pnc-27 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending PNC-27 is a peptide that has been sold online as a treatment or cure for cancer. The FDA has warned consumers not to buy or use it. It has not been tested in patients, and the agency found bacteria in samples. - **Legal lane:** not FDA-approved. Subject of an FDA consumer warning. - **Evidence grade:** D - **Sold as:** inhaled solution, intravenous solution and suppositories - **Established human dose:** none ## What it is A synthetic peptide designed to bind a protein found on cancer cells. In small laboratory studies it killed tumor cells in a dish. Sellers describe it as a nontoxic cure for any cancer. ## What the evidence shows The evidence is cell studies. The FDA says it has not evaluated or approved PNC-27 as safe and effective for any disease, including any form of cancer. We found no clinical trial in patients. ## Legal status - In January 2017 the FDA warned consumers not to purchase or use PNC-27. - An FDA laboratory found the bacteria Variovorax paradoxus in a sample of the inhaled solution. A second sample, tested in March 2017, contained Ralstonia insidiosa. - It is not approved for any use and cannot be lawfully sold as a treatment. ## Reported dosing **We do not publish dosing for this compound.** No dose has been established, and the FDA advises against using it at all. ## Safety - A contaminated product can cause serious, potentially life-threatening infection. People with cancer often have weakened immune systems, which raises that risk. - The larger danger is delay. Choosing an untested product over treatment that works can cost the chance of a cure. - The FDA recommends that anyone who has used it and has concerns contact a health care provider. ## Common questions ### Does PNC-27 cure cancer? There is no clinical evidence that it does. It has only been studied in cells. ### What did the FDA say about PNC-27? In 2017 it warned consumers not to buy or use it, after finding bacteria in samples. ### Is PNC-27 FDA-approved? No. ## Sources - [FDA: warning to cancer patients not to use PNC-27 products](https://www.fda.gov:443/Drugs/DrugSafety/ucm536094.htm) - [Pharmacy Times: FDA warning over unapproved cancer cure](https://www.pharmacytimes.com/view/fda-issues-warning-over-unapproved-cancer-cure) - [Cure Today: FDA warns against so-called cancer cure](https://curetoday.com/view/fda-warns-against-socalled-cancer-cure) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Progesterone Source: https://aminodesk.com/library/progesterone Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Progesterone is a hormone, not a peptide. It appears on peptide clinic menus as part of hormone therapy. The capsule form is FDA-approved for two specific uses in women, and its label carries a boxed warning that applies when it is taken with estrogen. - **Legal lane:** FDA-approved, prescription only - **Evidence grade:** A for its approved uses - **Forms:** capsules by mouth; also made as injections in oil and vaginal products - **Brand:** Prometrium, and generics ## What it is Progesterone is one of the two main female sex hormones. The capsules contain micronized progesterone made from a plant source that is chemically identical to the progesterone the ovaries produce. ## What the evidence shows The approved uses rest on controlled trials reported in the label. The main one is protective: estrogen taken alone after menopause can cause the lining of the uterus to overgrow, and adding progesterone prevents that. Clinics also promote progesterone for sleep, mood and general wellbeing. Those are not approved uses, and this page does not grade them. ## Legal status - **Approved use 1:** preventing overgrowth of the uterine lining in postmenopausal women with a uterus who are taking conjugated estrogens. - **Approved use 2:** secondary amenorrhea, meaning periods that have stopped. - Prescription only. It is not a controlled substance. ## Label dosing - **With estrogen after menopause:** 200 mg by mouth once a day at bedtime, for 12 days in a row in each 28-day cycle. - **Secondary amenorrhea:** 400 mg once a day at bedtime for 10 days. Those are the capsule label's schedules. Other forms have their own labels. The dose on your prescription is the one to follow. ## Safety - **Boxed warning:** estrogen plus progestin therapy carries warnings about cardiovascular disorders, breast cancer and probable dementia. The label says to use the lowest effective dose for the shortest time that fits the goals of treatment. - **Peanut allergy:** the capsules contain peanut oil and must not be used by anyone allergic to peanuts. - **Not for use with:** unexplained vaginal bleeding, or a current or past cancer of the breast or uterus without a clinician's advice. - **Drowsiness and dizziness:** among the effects reported in trials, which is why it is taken at bedtime. ## Common questions ### Is progesterone a peptide? No. It is a steroid hormone. Peptide clinics offer it as part of hormone therapy. ### What is progesterone approved for? The capsules are approved to prevent overgrowth of the uterine lining in postmenopausal women taking estrogen, and to treat periods that have stopped. ### What is the label dose? 200 mg at bedtime for 12 days of each 28-day cycle with estrogen, or 400 mg at bedtime for 10 days for absent periods. ### Who should not take the capsules? Anyone allergic to peanuts, because the capsules contain peanut oil. ## Sources - [Prometrium prescribing information: indications and contraindications](https://prescriberpoint.com/therapies/prometrium-1cf237f) - [Progesterone capsules prescribing information: dosage and boxed warning](https://prescriberpoint.com/therapies/progesterone-7d73f08) - [RxList: Prometrium description and warnings](https://www.rxlist.com/prometrium-side-effects-drug-center.htm) - [Drugs.com: Prometrium consumer information](https://www.drugs.com/cdi/prometrium.html) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # PT-141 (bremelanotide, Vyleesi) Source: https://aminodesk.com/library/pt-141 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending PT-141 is the research name for bremelanotide, which the FDA approved in 2019 as Vyleesi. The approval is narrow: low sexual desire in premenopausal women. It is not approved for men, for postmenopausal women, or to improve sexual performance. - **Legal lane:** FDA-approved, prescription only - **Evidence grade:** A for its approved use - **Form:** single-dose autoinjector, used as needed - **Brand:** Vyleesi ## What it is Bremelanotide activates melanocortin receptors in the brain, the same receptor family that [Melanotan II](https://aminodesk.com/library/melanotan-ii) acts on. It was developed from that line of research, which is why it shares some of the same side effects, including skin darkening. ## What the evidence shows Approval rested on two identical Phase 3 trials, called RECONNECT, in about 1,250 premenopausal women with acquired low sexual desire. Over 24 weeks, bremelanotide improved desire scores and reduced distress about low desire compared with placebo, and a 52-week open-label extension found the improvement held. The effect was measured on questionnaires. An editorial published alongside the trials noted that the studies did not show an increase in the number of sexual events. ## Dosing on the label - 1.75 mg injected under the skin of the abdomen or thigh, as needed, at least 45 minutes before expected sexual activity. - No more than one dose in 24 hours. - No more than 8 doses a month. - Stop after 8 weeks if there is no improvement. The vials of "PT-141" sold online are the same molecule in unregulated powder form. Their purity and content are unverified, and nothing about men or daily use has been established by the trials above. ## Side effects and warnings - **Nausea** is the most common side effect and the main reason people stopped in trials, usually after the first dose. Flushing and headache were also common. - **Blood pressure:** each dose raises blood pressure and lowers heart rate for several hours, usually back to normal within 12 hours. It is contraindicated with uncontrolled high blood pressure or known heart disease. - **Skin darkening:** patches of darker skin on the face, gums or breasts appeared in 1% of trial patients at up to 8 doses a month, and in 38% of people in a study of daily dosing for 8 days. It did not always fade after stopping. - **Naltrexone:** it can sharply reduce absorption of oral naltrexone, which matters for anyone taking it for alcohol or opioid addiction. ## Common questions ### What is PT-141 approved for? As Vyleesi, it is FDA-approved for low sexual desire in premenopausal women. It is not approved for men or for postmenopausal women. ### What is the Vyleesi dose? The label dose is 1.75 mg injected under the skin as needed, at least 45 minutes before expected sexual activity. The limits are one dose in 24 hours and 8 doses a month. ### What are the side effects of PT-141? Nausea is the most common, along with flushing and headache. Each dose raises blood pressure for several hours, and patches of darker skin appeared in 1% of trial patients. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA label: Vyleesi (bremelanotide), 2019](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) - [Kingsberg et al. 2019: the two RECONNECT Phase 3 trials, Obstetrics & Gynecology (PubMed)](https://pubmed.ncbi.nlm.nih.gov/31599840/) - [Simon et al. 2019: 52-week open-label extension (PubMed)](https://pubmed.ncbi.nlm.nih.gov/31599847/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # PT-141 + oxytocin blend Source: https://aminodesk.com/library/pt-141-oxytocin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending This blend combines PT-141 and oxytocin in one product. It is sold for desire and intimacy. Both ingredients are in FDA-approved drugs, but the combination has no trial behind it and no label. - **Legal lane:** each ingredient is in an FDA-approved drug. The combination is a compounded product that the FDA has not reviewed. - **Evidence grade:** D for the combination - **What is in it:** PT-141 and oxytocin - **Established human dose:** none ## What it is A premixed product sold by peptide suppliers and some clinics. The ingredients: - **[PT-141](https://aminodesk.com/library/pt-141):** bremelanotide, the active ingredient of an FDA-approved drug for low sexual desire in premenopausal women. - **[oxytocin](https://aminodesk.com/library/oxytocin):** an FDA-approved hospital drug for labor; its use for bonding and desire is off-label. It is usually sold as a nasal spray, a lozenge or an injection, by sexual-health and telehealth clinics. ## What the evidence shows We found no trial of this combination. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown. The approved use of PT-141 is narrow, and the approved use of oxytocin is in childbirth. The idea that one supplies desire and the other closeness is marketing logic. Nobody has tested the pair. ## Legal status - **PT-141:** approved as an injection for one use. Other forms and uses are off-label. - **Oxytocin:** approved for use in labor. Other uses are off-label. - The combination is not an approved product. Where a pharmacy compounds it on a prescription, it has no FDA-reviewed label, and quality depends on the pharmacy. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it. - The ratio is fixed by the seller. You cannot adjust one ingredient without moving the other. - No safety or absorption work exists on the mixture. - PT-141 can raise blood pressure for a time and commonly causes nausea. The approved product's label has limits on how often it is used. - How much of either ingredient is absorbed from a spray or lozenge is uncertain. - Ask the prescriber which pharmacy makes it and what strength of each ingredient it holds. ## Common questions ### What is in this blend? PT-141 and oxytocin. ### Has this blend been tested in people? We found no human trial of the combination. ### Is this blend legal? It is not an approved product. Some pharmacies compound it on prescription, since both ingredients are in approved drugs. ## Sources - [Vyleesi (bremelanotide) prescribing information](https://www.drugs.com/pro/vyleesi.html) - [Oxytocin injection prescribing information](https://www.drugs.com/pro/oxytocin.html) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Rapamycin (sirolimus) Source: https://aminodesk.com/library/rapamycin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Rapamycin, also called sirolimus, is a prescription drug approved to prevent kidney transplant rejection. It is not a peptide. It extends lifespan in mice more reliably than any other drug, and many people take it off-label hoping for the same. The first year-long human trial did not meet its main goal. - **Legal lane:** FDA-approved for transplant and a rare lung disease. Longevity use is off-label. - **Evidence grade:** B for longevity: one real trial, small and with a missed main goal. A for the approved uses. - **Form:** tablet or liquid by mouth - **Brand:** Rapamune, and generics ## What it is Rapamycin blocks mTOR, a switch inside cells that drives growth. At transplant doses, taken daily, it suppresses the immune system. The longevity idea is that a lower dose taken once a week might slow aging without that effect. Whether it does is the open question. ## What the evidence shows - **Animals:** it extends lifespan in mice, in results repeated across laboratories. - **People:** the PEARL trial, published in April 2025, enrolled 125 adults aged 50 to 85 and gave placebo, 5 mg or 10 mg once a week for 48 weeks. It did not reduce belly fat, which was its main goal. The drug appeared safe over the year. Women on the higher dose gained lean mass and reported less pain. PEARL did not test whether rapamycin slows aging or extends life. No human trial has. ## Legal status - FDA-approved since 1999 to prevent rejection after kidney transplant, and for lymphangioleiomyomatosis, a rare lung disease. - Prescribing it for longevity is off-label. Insurance does not cover that use. - Prescription only. It is not a controlled substance. ## Label and trial dosing For the rare lung disease, the label starts at 2 mg a day and adjusts the dose to a target blood level. Transplant dosing is also guided by blood levels. The longevity trial used something different: 5 mg or 10 mg once a week. That is what was tested, in a monitored study. It is not a label dose and not a recommendation. ## Safety - **Boxed warning:** immune suppression, with a higher risk of infection and possibly of cancer, at the doses used in transplant. - **Cholesterol:** raised cholesterol is among the label's listed effects. - **Mouth sores:** a well-known side effect of this drug class. - **Who should be most careful:** anyone with an active infection, a cancer history or a weakened immune system. This is a decision for a clinician who knows your history. - The weekly doses used for longevity have one year of trial data in about a hundred people. Longer-term safety at those doses is unknown. ## Common questions ### Is rapamycin a peptide? No. It is a small-molecule prescription drug taken by mouth. ### Does rapamycin slow aging in humans? Nobody knows. It extends lifespan in mice. The one year-long human trial did not test aging itself and missed its main goal, which was reducing belly fat. ### Is rapamycin FDA-approved for longevity? No. It is approved for kidney transplant and a rare lung disease. Longevity use is off-label. ### What dose did the longevity trial use? 5 mg or 10 mg once a week for 48 weeks, in a monitored study. ## Sources - [Pfizer: Rapamune prescribing information, including the boxed warning and dosing](https://labeling.pfizer.com/showlabeling.aspx?id=139) - [PEARL trial: safety and efficacy of rapamycin on healthspan metrics after one year (preprint of the published paper)](https://medrxiv.org/content/10.1101/2024.08.21.24312372v1.full.txt) - [Summary of the PEARL results as published in Aging, April 2025](https://tetrapod.pages.dev/en/news/rapamycin-pearl-trial-biological-age-women-2025) - [Food Medicine Center: review of the rapamycin longevity evidence](https://foodmedcenter.org/rapamycin-slow-aging/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Retatrutide Source: https://aminodesk.com/library/retatrutide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Retatrutide, often called "reta", is Eli Lilly's experimental weekly injection. Its Phase 3 results are among the strongest reported for any weight-loss drug. It is not approved, and it cannot be legally sold for human use. - **Legal lane:** investigational. No legal access outside a clinical trial. - **Evidence grade:** B - **Form:** weekly injection under the skin - **FDA filing:** Lilly plans to submit in the first quarter of 2027 ## What it is Retatrutide is a single molecule that activates three hormone receptors: GIP, GLP-1 and glucagon. Semaglutide acts on one of these and tirzepatide on two. ## What the evidence shows Lilly reported two pivotal Phase 3 trials in July 2026, each lasting 80 weeks. | Trial | Who was studied | Average weight loss | | --- | --- | --- | | TRIUMPH-2 | 1,152 adults with obesity or overweight and type 2 diabetes | 12.7% (4 mg), 19.1% (9 mg), 20.8% (12 mg) | | TRIUMPH-3 | 1,949 adults with severe obesity and cardiovascular disease | 21.6% (9 mg), 22.6% (12 mg), versus 3.2% on placebo | An earlier Phase 2 trial, published in the New England Journal of Medicine in 2023, reported 24.2% average weight loss at 48 weeks on the 12 mg dose. The Phase 3 figures are topline company results. Full data had not yet been published in a peer-reviewed journal when Lilly announced them, which is why this page grades the evidence B and not A. The grade will change if the FDA approves it. ## Dosing used in the trials There is no approved dose. In the Phase 3 trials, participants started at 2 mg once a week and stepped up every four weeks: - To a 9 mg target: 2 mg, 4 mg, 6 mg, then 9 mg. - To a 12 mg target: 2 mg, 4 mg, 6 mg, 9 mg, then 12 mg. This was done under trial monitoring with pharmaceutical-grade product. It is a description of the studies, not guidance for self-use. ## Side effects - The most common were diarrhea (up to about 34% of participants), nausea (up to 28%) and vomiting. - About 6% of participants on retatrutide in TRIUMPH-3 reported dysesthesia, an abnormal skin sensation, compared with 1.3% on placebo. - In TRIUMPH-3, 9.8% (9 mg) and 13.5% (12 mg) stopped treatment because of side effects, versus 4.8% on placebo. ## Legal status In Lilly's own words, retatrutide "cannot be legally sold or marketed for human use." Every vial sold online as retatrutide is an unapproved product from an unverified source. The FDA has sent warning letters to sellers, and Lilly sued six of them in August 2026. See the [tracker](https://aminodesk.com/tracker). ## Common questions ### Is retatrutide FDA-approved? No. It is investigational. Eli Lilly plans to submit it to the FDA in the first quarter of 2027, and there is no legal access outside a clinical trial. ### How much weight did people lose on retatrutide? In the two Phase 3 trials Lilly reported in July 2026, average weight loss over 80 weeks ranged from 19.1% to 22.6% on the 9 mg and 12 mg doses. These are topline company results. ### Can I buy retatrutide legally? No. Every vial sold online as retatrutide is an unapproved product from an unverified source. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA: Concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) - [Jastreboff et al., 2023: Phase 2 trial of retatrutide, New England Journal of Medicine (PubMed)](https://pubmed.ncbi.nlm.nih.gov/37366315/) - [Eli Lilly: TRIUMPH-2 and TRIUMPH-3 topline results, July 23, 2026](https://investor.lilly.com/node/54736) - [HCPLive: retatrutide Phase 3 summary](https://www.hcplive.com/view/retatrutide-meets-phase-3-weight-loss-endpoints-in-2-obesity-trials) - [VialAudit: FDA letters and Lilly lawsuits](https://vialaudit.com/articles/fda-peptide-enforcement-2024-2026) This compound appears in widely promoted weight-loss stacks alongside the others. No trial has tested those combinations; see [blends and stacks](https://aminodesk.com/stacks). Seen it sold as "GLP-3" or "reta"? See [what seller code names mean](https://aminodesk.com/guides/seller-code-names). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Retatrutide + cagrilintide blend Source: https://aminodesk.com/library/retatrutide-cagrilintide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending This blend combines retatrutide and cagrilintide in one product. It is sold for maximum weight loss. Neither drug is approved, they belong to rival companies, and we found no trial that has combined them. - **Legal lane:** no lawful route. Both ingredients are investigational drugs that cannot be prescribed or compounded. - **Evidence grade:** D for the combination - **What is in it:** retatrutide and cagrilintide - **Established human dose:** none ## What it is A premixed product sold by peptide suppliers and some clinics. The ingredients: - **[retatrutide](https://aminodesk.com/library/retatrutide):** an investigational weight-loss drug from Eli Lilly; not approved. - **[cagrilintide](https://aminodesk.com/library/cagrilintide):** an investigational amylin drug from Novo Nordisk; not approved, and the FDA has said it cannot be compounded. The idea copies [CagriSema](https://aminodesk.com/library/cagrisema), which pairs cagrilintide with semaglutide and has been through large trials as a single product. Swapping in retatrutide makes a different combination that has not. ## What the evidence shows We found no trial of this combination. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown. Each drug has strong trial results on its own, in monitored studies with set doses and slow step-ups. Stacking two potent appetite drugs is not a small change. The side effects of each are mostly in the stomach and gut, and they would be expected to add up. ## Legal status - **Retatrutide:** not approved. Available only in clinical trials. - **Cagrilintide:** not approved, and the FDA has said it cannot be compounded. - Anything sold as this blend comes from an unregulated supplier. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it. - The ratio is fixed by the seller. You cannot adjust one ingredient without moving the other. - No safety or absorption work exists on the mixture. - Nausea, vomiting and dehydration are the predictable risks of combining two drugs of this kind. - A vial from an unregulated supplier may not contain what the label says, in either identity or amount. ## Common questions ### What is in this blend? Retatrutide and cagrilintide. ### Has this blend been tested in people? We found no human trial of the combination. ### Is this blend legal? No. Both ingredients are investigational drugs with no lawful route outside a clinical trial. ## Sources - [Lilly: results for its amylin drug, for context on the amylin class](https://investor.lilly.com/node/53246) - [Healthline: CagriSema, the tested cagrilintide combination](https://www.healthline.com/health/drugs/cagrisema-for-weight-loss) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Selank Source: https://aminodesk.com/library/selank Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 Selank is a short synthetic peptide approved in Russia as a nasal spray for anxiety. It has small published trials behind it, all from Russian groups, and no approval or compounding route in the United States. - **Legal lane:** not FDA-approved. Not eligible for US pharmacy compounding. - **Evidence grade:** C - **Form:** intranasal - **Approved elsewhere:** Russia, for generalized anxiety and related conditions ## What it is Selank is a seven-amino-acid analog of tuftsin, a naturally occurring immune peptide, modified so it lasts longer in the body. It is studied as an anxiolytic that does not sedate. ## What the evidence shows - Russian clinical trials, generally with 60 to 80 participants, reported reductions in anxiety scores in patients with generalized anxiety disorder and related diagnoses. - Those trials compared Selank favorably with low-dose benzodiazepines on anxiety measures, without the sedation and dependence seen with that class. - No Western randomized controlled trials have been published, and the Russian trials have not been independently replicated. Treat the Russian approval as real but limited evidence: small studies, one country's regulator, no replication elsewhere. ## Legal status Selank is not FDA-approved. Its compounding nomination was withdrawn, it is not eligible for 503A compounding, and it was not included in the October 2026 policy. The FDA has flagged immunogenicity concerns and insufficient safety information for peptides in this group. ## Reported dosing **No US-approved dose exists.** The Russian product has its own label, which is not available here. Figures repeated across catalog sites fall in the range of 250 to 500 micrograms a day intranasally, usually for two to four weeks. Sources that list these describe the underlying evidence as mixed. ## Safety - Trials reported it as well tolerated, with nasal irritation the main complaint. - No long-term safety data exists outside Russia. - Anxiety that is persistent or disabling is a reason to see a clinician, not to self-treat with an unapproved peptide. ## Common questions ### What is Selank used for? It is approved in Russia as a nasal spray for generalized anxiety and related conditions. ### Does Selank work for anxiety? Russian trials, generally with 60 to 80 participants, reported reductions in anxiety scores. No Western randomized controlled trials have been published, and the Russian trials have not been independently replicated. ### Is Selank legal in the US? It is not FDA-approved, is not eligible for 503A pharmacy compounding, and was not included in the October 2026 policy. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Zozulia et al. 2008: Selank versus medazepam in generalized anxiety disorder and neurasthenia (in Russian)](https://pubmed.ncbi.nlm.nih.gov/18454096/) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [Superpower: Selank evidence and regulatory status](https://superpower.com/guides/selank) - [PepEasy: Selank overview](https://pepeasy-wiki.pages.dev/peptides/selank) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Semaglutide (Wegovy, Ozempic) Source: https://aminodesk.com/library/semaglutide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Semaglutide is the GLP-1 medication behind Wegovy and Ozempic. It is FDA-approved, backed by large trials, and now available as a weekly injection or a daily pill. - **Legal lane:** FDA-approved, prescription only - **Evidence grade:** A - **Forms:** weekly injection under the skin; daily tablet - **Brands:** Wegovy (weight), Ozempic and Rybelsus (type 2 diabetes) - **Self-pay cost:** from $149 a month ## What it is Semaglutide mimics GLP-1, a hormone your gut releases after eating. It slows stomach emptying and acts on appetite signals in the brain, so people feel full sooner and eat less. ## What the evidence shows In its main weight-loss trial, adults on the 2.4 mg weekly injection lost an average of 14.9% of their body weight over 68 weeks. In the main trial of the 25 mg daily pill, the average was 13.6%. Results vary from person to person, and weight tends to return when treatment stops. ## Dosing on the FDA label These schedules come from the Wegovy prescribing information. The dose rises in steps to reduce stomach side effects. A prescriber may slow the schedule if a step is not tolerated. ### Weekly injection | Weeks | Dose, once a week | Stage | | --- | --- | --- | | 1 to 4 | 0.25 mg | Starting dose | | 5 to 8 | 0.5 mg | Step up | | 9 to 12 | 1 mg | Step up | | 13 to 16 | 1.7 mg | Step up | | 17 onward | 2.4 mg (or 1.7 mg) | Maintenance | For weight loss in adults, the label allows an increase to 7.2 mg once a week for people who have tolerated 2.4 mg for at least four weeks and need more weight reduction. That is the maximum dose. ### Daily tablet | Days | Dose, once a day | Stage | | --- | --- | --- | | 1 to 30 | 1.5 mg | Starting dose | | 31 to 60 | 4 mg | Step up | | 61 to 90 | 9 mg | Step up | | 91 onward | 25 mg | Maintenance | The tablet is swallowed whole with plain water only, no more than 4 ounces, and never more than one tablet a day. Ozempic, the diabetes brand, uses a different schedule. Do not use one brand's schedule for another. ## Side effects and warnings - The most common side effects are in the gut: nausea, diarrhea, vomiting and constipation, especially while the dose is rising. - The label carries a boxed warning about thyroid C-cell tumors, seen in rodent studies. It should not be used by people with a personal or family history of medullary thyroid cancer or MEN 2. - The full label lists other serious risks. Read the Medication Guide that comes with the prescription and raise your history with the prescriber. ## What it costs without insurance | Product | Manufacturer self-pay price, per month | | --- | --- | | Wegovy pill | $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg) | | Wegovy pen | $199 for the first two fills for new patients, then $349 | Prices were checked in October 2026 and change often. The $199 pen price is an introductory offer listed through December 31, 2026. People with commercial insurance may pay less with a manufacturer savings card. ## Compounded semaglutide Compounded semaglutide is made to order by a compounding pharmacy on a prescription, and it is what most lower-priced telehealth programs supply. It is not Wegovy or Ozempic: it is not FDA-approved, and the agency has not reviewed it for safety, effectiveness or quality. Since the shortage ended in February 2025, a pharmacy can compound it only when a prescriber decides an individual patient needs it, which is why a licensed provider reviews your case first. The FDA had received 990 adverse event reports linked to compounded semaglutide as of May 31, 2026, so where it comes from matters. Use a provider that requires a prescription, and ask which pharmacy makes it. ## Common questions ### Is semaglutide FDA-approved? Yes. It is approved as Wegovy for weight, and as Ozempic and Rybelsus for type 2 diabetes. All are prescription only. ### How much weight do people lose on semaglutide? In the main trial of the 2.4 mg weekly injection, adults lost an average of 14.9% of their body weight over 68 weeks. In the main trial of the 25 mg daily pill, the average was 13.6%. Results vary, and weight tends to return when treatment stops. ### What is the starting dose of Wegovy? The Wegovy label starts the weekly injection at 0.25 mg for weeks 1 to 4, then raises it in steps to a maintenance dose of 2.4 mg (or 1.7 mg). Ozempic uses a different schedule. ### Is compounded semaglutide legal? Yes, in limited cases. Since the shortage ended in February 2025, a pharmacy can compound it only when a prescriber decides an individual patient needs it. Compounded semaglutide is not FDA-approved. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA: Concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) - [FDA: Alert on dosing errors with compounded injectable semaglutide](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded) - [Wilding et al., 2021: STEP 1 trial of weekly semaglutide 2.4 mg, New England Journal of Medicine (PubMed)](https://pubmed.ncbi.nlm.nih.gov/33567185/) - [Wharton et al., 2025: OASIS 4 trial of oral semaglutide 25 mg, New England Journal of Medicine (PubMed)](https://pubmed.ncbi.nlm.nih.gov/40934115/) - [Wegovy prescribing information (Novo Nordisk)](https://www.novo-pi.com/wegovy.pdf) - [Wegovy label, FDA, 2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf) - [Wegovy dosing schedule (Novo Nordisk)](https://www.novomedlink.com/obesity/products/treatments/wegovy/dosing-administration/dosing.html) - [Self-pay price tracker](https://glp1-us.com/trumprx/) - [Compounded GLP-1 rules and adverse event counts](https://glp1numbers.com/guides/compounded-glp1-crackdown) Choosing between the two approved options? See [semaglutide vs tirzepatide](https://aminodesk.com/compare/semaglutide-vs-tirzepatide). Losing weight on a GLP-1? See [protein and muscle on GLP-1 medications](https://aminodesk.com/guides/protein-on-glp-1). Taking a prescribed GLP-1? Keep a private record of shots, weight and protein with the [GLP-1 log](https://aminodesk.com/glp1-log). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Semax Source: https://aminodesk.com/library/semax Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 Semax is a nasal peptide developed in Russia, where it is an approved medicine for stroke care. In the US it is not FDA-approved, and it is used mostly for focus and cognition, a use with much thinner evidence. - **Legal lane:** compounded on prescription under the October 2026 interim policy. Not FDA-approved. - **Evidence grade:** C - **Form covered by the policy:** Semax free base, intranasal only - **Established human dose:** none in the US. Russian clinical practice is described below. ## What it is Semax is a synthetic seven-amino-acid peptide modeled on a fragment of the hormone ACTH. It is given as nasal drops or spray. ## What the evidence shows The strongest human evidence is in stroke recovery, from Russian clinical trials published in 1997 and 2018, where Semax was added to standard hospital care. Those trials are small to mid-sized and have had little replication outside Russia. No large multi-center trials have been run in Western populations. For focus and memory in healthy people, the evidence is limited to small or older studies. Much of the foundational research is in Russian-language journals and is hard to evaluate independently. The July 2026 FDA advisory committee considered Semax for cerebral ischemia, migraine and trigeminal neuralgia, and recommended it. ## Legal status Semax left the FDA's restricted category in April 2026 and is covered by the HHS interim policy published October 30, 2026. The policy covers the nasal form only. Semax is prohibited in sport as a non-approved substance. ## Reported dosing There is no FDA-approved Semax product and no official US dosing. What follows describes Russian clinical practice and published studies, as summarized in the sources below. | Setting | Strength | Reported use | | --- | --- | --- | | Cognition studies | 0.1% nasal solution | Roughly 400 to 600 micrograms a day, split into one to three doses, often for one to four weeks | | Stroke care, in hospital | 1% nasal solution | Roughly 6,000 micrograms a day in courses of five to ten days, under clinician direction | Note the tenfold difference in strength between the two solutions. Variants such as N-acetyl Semax are dosed differently and are not interchangeable. ## Safety - Semax is generally reported as well tolerated, with nasal irritation the most common complaint. - Long-term safety data and studies of interactions with psychiatric medications are lacking. ## Common questions ### What is Semax? Semax is a synthetic seven-amino-acid peptide given as nasal drops or spray. It is an approved medicine in Russia for stroke care. It is not FDA-approved. ### Does Semax improve focus? The evidence for focus and memory in healthy people is limited to small or older studies. The strongest human evidence is in stroke recovery, from Russian trials with little replication elsewhere. ### Is Semax legal in the US? The nasal form can be compounded on prescription under the HHS interim policy published October 30, 2026. Semax is prohibited in sport. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Gusev et al. 1997: Semax in the acute period of ischemic stroke (clinical study, in Russian)](https://pubmed.ncbi.nlm.nih.gov/11517472/) - [FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (agenda and briefing documents)](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [HHS: 503A peptide enforcement discretion policy (PDF)](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [Rite Aid: Semax status and tolerability](https://riteaid.com/peptides/semax) - [Dr. Lewis: limits of the Semax evidence](https://drlewis.com/semax-for-focus-mood/) - [GoodRx: FDA developments on peptides](https://www.goodrx.com/health-topic/peptides/what-peptides-are-fda-approved) (policy forms and routes; committee votes) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Semax + Selank blend Source: https://aminodesk.com/library/semax-selank Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending This blend combines Semax and Selank in one product. It is sold for focus with less anxiety. We found no trial of the two together, and a mixed product falls outside the 2026 compounding policy. - **Legal lane:** outside the October 2026 policy. Not FDA-approved. - **Evidence grade:** D for the combination - **What is in it:** Semax and Selank - **Established human dose:** none ## What it is A premixed product sold by peptide suppliers and some clinics. The ingredients: - **[Semax](https://aminodesk.com/library/semax):** one of the six peptides in the October 2026 policy; its human evidence is small, mostly Russian studies. - **[Selank](https://aminodesk.com/library/selank):** a Russian anti-anxiety peptide; not one of the six policy peptides. ## What the evidence shows We found no trial of this combination. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown. The case for mixing them is that they act by different routes, so the effects should add up. That is a hypothesis. Nobody has measured whether the mixture does better than its parts, or whether it is as safe. ## Legal status In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it. This blend is outside the policy on two counts: it holds more than one active ingredient, and Selank is not one of the six peptides. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it. - The ratio is fixed by the seller. You cannot adjust one ingredient without moving the other. - No safety or absorption work exists on the mixture. - A product made outside the pharmacy system has no verified contents or sterility. ## Common questions ### What is in this blend? Semax and Selank. ### Has this blend been tested in people? We found no human trial of the combination. ### Is this blend legal? Not under the October 2026 policy. It holds two active ingredients, and Selank is not one of the six peptides the policy covers. ## Sources - [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/) - [Superpower: Semax and Selank, quality of the human evidence](https://superpower.com/guides/semax) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Sermorelin Source: https://aminodesk.com/library/sermorelin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 Sermorelin prompts the body to release its own growth hormone. It was once an FDA-approved drug for children. Today it is available only as a compounded prescription, mostly for adult uses that have not been tested in controlled trials. - **Legal lane:** long-standing compounded prescription. No FDA-approved product is currently sold. - **Evidence grade:** B - **Form:** injection under the skin - **Typical cost:** roughly $100 to $350 a month ## What it is Sermorelin is the first 29 amino acids of growth-hormone-releasing hormone, the signal the brain sends to the pituitary gland. It does not supply growth hormone. It tells the pituitary to release its own, and it is cleared from the blood within minutes. ## What the evidence shows Sermorelin has real clinical history. The FDA approved it in the 1990s under the brand name Geref, first as a diagnostic test and then, in 1997, to treat growth failure in children with growth hormone deficiency. The manufacturer discontinued it in 2008 for commercial reasons. The FDA later confirmed it was not withdrawn over safety or effectiveness. That history shows sermorelin does raise growth hormone. It does not show that it delivers the adult benefits it is sold for today, such as better body composition, sleep or slower aging. Adult studies are small or uncontrolled, and there are no randomized trials for those outcomes. ## Legal status Licensed pharmacies can compound sermorelin on prescription, and have done so for years. Compounded sermorelin is not an FDA-approved product. Sermorelin is prohibited in sport at all times. ## Reported dosing There is no current FDA label for adult use. The figure most often reported for prescriber-directed adult use is 200 to 500 micrograms injected under the skin once nightly, usually before bed. Two independent summaries give that range. It reflects prescriber practice, not a modern dose-finding trial. Oral and under-the-tongue forms are also sold. Peptides are poorly absorbed through the gut, and published validation for those forms is scarce. ## Safety - The body can form antibodies to sermorelin, which may blunt the response over time. - Compounded products are not checked by the FDA for potency or sterility, so pharmacy quality matters. ## What it costs Listings we have seen run from about $100 to $350 a month for a compounded prescription, depending on the provider and form. ## Common questions ### Is sermorelin FDA-approved? Not currently. It was approved in the 1990s under the brand name Geref, and the manufacturer discontinued it in 2008 for commercial reasons. Today it is available only as a compounded prescription. ### Is sermorelin the same as growth hormone? No. It does not supply growth hormone. It tells the pituitary gland to release its own. ### What is the usual sermorelin dose? There is no current FDA label for adult use. The figure most often reported for prescriber-directed adult use is 200 to 500 micrograms under the skin once nightly. It reflects prescriber practice, not a modern dose-finding trial. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Federal Register (2013): FDA determination that Geref (sermorelin) was not withdrawn for reasons of safety or effectiveness](https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams) - [FDA orphan drug record: sermorelin acetate (Geref), approved 1997](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687) - [Peptide Journal: sermorelin profile and approval history](https://peptidejournal.org/peptides/sermorelin-ghrh-analog-research-profile) - [Superpower: sermorelin evidence summary](https://superpower.com/guides/peptides/sermorelin) - [FormBlends: adult dosing in practice and cost](https://formblends.com/articles/peptide-hub/sermorelin) - [Sermorelin and NAD+ price listings](https://muscleandbrawn.com/performance/longevity/longevity-peptides-cost/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # SLU-PP-332 Source: https://aminodesk.com/library/slu-pp-332 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 SLU-PP-332 is the compound behind the "exercise in a pill" headlines. The mouse results are real and striking. There are no human trials of any kind, which is why this page covers status and risk only. - **Legal lane:** preclinical research compound. Not approved anywhere. - **Evidence grade:** D - **Human trials:** none registered - **Not a peptide:** a small molecule ## What it is SLU-PP-332 is a pan-agonist of the estrogen-related receptors ERR alpha, beta and gamma, developed at Saint Louis University. Despite the name, these are not the classical estrogen receptors and this is not estrogen therapy. ERRs sit downstream of exercise in muscle, liver and heart, which is the basis for the "exercise mimetic" framing. ## What the evidence shows - Healthy mice given the compound ran about 70% longer and 45% further than untreated mice. - Obese mice on a high-fat diet, dosed for four weeks, weighed about 12% less than placebo controls while eating the same amount of food. - A later laboratory study exposed cultured muscle cells from inactive women to the compound and saw changes in exercise-related markers. No person received the compound in that study. - No human trial has been conducted or registered. One of the researchers involved estimated years of further animal work, toxicology and dose-finding before human testing. ## The specific unknown The receptors it activates are concentrated in heart and liver as well as muscle. Turning all three ERR subtypes on continuously in those tissues has not been characterized in a human being at any dose, over any period. Earlier compounds in the broader exercise-mimetic space have been abandoned over safety findings in animals, which is a reason to treat the category cautiously rather than a verdict on this one. ## Dosing **We do not publish a protocol for this compound.** There is no human pharmacokinetic or toxicology data, so there is no basis for a dose. The figures circulating on vendor sites are not derived from any study in people. ## Common questions ### Is SLU-PP-332 a peptide? No. It is a small molecule that activates the estrogen-related receptors. These are not the classical estrogen receptors. ### Has SLU-PP-332 been tested in humans? No. No human trial has been conducted or registered. ### What did the mouse studies show? Healthy mice given the compound ran about 70% longer and 45% further. Obese mice dosed for four weeks weighed about 12% less than controls while eating the same amount. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Billon et al. 2023: synthetic ERR agonist enhances exercise capacity in mice (ACS Chem Biol)](https://pubmed.ncbi.nlm.nih.gov/36988910/) - [Billon et al. 2024: a synthetic ERR agonist alleviates metabolic syndrome in mice (J Pharmacol Exp Ther)](https://pubmed.ncbi.nlm.nih.gov/37739806/) - [Freethink: the mouse endurance and weight studies](https://freethink.com/health/weight-loss-drug-exercise-pill) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # SNAP-8 (acetyl octapeptide-3) Source: https://aminodesk.com/library/snap-8 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending SNAP-8 is a cosmetic peptide used in wrinkle creams and serums, marketed as a topical alternative to Botox. The wrinkle-reduction numbers come from its manufacturer. No independent study has tested it on its own. - **Legal lane:** legal as a cosmetic ingredient. Not a drug and not FDA-approved to treat anything. - **Evidence grade:** C. Manufacturer data in people; nothing independent. - **Form:** cream or serum on the skin - **Also called:** acetyl octapeptide-3 ## What it is An eight-amino-acid peptide developed by the Spanish ingredient company Lipotec. It is a longer version of Argireline, an older cosmetic peptide. Both are meant to interfere with the signal that makes facial muscles contract, which is the same pathway Botox blocks by injection. ## What the evidence shows The manufacturer's study reported about a 30% reduction in wrinkle depth after 28 days of twice-daily use of a 10% preparation. The published randomized trials in this family tested Argireline, not SNAP-8. The practical doubt is delivery. The target sits at the junction of nerve and muscle, well below the skin's outer barrier, and it is unclear how much of a peptide in a cream gets there. ## Legal status - Sold legally as a cosmetic ingredient. - A cosmetic may not claim to treat a condition or change how the body works. It is not approved as a drug. - Injecting it is not an approved use and has not been studied. ## Reported dosing There is no medical dose. It is a cosmetic ingredient, used at whatever concentration the product maker chooses. Follow the product label. ## Safety - A cosmetic ingredient safety panel has not flagged specific concerns at the levels used in products, according to one summary. - Any effect is modest and stops when you stop using it. - Vials sold for injection are research chemicals with no verified contents. ## Common questions ### Does SNAP-8 work like Botox? It targets the same pathway from the skin surface, but the effect is far smaller and independent proof is lacking. ### Is SNAP-8 FDA-approved? No. It is a cosmetic ingredient, not a drug. ### How is SNAP-8 different from Argireline? It is the same idea with two extra amino acids. Argireline has the published trials; SNAP-8 has manufacturer data. ## Sources - [Outliyr: SNAP-8 evidence assessment](https://outliyr.com/reports/snap-8) - [Peptadex: the sponsor-funded study and safety panel note](https://peptadex.pages.dev/peptides/snap-8) - [Peptide Protocol Wiki: origin and relation to Argireline](https://www.peptideprotocolwiki.com/peptides/snap-8) - [Superpower: cosmetic wrinkle peptides compared](https://superpower.com/guides/botox-like-peptides) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # SS-31 (elamipretide, Forzinity) Source: https://aminodesk.com/library/ss-31 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending SS-31 is the research name for elamipretide. In September 2025 the FDA gave it accelerated approval as Forzinity, the first treatment for Barth syndrome, a rare inherited mitochondrial disease that affects about 150 people in the US. Online it is sold for energy and longevity, uses that have not been tested. - **Legal lane:** FDA-approved for Barth syndrome only (accelerated approval) - **Evidence grade:** B - **Form:** daily injection under the skin - **Brand:** Forzinity ## What it is Elamipretide binds to cardiolipin, a fat in the inner membrane of mitochondria, the parts of the cell that produce energy. In Barth syndrome, cardiolipin is abnormal. ## What the evidence shows The trial behind the approval enrolled 12 patients. It missed both of its main goals: elamipretide did not beat placebo on walking distance or on fatigue scores. The FDA granted accelerated approval based on an improvement in knee-muscle strength, which it judged reasonably likely to predict real benefit, and required a new placebo-controlled trial to confirm it. That is why the grade is B, even though the drug is approved. There is no published evidence that it improves energy, endurance or aging in healthy people. ## Dosing on the label For patients with Barth syndrome weighing at least 30 kg, the label dose is 40 mg injected under the skin once a day. The dose is reduced in severe kidney impairment, because the drug leaves the body through the kidneys. **No dose is established for any other use.** ## Side effects - Injection-site reactions were the most common side effect, mostly mild to moderate. - The approved product contains benzyl alcohol, which carries a warning for newborns. ## Common questions ### What is SS-31 approved for? As Forzinity (elamipretide), it received FDA accelerated approval in September 2025 for Barth syndrome only. ### Does SS-31 improve energy or slow aging? There is no published evidence that it improves energy, endurance or aging in healthy people. ### What is the label dose? For patients with Barth syndrome weighing at least 30 kg, 40 mg injected under the skin once a day. No dose is established for any other use. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [DailyMed: Forzinity (elamipretide) label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75) - [FDA Drug Trials Snapshot: Forzinity](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-forzinity) - [FDA: accelerated approval of the first treatment for Barth syndrome](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Survodutide Source: https://aminodesk.com/library/survodutide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Survodutide is an experimental weekly weight-loss injection from Boehringer Ingelheim and Zealand Pharma. It has finished several Phase 3 trials but, as of November 2026, is not approved for any use. - **Legal lane:** investigational. Not approved in any country. - **Evidence grade:** B - **Form:** weekly injection under the skin - **Also studied in:** fatty liver disease (MASH) ## What it is Survodutide activates two receptors, GLP-1 and glucagon, the same pairing as [mazdutide](https://aminodesk.com/library/mazdutide). The glucagon side is meant to increase fat burning in the liver, which is why it is also being tested in liver disease. ## What the evidence shows - **SYNCHRONIZE-1** (New England Journal of Medicine, 2026): 725 adults with obesity and no diabetes, treated for 76 weeks. Average weight loss was 12.2% on 3.6 mg and 13.0% on 6.0 mg, against 5.4% on placebo. Among people who stayed on the 6.0 mg dose, it was 16.6%. - **SYNCHRONIZE-2:** in 752 adults with type 2 diabetes, the 6.0 mg dose produced 9.8% weight loss against 3.9% on placebo. - **SYNCHRONIZE-CVOT** (The Lancet, November 2026): met its goal of showing no increase in heart and stroke risk. These are large, well-run trials. The grade is B because the drug is not approved and its weight loss is smaller than the approved [tirzepatide](https://aminodesk.com/library/tirzepatide) in separate trials. ## Dosing used in the trials There is no approved dose. Trials gave survodutide once a week and raised the dose gradually to a maintenance dose of 3.6 mg or 6.0 mg. The dose-raising period is where most side effects and dropouts happened, and newer trials use slower, more flexible schedules. ## Side effects - Stomach and gut side effects were very common: 81% on 3.6 mg and 90% on 6.0 mg in SYNCHRONIZE-1, against 48% on placebo, mostly mild to moderate. - In the diabetes trial, 18% of people on survodutide stopped because of them, against 1.2% on placebo. ## Legal status Survodutide is not approved for any use. The FDA has named it among the drugs it has warned research-chemical sellers about. ## Common questions ### Is survodutide approved? No. As of November 2026 it is not approved for any use in any country. ### How much weight did people lose on survodutide? In SYNCHRONIZE-1, average weight loss over 76 weeks was 12.2% on 3.6 mg and 13.0% on 6.0 mg, against 5.4% on placebo. ### What are the side effects of survodutide? Stomach and gut side effects were very common: 81% on 3.6 mg and 90% on 6.0 mg in SYNCHRONIZE-1, against 48% on placebo, mostly mild to moderate. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [le Roux et al. 2026: SYNCHRONIZE-1, New England Journal of Medicine (PubMed)](https://pubmed.ncbi.nlm.nih.gov/42253238/) - [SYNCHRONIZE-2: survodutide in adults with obesity and type 2 diabetes (University of Glasgow repository)](https://eprints.gla.ac.uk/396782/) - [AJMC: SYNCHRONIZE-CVOT results, November 2026](https://www.ajmc.com/view/survodutide-meets-cv-safety-end-point-in-synchronize-cvot) - [FDA: Concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # TB-500 Source: https://aminodesk.com/library/tb-500 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 TB-500 is sold for injury recovery and is often paired with BPC-157. It can now be compounded on prescription, but it has no completed human trials of its own. The human research people cite was done on a different, larger molecule. - **Legal lane:** compounded on prescription under the October 2026 interim policy. Not FDA-approved. - **Evidence grade:** D - **Form covered by the policy:** TB-500 acetate as an injection under the skin or into muscle - **Established human dose:** none ## What it is TB-500 is the market name for a synthetic peptide based on thymosin beta-4, a 43-amino-acid protein found in most human cells and involved in tissue repair. TB-500 is a short piece of that protein, not the whole thing. Sources do not agree on exactly which piece. Most describe a seven-amino-acid fragment, some describe a longer one, and reviewers note that products sold under the name do not always contain the same sequence. That uncertainty is part of the risk. ## What the evidence shows For TB-500 itself, the evidence is from cells and animals. Reviews published in 2026 found no completed, peer-reviewed human trials of the fragment. One early-phase trial was registered in 2026. The human studies often quoted in TB-500 marketing used full-length thymosin beta-4: eye drops tested for dry eye and corneal injury, and a small dose-escalation study in venous leg ulcers. Those results do not transfer automatically to a fragment given by injection for a tendon or muscle injury. In July 2026 an FDA advisory committee considered TB-500 for wound healing and voted 8 to 6 to recommend it. FDA scientists had recommended against. ## Legal status TB-500 was restricted from compounding in 2023, removed from the restricted category in April 2026, and included in the HHS interim policy published October 30, 2026. That policy allows state-licensed pharmacies to compound it on an individual prescription. It is not approval and can be revised. TB-500 is prohibited in sport. ## Reported dosing **No dose has been established in human trials.** There is no human dose-response data for TB-500. A pattern often repeated online is 2 to 2.5 mg injected under the skin twice a week for four to six weeks. The source we found for it labels it anecdotal. It does not come from a clinical study. If a clinician prescribes TB-500, follow the dose on the prescription and ask what it is based on. ## Safety - Human safety data for the fragment is essentially absent. - Because product identity varies, what is in a vial bought outside a pharmacy is a real unknown. ## Common questions ### Is TB-500 the same as thymosin beta-4? No. TB-500 is a short piece of thymosin beta-4, a 43-amino-acid protein. The human studies quoted in TB-500 marketing used the full-length protein, not the fragment. ### Is TB-500 legal? State-licensed pharmacies may compound it on an individual prescription under the HHS interim policy published October 30, 2026. That is not approval and can be revised. TB-500 is prohibited in sport. ### What is the usual TB-500 dose? No dose has been established in human trials. The pattern often repeated online, 2 to 2.5 mg under the skin twice a week for four to six weeks, is anecdotal and does not come from a clinical study. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Ruff et al. 2010: intravenous thymosin beta-4 in healthy volunteers, randomized placebo-controlled (full-length protein, not TB-500)](https://pubmed.ncbi.nlm.nih.gov/20536472/) - [Guarnera et al. 2010: topical thymosin beta-4 for venous ulcers, Phase 2 (full-length protein, not TB-500)](https://pubmed.ncbi.nlm.nih.gov/20536470/) - [FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (agenda and briefing documents)](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) - [HHS: 503A peptide enforcement discretion policy (PDF)](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [Scoping review of thymosin beta-4 and TB-500 in tissue healing (preprint)](https://www.preprints.org/manuscript/202605.1124/v1) - [Superpower: TB-500 evidence summary](https://superpower.com/guides/peptides/tb-500) - [Outliyr: TB-500 report (anecdotal protocol)](https://outliyr.com/?p=73678) - [GoodRx: FDA developments on peptides](https://www.goodrx.com/health-topic/peptides/what-peptides-are-fda-approved) (policy forms and routes; committee votes) - [HealingMaps: committee vote margins](https://healingmaps.com/kpv-peptide-anti-inflammatory-wound-healing/) This compound is often sold inside a blend, such as Wolverine or KLOW. A vial holding more than one peptide falls outside the 2026 compounding policy; see [blends and stacks](https://aminodesk.com/stacks). See how the two repair peptides differ: [BPC-157 vs TB-500](https://aminodesk.com/compare/bpc-157-vs-tb-500). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Tesamorelin (Egrifta) Source: https://aminodesk.com/library/tesamorelin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Tesamorelin is an FDA-approved daily injection that prompts the body to release growth hormone. Its approval is narrow: reducing excess abdominal fat in people with HIV who have lipodystrophy. - **Legal lane:** FDA-approved, prescription only - **Evidence grade:** A for its approved use - **Form:** daily injection under the skin - **Brand:** Egrifta ## What it is Tesamorelin is a synthetic version of growth-hormone-releasing factor. Like [sermorelin](https://aminodesk.com/library/sermorelin), it signals the pituitary gland to release the body's own growth hormone. Unlike sermorelin, it has a current FDA-approved product. ## What the evidence shows The FDA approved tesamorelin in November 2010 on the strength of two placebo-controlled trials in 816 adults with HIV and excess abdominal fat. Over 26 weeks, deep abdominal fat measured by CT scan fell 15% on the drug while rising 5% on placebo in the first trial, and fell 11% versus 1% in the second. Pooled, the treatment effect was about 15%. Two limits matter. The fat returned within months when people stopped. And the trials did not test whether treatment lowers cardiovascular risk. ## Dosing on the label Tesamorelin is injected under the skin once a day. The milligram dose depends on which formulation is dispensed; one version is labeled at 1.4 mg a day, and a newer formulation approved in March 2025 uses a different amount. Follow the label for the specific product. ## Side effects - Joint pain, muscle pain, swelling and injection-site redness or itching were the most common. - Blood sugar control worsened more often on tesamorelin than on placebo, including some cases that met the criteria for diabetes. ## Use outside the approval Clinics prescribe tesamorelin off-label for general fat loss and "growth hormone optimization". The approval trials were in people with HIV-related lipodystrophy, so results in other groups should not be assumed. ## Common questions ### What is tesamorelin approved for? Reducing excess abdominal fat in people with HIV who have lipodystrophy. The FDA approved it in November 2010 under the brand name Egrifta. ### Does tesamorelin reduce belly fat? In the approval trials, in adults with HIV, the pooled treatment effect on deep abdominal fat was about 15% over 26 weeks. The fat returned within months when people stopped. ### What are the side effects of tesamorelin? Joint pain, muscle pain, swelling and injection-site reactions were the most common. Blood sugar control worsened more often on tesamorelin than on placebo. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [Falutz et al., 2007: first Phase 3 trial of tesamorelin, New England Journal of Medicine (PubMed)](https://pubmed.ncbi.nlm.nih.gov/18057338/) - [Falutz et al., 2010: second Phase 3 trial, including what happened after stopping (PubMed)](https://pubmed.ncbi.nlm.nih.gov/20101189/) - [Falutz et al., 2010: pooled analysis of the two Phase 3 trials (PubMed)](https://pubmed.ncbi.nlm.nih.gov/20554713/) - [HIV i-Base: tesamorelin approval and trial results](https://i-base.info/htb/14188) - [CenterWatch: Egrifta dosing and trial detail](https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/1122/egrifta-tesamorelin-for-injection) - [Drugs.com: Egrifta approval history](https://www.drugs.com/nda/tesamorelin_091105.html) This compound appears in widely promoted weight-loss stacks alongside the others. No trial has tested those combinations; see [blends and stacks](https://aminodesk.com/stacks). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Tesamorelin + ipamorelin blend Source: https://aminodesk.com/library/tesamorelin-ipamorelin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending This blend puts tesamorelin and ipamorelin in one vial. It is sold for fat loss and growth hormone support. No trial has tested the combination in people, and one of the two ingredients cannot be legally compounded. - **Legal lane:** not FDA-approved as a blend. Ipamorelin is not eligible for pharmacy compounding. - **Evidence grade:** D for the combination - **What is in it:** tesamorelin and ipamorelin - **Established human dose:** none ## What it is A premixed vial sold by peptide suppliers and some clinics. The ingredients: - **[tesamorelin](https://aminodesk.com/library/tesamorelin):** FDA-approved as Egrifta, only to reduce excess abdominal fat in people with HIV and lipodystrophy. - **[ipamorelin](https://aminodesk.com/library/ipamorelin):** not approved; an FDA advisory committee voted 0 to 12 against allowing it to be compounded. Tesamorelin on its own has real trial evidence, in a specific group: it reduced deep abdominal fat in people with HIV, the fat returned when treatment stopped, and it can worsen blood sugar. None of that was tested in combination with ipamorelin. ## What the evidence shows There is no trial of this blend. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown. The case for mixing them is that they act by different routes, so the effects should add up. That is a hypothesis. Nobody has measured whether the mixture does better than its parts, or whether it is as safe. ## Legal status - **Tesamorelin:** a prescription drug approved for one use. Prescribing it for general fat loss is off-label. - **Ipamorelin:** not approved, and an FDA advisory committee voted 0 to 12, with one abstention, against allowing it to be compounded. - A vial combining the two has no approved product and no compounding route behind it. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it. - The ratio is fixed by the seller. You cannot adjust one ingredient without moving the others. - No safety or absorption work exists on the mixture. - Tesamorelin can worsen blood sugar. Adding a second growth hormone releaser has not been studied. - A product made outside the pharmacy system has no verified contents or sterility. ## Common questions ### What is in this blend? tesamorelin and ipamorelin, mixed in one vial. ### Has this blend been tested in people? No. There is no human trial of the combination. ### Is this blend legal? No approved product combines them, and ipamorelin is not eligible for compounding. ## Sources - [Beck et al. 2014: randomized trial of ipamorelin for postoperative ileus (PubMed)](https://pubmed.ncbi.nlm.nih.gov/25331030/) - [FDA briefing document: ipamorelin-related bulk drug substances (October 2024)](https://www.fda.gov/media/182088/download) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) The repair blends are compared on [blends and stacks](https://aminodesk.com/stacks). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Tesofensine Source: https://aminodesk.com/library/tesofensine Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Tesofensine is a pill that suppresses appetite by acting on three brain chemicals. It is not a peptide. A mid-stage trial showed strong weight loss, and the same trial showed the problem that has kept it from approval: it raises heart rate and blood pressure. - **Legal lane:** not FDA-approved. No prescription product exists in the US. - **Evidence grade:** B. One good mid-stage trial, no completed US program. - **Form:** capsule by mouth, once a day - **Type:** triple monoamine reuptake inhibitor, not a peptide ## What it is Tesofensine blocks the reuptake of serotonin, noradrenaline and dopamine. It was first developed for Parkinson's and Alzheimer's disease, where it did not work. Weight loss in those trials led to its being tested for obesity. ## What the evidence shows The main evidence is one Phase 2 trial published in The Lancet in 2008. It followed 203 adults with obesity at five Danish centers for 24 weeks, testing 0.25 mg, 0.5 mg and 1 mg a day against placebo. At 0.5 mg, average weight loss was 9.2%, against 2.0% on placebo. That was about double what the weight-loss drugs of the time achieved. The 1 mg dose produced more weight loss and more side effects. A later program in Mexico, reported as 372 patients, broadly matched the weight loss. No large trial has tested heart outcomes. ## Legal status - Not FDA-approved, and no US Phase 3 program was running when we checked. - Reports on its status in Mexico conflict. Some say it was approved there in 2023; a more recent summary says approval was still being pursued. We could not settle this from a primary source. - Some US sellers and pharmacies have marketed it. No approved product stands behind those sales. ## Reported dosing **No approved dose exists in the US.** The Phase 2 trial tested 0.25 mg, 0.5 mg and 1 mg once a day, and later work continued with 0.5 mg. Those are trial doses in monitored studies, not a recommendation. The drug stays in the body a long time, with a half-life reported at about nine days, so its effects persist for weeks after stopping. ## Safety - **Heart rate and blood pressure:** both rose in a dose-dependent way. This is the main safety concern, and the same mechanism drives the weight loss. - **Common effects:** dry mouth, insomnia, constipation and mood changes. - **Long-term safety:** not established. There is no heart-outcomes trial. - Anyone with heart disease, high blood pressure or a mood disorder has specific reasons for caution. ## Common questions ### Is tesofensine a peptide? No. It is a small-molecule drug taken as a capsule. ### How much weight did people lose on tesofensine? In the main trial, 9.2% of body weight over 24 weeks at 0.5 mg a day, against 2.0% on placebo. ### Is tesofensine FDA-approved? No. There is no approved product in the US. ### Why was it not approved? It raises heart rate and blood pressure, and no large trial has tested its effect on heart outcomes. ## Sources - [Astrup et al., 2008: tesofensine Phase 2 trial, The Lancet (PubMed)](https://pubmed.ncbi.nlm.nih.gov/18950853/) - [Superpower: tesofensine regulatory status as of September 2026](https://superpower.com/guides/peptide-science/tesofensine) - [Superpower: an earlier summary reporting Mexican approval in 2023](https://superpower.com/guides/peptides/tesofensine) - [TrimRx: review of the tesofensine trials, including the Mexican program (a seller's article)](https://trimrx.com/blog/?p=107159) - [FormBlends: trial size, half-life and status (a seller's article)](https://www.formblends.com/peptides/tesofensine) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Testosterone (cypionate, enanthate) Source: https://aminodesk.com/library/testosterone Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Testosterone is a steroid hormone, not a peptide, but it is sold by the same clinics. It is FDA-approved for men with low testosterone tied to a medical condition, it is a controlled substance, and its label changed in 2025 after a large safety trial. - **Legal lane:** FDA-approved, prescription only. Schedule III controlled substance. - **Evidence grade:** A for its approved use - **Forms:** injections into muscle (cypionate, enanthate, undecanoate), gels, patches, pellets and oral capsules - **Approved for:** men with low testosterone and an associated medical condition ## What it is Testosterone is the main male sex hormone. The injectable forms, testosterone cypionate and testosterone enanthate, are testosterone attached to a fatty acid so that an injection in oil releases slowly over weeks. Cypionate has been on the US market since the 1950s. ## What the evidence shows The largest safety trial is TRAVERSE, published in 2023. It followed 5,246 men with symptoms of low testosterone and existing or raised heart risk for about 33 months. Major heart events occurred in 7.0% of men on testosterone gel and 7.3% on placebo, so testosterone was no worse than placebo on that measure. Separate blood pressure monitoring studies, which the FDA required of manufacturers, found that testosterone products raise blood pressure across the class. The A grade is for the approved use. Use by men whose testosterone is low only because of age is the contested area, covered below. ## Legal status - **Approved use:** the FDA states that testosterone is approved only for men who lack or have low testosterone together with an associated medical condition. Labels require low morning testosterone measured on at least two separate days before starting. - **Controlled substance:** testosterone is in Schedule III under the Anabolic Steroids Control Act. - **February 2025:** the FDA required a blood pressure warning on every testosterone product and recommended removing the boxed warning language about heart risk, based on TRAVERSE. It kept the statement that safety and effectiveness in age-related low testosterone have not been established. - **June 18, 2026:** HHS requested further class-wide changes: removing that age-related limitation, narrowing the prostate cancer contraindication to metastatic disease, and updating the warnings on enlarged prostate. These were requests, not final label changes, when we checked. Testosterone is prohibited in sport. ## Label dosing For testosterone cypionate injection, the FDA label gives 50 mg to 400 mg every two to four weeks, injected deep into the gluteal muscle, with the dose and schedule set for the individual. The reference listings give the same range for testosterone enanthate. Clinics often prescribe other schedules. Those are prescriber decisions, not the label, and we have no single source to report for them. The dose on your prescription is the one to follow. ## Safety - **Blood pressure:** raised across the class. Since 2025 every testosterone label carries a warning about it. - **Fertility:** testosterone can lower sperm production. This matters for anyone planning to father a child. - **Blood clots:** labels carry a warning about clots in the veins. - **Prostate:** current labels generally advise against use in men with known or suspected prostate cancer. - **Children and partners:** gels can transfer to others through skin contact. - **Misuse:** doses above the prescribed range carry serious heart, liver and psychiatric risks described in the label's abuse section. ## Common questions ### Is testosterone a peptide? No. It is a steroid hormone. It appears here because the same clinics sell it alongside peptides. ### Is testosterone a controlled substance? Yes. It is a Schedule III controlled substance in the US and requires a prescription. ### Does testosterone raise heart risk? In the TRAVERSE trial, major heart events were similar on testosterone and placebo, 7.0% and 7.3%. Testosterone does raise blood pressure, and labels now carry a warning about that. ### What is the label dose of testosterone cypionate? The FDA label gives 50 mg to 400 mg every two to four weeks by injection into muscle, set for the individual. ## Sources - [FDA: class-wide labeling changes for testosterone products (February 28, 2025)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-issues-class-wide-labeling-changes-testosterone-products) - [FDA label: testosterone cypionate injection (dosage, hypogonadism confirmation, Schedule III)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216318s002lbl.pdf) - [Pfizer: Depo-Testosterone dosage and administration](https://www.pfizermedical.com/testosterone/dosage-admin) - [Urology Times: HHS requests testosterone label updates, with TRAVERSE figures (June 19, 2026)](https://www.urologytimes.com/view/hhs-requests-testosterone-therapy-label-updates-citing-new-safety-data) - [Healio: FDA label changes and the retained age-related limitation (March 2025)](https://www.healio.com/news/endocrinology/20250303/fda-recommends-removing-black-box-warning-for-cv-risk-from-all-testosterone-product-labels) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Thymalin Source: https://aminodesk.com/library/thymalin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Thymalin is an extract of calf thymus that has been a registered immune drug in Russia since the Soviet era. It is sold abroad for immune support and longevity. The human evidence comes from the group that developed it and has not been independently repeated. - **Legal lane:** registered in Russia. Not FDA-approved and not available by prescription in the US. - **Evidence grade:** C. Human studies exist, but they are unblinded or single-source. - **Form:** injection into muscle - **What it is:** a mixture of thymus peptides, not a single molecule ## What it is A preparation of small peptides extracted from the thymus glands of calves. It was approved as a drug in the Soviet Union in 1982 for immune deficiency states. It was developed by Vladimir Khavinson and Vladimir Morozov, and it is the starting point for the family of short peptides sold as bioregulators. Two of those, Thymogen and Vilon, are single peptides identified from this extract. ## What the evidence shows The most-cited study followed 266 elderly people for six to eight years and reported lower mortality in those given thymus and pineal extracts. It was not blinded, it comes from the developers, and it has not been reproduced elsewhere in more than twenty years. Inside Russia the drug has critics. A vice president of the Russian Society of Evidence-Based Medicine Specialists has said it was approved with very little evidence of effectiveness, and a Russian drug handbook cited by St. Petersburg journalists lists it as having no proven efficacy. ## Legal status - A registered prescription drug in Russia. - Not approved by the FDA. - Not eligible for pharmacy compounding in the US, according to the research summary we read, and not one of the six peptides in the October 2026 policy. ## Reported dosing **We do not publish a protocol for this compound.** The Russian product has its own label, which we have not been able to check directly. The schedules on English-language sites come from sellers and enthusiast guides. ## Safety - It is an animal tissue extract. Extracts are harder to standardize than a single synthetic peptide, so two products with this name may not hold the same thing. - What is sold internationally under this name by research suppliers is not the registered Russian product. - No safety data of the kind the FDA requires exists. ## Common questions ### Is Thymalin FDA-approved? No. It is registered in Russia only. ### Is Thymalin a single peptide? No. It is a mixture of peptides extracted from calf thymus. ### Does Thymalin extend life? One unblinded study from its developers reported lower mortality in elderly people. Nobody has repeated it. ## Sources - [Molecules, 2021: history of Thymalin (1982) and Thymogen (1990) registration](https://mdpi.com/1420-3049/26/21/6550) - [Khavinson and Morozov, 2003: the 266-person elderly cohort (PubMed)](https://pubmed.ncbi.nlm.nih.gov/14523363/) - [Paper (St. Petersburg), 2024: Khavinson's drugs and their critics in evidence-based medicine](https://papernews.online/en/he-promised-to-extend-the-lives/) - [Rite Aid: Thymalin status and standardization cautions](https://riteaid.com/peptides/thymalin) - [The Peptide Column: bioregulator research summary and legal status](https://the-peptide-column.pages.dev/bioregulators) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Thymogen (Glu-Trp) Source: https://aminodesk.com/library/thymogen Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Thymogen is a peptide of just two amino acids, glutamic acid and tryptophan. It was identified in the search for the active part of the thymus extract Thymalin and has been a registered immune drug in Russia since 1990. It is not approved in the US. - **Legal lane:** registered in Russia. Not FDA-approved. - **Evidence grade:** C. Decades of clinical use in one country; little that meets modern trial standards. - **Form:** injection and nasal spray in Russia - **What it is:** the dipeptide Glu-Trp ## What it is Researchers looking for the active components of [Thymalin](https://aminodesk.com/library/thymalin) arrived at the dipeptide Glu-Trp, which was registered as the drug Thymogen in 1990. A review of Russian peptide medicines lists it among the country's original registered peptide drugs, as an immune stimulant. ## What the evidence shows The clinical record is Russian and comes largely from the group that developed it. Their own reviews describe use in infections and in older patients. A Russian drug handbook cited by St. Petersburg journalists lists Thymogen, like Thymalin, as having no evidence-based effectiveness. We found no large blinded trial in the sources we reviewed. ## Legal status - A registered drug in Russia. - Not approved by the FDA. - Not eligible for pharmacy compounding in the US, according to the research summary we read, and not one of the six peptides in the October 2026 policy. ## Reported dosing **We do not publish a protocol for this compound.** The Russian product has its own label, which we have not been able to check directly. Figures on seller sites are not a source. ## Safety - A published chemistry review describes it as free of allergic and other side reactions. That is the developers' literature, not an independent safety review. - Products sold abroad under this name are not the registered Russian product and have no verified contents. ## Common questions ### What is Thymogen? A two-amino-acid peptide, Glu-Trp, registered as an immune drug in Russia. ### Is Thymogen FDA-approved? No. ### How is Thymogen related to Thymalin? It was identified as an active component of the Thymalin thymus extract and then made synthetically. ## Sources - [Molecules, 2021: history of Thymalin (1982) and Thymogen (1990) registration](https://mdpi.com/1420-3049/26/21/6550) - [Review of peptide drugs registered in the Russian Federation](https://pmc.ncbi.nlm.nih.gov/articles/PMC9030433) - [Paper (St. Petersburg), 2024: Khavinson's drugs and their critics in evidence-based medicine](https://papernews.online/en/he-promised-to-extend-the-lives/) - [Khavinson, Kuznik and Ryzhak, 2014: the developers' own review of clinical use](https://khavinson.info/assets/files/2014-Khavinson_Kuznik.pdf) - [The Peptide Column: bioregulator research summary and legal status](https://the-peptide-column.pages.dev/bioregulators) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Thymosin alpha-1 Source: https://aminodesk.com/library/thymosin-alpha-1 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Thymosin alpha-1 is an immune-signaling peptide originally found in the thymus. It is sold as a prescription drug, Zadaxin (thymalfasin), in many countries for chronic hepatitis B. It is not FDA-approved, and an FDA advisory committee voted against allowing it to be compounded. - **Legal lane:** approved outside the US; no lawful US route - **Evidence grade:** B - **Form:** injection under the skin - **Brand abroad:** Zadaxin ## What it is Thymosin alpha-1 is a 28-amino-acid peptide that influences how T cells mature and respond. The drug version is made synthetically and matches the natural sequence. It is unrelated to [TB-500](https://aminodesk.com/library/tb-500), which comes from a different thymus protein, thymosin beta-4. ## What the evidence shows Most of the human evidence is in chronic hepatitis B, including randomized trials in Asia and Europe, with mixed results across studies. Clinics in the US promote it for general immune support and recovery, which are not the uses it was tested and approved for. FDA reviewers evaluated it for hepatitis B, hepatitis C, HIV and other uses in 2024. At the December 2024 advisory committee meeting, members voted 17 to 4 against adding it to the list of substances pharmacies may compound, citing a lack of compelling evidence of effectiveness and safety. ## Dosing where it is approved The approved hepatitis B regimen abroad is 1.6 mg injected under the skin twice a week, for about six months, under a doctor's care. That is a dose for a specific liver infection. No dose is established for immune support in healthy people. ## Legal status There is no FDA-approved product, the advisory committee recommended against compounding it, and it is not one of the six peptides covered by the October 2026 HHS policy. Products sold in the US are research chemicals. ## Safety - It was generally well tolerated in the hepatitis trials. - Because it is meant to stimulate the immune system, people with autoimmune disease or an organ transplant have particular reason not to use it without a doctor. ## Common questions ### Is thymosin alpha-1 FDA-approved? No. It is sold abroad as Zadaxin for chronic hepatitis B. In December 2024 an FDA advisory committee voted 17 to 4 against allowing pharmacies to compound it. ### Is thymosin alpha-1 the same as TB-500? No. They are unrelated. TB-500 comes from a different thymus protein, thymosin beta-4. ### What is the usual thymosin alpha-1 dose? The approved hepatitis B regimen abroad is 1.6 mg under the skin twice a week for about six months, under a doctor's care. No dose is established for immune support in healthy people. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA briefing document: evaluation of thymosin alpha-1, December 2024 (PDF)](https://www.fda.gov/media/183820/download) - [FDA: minutes of the December 4, 2024 Pharmacy Compounding Advisory Committee, with votes (PDF)](https://fda.gov/media/185642/download) - [Iino et al. 2005: thymosin alpha-1 in Japanese patients with chronic hepatitis B (PubMed)](https://pubmed.ncbi.nlm.nih.gov/15914092/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Thymulin Source: https://aminodesk.com/library/thymulin Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Thymulin is a hormone of nine amino acids made by the thymus. It is active only when a zinc atom is attached. It is sold as an immune and anti-aging peptide. The solid human research is about zinc, not about injecting thymulin. - **Legal lane:** not FDA-approved. Sold as a research chemical. - **Evidence grade:** D for the injected peptide - **Form:** injection - **Formerly called:** serum thymic factor ## What it is A peptide produced by the lining cells of the thymus that helps T cells mature. It binds zinc one to one, and without zinc it is inactive. It is a different thing from the Russian thymus products Thymalin and Thymogen, and from thymosin alpha-1. ## What the evidence shows In human studies, people with mild zinc deficiency had low thymulin activity in the blood, and zinc supplements corrected it. That is a finding about nutrition and the body's own hormone. The same 1988 paper mentions earlier reports of thymulin being used in some immune deficiency diseases. We found no modern controlled trial of injected thymulin for immunity, aging or anything else in the sources we reviewed. ## Legal status - Not FDA-approved for any use. - Not one of the six peptides in the October 2026 compounding policy. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established in a controlled human trial. ## Safety - Because the hormone depends on zinc, low zinc is the first thing to rule out, and that is a blood test and a conversation with a clinician, not an injection. - No safety data exists for the injected product as sold. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### What is thymulin? A nine-amino-acid hormone made by the thymus that requires zinc to be active. ### Does zinc affect thymulin? Yes. In human studies, mild zinc deficiency lowered thymulin activity and zinc supplements restored it. ### Is thymulin the same as Thymalin? No. Thymalin is a calf-thymus extract from Russia. Thymulin is a single defined hormone. ## Sources - [Prasad et al., 1988: serum thymulin in human zinc deficiency (PubMed)](https://pubmed.ncbi.nlm.nih.gov/3262625/) - [Dardenne and Pleau, 1994: interactions between zinc and thymulin (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2364880) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Tirzepatide (Zepbound, Mounjaro) Source: https://aminodesk.com/library/tirzepatide Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Tirzepatide is the medication behind Zepbound and Mounjaro. It is FDA-approved, given as a weekly injection, and produced some of the largest average weight loss seen in trials. - **Legal lane:** FDA-approved, prescription only - **Evidence grade:** A - **Form:** weekly injection under the skin - **Brands:** Zepbound (weight, sleep apnea), Mounjaro (type 2 diabetes) - **Self-pay cost:** from $299 a month ## What it is Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1. Like semaglutide, it reduces appetite and slows stomach emptying. ## What the evidence shows In its main weight-loss trial, adults on the highest dose, 15 mg a week, lost an average of 20.9% of their body weight over 72 weeks. Results vary, and weight tends to return when treatment stops. ## Dosing on the FDA label This schedule comes from the Zepbound prescribing information. | Stage | Dose, once a week | Notes | | --- | --- | --- | | Weeks 1 to 4 | 2.5 mg | For starting treatment only. Not approved as a maintenance dose. | | From week 5 | 5 mg | First maintenance-level dose. | | Further steps | 7.5 mg, 10 mg, 12.5 mg, 15 mg | Increases of 2.5 mg, each after at least four weeks on the current dose. | | Maintenance | 5 mg, 10 mg or 15 mg | For sleep apnea: 10 mg or 15 mg. Maximum is 15 mg. | The prescriber chooses the maintenance dose based on response and how well each step is tolerated. If a dose is missed, the label says to take it as soon as possible within four days. ## Side effects and warnings - The most common side effects are in the gut, including nausea, diarrhea, vomiting and constipation. - The label carries a boxed warning about thyroid C-cell tumors, seen in rat studies. It should not be used by people with a personal or family history of medullary thyroid cancer or MEN 2. - The full label lists other serious risks. Read the Medication Guide and raise your history with the prescriber. ## What it costs without insurance | Zepbound dose | Manufacturer self-pay price, per month | | --- | --- | | 2.5 mg | $299 | | 5 mg | $399 | | 7.5 mg to 15 mg | $449 | Prices were checked in October 2026 and change often. They apply to vials and pens bought through the manufacturer's self-pay program. ## Compounded tirzepatide Compounded tirzepatide is made to order by a compounding pharmacy on a prescription, and it is what most lower-priced telehealth programs supply. It is not Zepbound or Mounjaro, and it is not FDA-approved. Since the shortage ended in December 2024, a pharmacy can compound it only when a prescriber decides an individual patient needs it, which is why a licensed provider reviews your case first. The FDA had received more than 730 adverse event reports linked to compounded tirzepatide as of May 31, 2026, so where it comes from matters. Use a provider that requires a prescription, and ask which pharmacy makes it. ## Common questions ### Is tirzepatide FDA-approved? Yes. It is approved as Zepbound for weight and sleep apnea, and as Mounjaro for type 2 diabetes. Both are prescription only. ### How much weight do people lose on tirzepatide? In its main weight-loss trial, adults on the highest dose, 15 mg a week, lost an average of 20.9% of their body weight over 72 weeks. Results vary, and weight tends to return when treatment stops. ### What is the starting dose of Zepbound? The Zepbound label starts at 2.5 mg once a week for weeks 1 to 4, then moves to 5 mg. Further increases are 2.5 mg at a time, each after at least four weeks, up to a maximum of 15 mg. ### Is compounded tirzepatide legal? Yes, in limited cases. Since the shortage ended in December 2024, a pharmacy can compound it only when a prescriber decides an individual patient needs it. Compounded tirzepatide is not FDA-approved. Added in the latest update. These answers summarize the sections above; sources are listed below. ## Sources - [FDA: Concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) - [Jastreboff et al., 2022: SURMOUNT-1 trial of tirzepatide, New England Journal of Medicine (PubMed)](https://pubmed.ncbi.nlm.nih.gov/35658024/) - [Zepbound prescribing information (Eli Lilly)](https://pi.lilly.com/us/zepbound-uspi.pdf) - [Zepbound label, DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) - [GoodRx: Zepbound dosage and self-pay prices](https://goodrx.com/zepbound/dosage) - [Compounded GLP-1 rules and adverse event counts](https://glp1numbers.com/guides/compounded-glp1-crackdown) Choosing between the two approved options? See [semaglutide vs tirzepatide](https://aminodesk.com/compare/semaglutide-vs-tirzepatide). Losing weight on a GLP-1? See [protein and muscle on GLP-1 medications](https://aminodesk.com/guides/protein-on-glp-1). Taking a prescribed GLP-1? Keep a private record of shots, weight and protein with the [GLP-1 log](https://aminodesk.com/glp1-log). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Tirzepatide + BPC-157 blend Source: https://aminodesk.com/library/tirzepatide-bpc-157 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending This blend combines tirzepatide and BPC-157 in one product. It is sold for weight loss with fewer stomach side effects. The claim that BPC-157 eases tirzepatide's stomach side effects has not been tested, and no approved product combines them. - **Legal lane:** not an approved product. Tirzepatide alone is FDA-approved; the mixture is not. - **Evidence grade:** D for the combination - **What is in it:** tirzepatide and BPC-157 - **Established human dose:** none ## What it is A premixed product sold by peptide suppliers and some clinics. The ingredients: - **[tirzepatide](https://aminodesk.com/library/tirzepatide):** an FDA-approved drug, sold as Mounjaro and Zepbound. - **[BPC-157](https://aminodesk.com/library/bpc-157):** one of the six peptides in the October 2026 policy; almost all of its evidence is from animals. ## What the evidence shows We found no trial of this combination. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown. Tirzepatide's results come from large trials of tirzepatide alone, at set doses with a slow step-up. Nobody has tested whether adding BPC-157 reduces nausea, and nobody has checked whether mixing the two in one vial affects either one. ## Legal status In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it. BPC-157 is on the list, but only as a single-ingredient product. Tirzepatide is an approved brand-name drug. A vial that mixes them is neither the approved drug nor a product the policy covers. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown. ## Safety - If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it. - The ratio is fixed by the seller. You cannot adjust one ingredient without moving the other. - No safety or absorption work exists on the mixture. - With a mixed vial, raising or lowering the tirzepatide dose changes the BPC-157 dose with it. - The approved pens have verified contents and a label. A mixed vial has neither. - Side effects on tirzepatide are best handled with the prescriber, usually by slowing the step-up. ## Common questions ### What is in this blend? Tirzepatide and BPC-157. ### Has this blend been tested in people? We found no human trial of the combination. ### Is this blend legal? No approved product combines them. Tirzepatide is available by prescription on its own. ## Sources - [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Vesugen Source: https://aminodesk.com/library/vesugen Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Vesugen is one of the Russian short peptides sold as bioregulators. It is marketed for blood vessel support. The evidence comes almost entirely from the group that developed it, and no independent trial has tested it in people. - **Legal lane:** not FDA-approved. Not eligible for pharmacy compounding. Sold as a research chemical. - **Evidence grade:** D - **What it is:** a short synthetic peptide - **Established human dose:** none ## What it is Vesugen is a short synthetic peptide. It belongs to a family of peptides, two to four amino acids long, developed in St. Petersburg by Vladimir Khavinson's group. The idea behind them is that each organ makes its own short regulatory peptides, and that supplying them restores that organ. The group developed each target in two forms, a tissue extract and a short synthetic peptide. The synthetic ones are what research suppliers sell. ## What the evidence shows Vesugen has been tested on human cells taken from the mouth, in a study of cell aging and bone formation presented by the developers' network. That is cell work, not a clinical result. We found no controlled human trial of Vesugen in the sources we reviewed. For the family as a whole, the record is cell experiments, rodent studies, and small, often unblinded human studies run by the original group. Key findings have not been reproduced by independent teams. The most-cited human study, a 266-person cohort followed for six to eight years, tested thymus and pineal extracts, not this peptide, and was not blinded. ## Legal status - Not FDA-approved for any use. - Not eligible for pharmacy compounding, according to the research summary we read. - Not one of the six peptides in the October 2026 policy. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established in a controlled human trial. The course schedules that circulate come from the developers' own tradition and from sellers. ## Safety - No independent human safety data exists. - A peptide this small is often assumed to be harmless. That assumption has not been tested. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### What is Vesugen? A Russian short peptide, one of the Khavinson bioregulators, sold for blood vessel support. ### Is Vesugen FDA-approved? No. It is not approved and is not eligible for pharmacy compounding. ### Has Vesugen been tested in people? We found no controlled human trial. The evidence is cell and animal work from the group that developed it. ## Sources - [2019 conference abstract: Cartalax, Vesugen, Vilon and Epitalon on human oral-derived cells](https://khavinson.info/assets/files/pdf/2019-32_33.pdf) - [Overview of the Khavinson short peptides and the tiers of evidence behind them](https://ipsnews.net/business/?p=248484) - [The Peptide Column: bioregulator research summary and legal status](https://the-peptide-column.pages.dev/bioregulators) - [Khavinson and Morozov, 2003: the 266-person elderly cohort (PubMed)](https://pubmed.ncbi.nlm.nih.gov/14523363/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Vilon (Lys-Glu) Source: https://aminodesk.com/library/vilon Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Vilon is one of the Russian short peptides sold as bioregulators. It is marketed for immune support and anti-aging. The evidence comes almost entirely from the group that developed it, and no independent trial has tested it in people. - **Legal lane:** not FDA-approved. Not eligible for pharmacy compounding. Sold as a research chemical. - **Evidence grade:** D - **What it is:** the dipeptide Lys-Glu - **Established human dose:** none ## What it is Vilon is a peptide of two amino acids, lysine and glutamic acid. It was identified from the thymus extract Thymalin. It belongs to a family of peptides, two to four amino acids long, developed in St. Petersburg by Vladimir Khavinson's group. The idea behind them is that each organ makes its own short regulatory peptides, and that supplying them restores that organ. The group developed each target in two forms, a tissue extract and a short synthetic peptide. The synthetic ones are what research suppliers sell. ## What the evidence shows The developers reported that Vilon slowed tumor growth and extended lifespan in mice, and their reviews describe use in older patients. One independent assessment calls it the weakest-evidenced peptide in the family, because no outside laboratory has reproduced any of the findings. For the family as a whole, the record is cell experiments, rodent studies, and small, often unblinded human studies run by the original group. Key findings have not been reproduced by independent teams. The most-cited human study, a 266-person cohort followed for six to eight years, tested thymus and pineal extracts, not this peptide, and was not blinded. ## Legal status - Not FDA-approved for any use. - Not eligible for pharmacy compounding, according to the research summary we read. - Not one of the six peptides in the October 2026 policy. - What is sold online is a research chemical. ## Reported dosing **We do not publish a protocol for this compound.** No dose has been established in a controlled human trial. The course schedules that circulate come from the developers' own tradition and from sellers. ## Safety - No independent human safety data exists. - A peptide this small is often assumed to be harmless. That assumption has not been tested. - Products sold as research chemicals have no verified contents or sterility. ## Common questions ### What is Vilon? A Russian short peptide, one of the Khavinson bioregulators, sold for immune support and anti-aging. ### Is Vilon FDA-approved? No. It is not approved and is not eligible for pharmacy compounding. ### Has Vilon been tested in people? The developers describe clinical use in older patients. No independent or registered trial has tested it. ## Sources - [2002 cell study of Vilon, Epithalon and Cortagen in mouse spleen cells (PubMed)](https://pubmed.ncbi.nlm.nih.gov/12447482/) - [Outliyr: independent assessment of the Vilon evidence](https://outliyr.com/reports/vilon) - [Khavinson, Kuznik and Ryzhak, 2014: the developers' own review of clinical use](https://khavinson.info/assets/files/2014-Khavinson_Kuznik.pdf) - [Overview of the Khavinson short peptides and the tiers of evidence behind them](https://ipsnews.net/business/?p=248484) - [The Peptide Column: bioregulator research summary and legal status](https://the-peptide-column.pages.dev/bioregulators) - [Khavinson and Morozov, 2003: the 266-person elderly cohort (PubMed)](https://pubmed.ncbi.nlm.nih.gov/14523363/) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # VIP (vasoactive intestinal peptide, aviptadil) Source: https://aminodesk.com/library/vip Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending VIP is a signaling peptide the body makes in the gut, lungs and nerves. Its synthetic form is called aviptadil. Clinics prescribe it as a compounded nasal spray, mostly in protocols for mold-related illness. The best trials tested a different thing, an intravenous drip for severe COVID-19, and they did not show a benefit. - **Legal lane:** not FDA-approved. Pharmacies may compound it on prescription while the FDA reviews it. - **Evidence grade:** C for the nasal spray. One small series without a comparison group. - **Form:** compounded nasal spray - **Also called:** aviptadil, RLF-100, Zyesami ## What it is Vasoactive intestinal peptide is a chain of 28 amino acids. It was first isolated from the intestine and is found throughout the nervous system, lungs, gut and immune tissue. It relaxes blood vessels and airways and dampens some immune signals. It lasts only a very short time in the body, so how it is delivered matters a great deal. ## What the evidence shows - **Intravenous, severe COVID-19:** in a company-run trial of 196 patients, the main result did not reach statistical significance. In a larger government-backed trial, deaths at 90 days were 38% with aviptadil and 36% with placebo, and the trial was stopped early because it could not succeed. - **Nasal spray:** the main published support is a report on 20 patients with a diagnosis of chronic inflammatory response syndrome who used the spray and were followed over time. There was no placebo group. The diagnosis the spray is mostly prescribed for is itself contested. A medical training organization that reviewed VIP describes it as a peptide with real biology and a poor trial record, used without controlled evidence. ## Legal status - Not FDA-approved for any use. The FDA declined an emergency authorization request during the pandemic. - It sits in Category 1 of the FDA's list of substances nominated for compounding, which means it is under evaluation and pharmacies may compound it on prescription in the meantime. - That status can change when the FDA finishes its review. ## Reported dosing **No dose has been established in a controlled trial.** The 20-patient series used 50 micrograms as a nasal spray four times a day. That is what one uncontrolled report did, under a physician. It is not a tested dose. ## Safety - VIP widens blood vessels and increases secretion in the gut, so low blood pressure and diarrhea are the expected side effects, along with nasal irritation from a spray. - Long-term safety of the nasal spray has not been studied in a controlled trial. - A compounded spray has no FDA label. Quality depends on the pharmacy. ## Common questions ### Is VIP FDA-approved? No. It can be compounded on prescription while the FDA evaluates it. ### Did aviptadil work for COVID-19? No. The large trial was stopped early, with 90-day deaths of 38% on aviptadil and 36% on placebo. ### What is VIP nasal spray used for? Mostly protocols for chronic inflammatory response syndrome, a contested diagnosis linked to water-damaged buildings. The support is one small uncontrolled series. ## Sources - [Randomized trial of intravenous aviptadil in critical COVID-19 (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9555831) - [Superpower: the futility result and approval status](https://superpower.com/guides/peptides/aviptadil) - [FDA: bulk drug substances nominated for compounding under section 503A, by category](https://www.fda.gov/media/94155/download) - [Peptide Benchmark: Category 1 status and the 20-patient nasal spray series](https://peptidebenchmark.pages.dev/blog/vip-peptide-fda-category-1-pcac-history-cirs) - [Empire Medical Training: trial record, half-life and off-label use](https://www.empiremedicaltraining.com/antiaging-regenerative-workshops/resources/peptide-therapy/vip/) - [BioSpace: the 196-patient trial and the declined emergency authorization](https://www.biospace.com/neurorx-reports-positive-phase-iib-iii-rrlf-100-data-for-critically-ill-covid-19-patients) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Vitamin B12 injections (cyanocobalamin) Source: https://aminodesk.com/library/vitamin-b12 Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending Vitamin B12 injections are an FDA-approved treatment for people who are deficient because they cannot absorb the vitamin. B12 is not a peptide. Clinics sell the same injection as an energy and weight-loss shot, and the label lists no such use. - **Legal lane:** FDA-approved, prescription only - **Evidence grade:** A for treating deficiency - **Form:** injection into muscle or under the skin - **Also sold as:** an add-on in "lipo" and weight-loss shots ## What it is Cyanocobalamin is the most widely used form of vitamin B12. The body needs B12 to make blood cells and to maintain nerves. Some people cannot absorb it from food, most often because of pernicious anemia or stomach or bowel disease or surgery. For them, the label says absorption by mouth is too unreliable, and injections are the treatment. ## What the evidence shows For deficiency the benefit is well established. Prompt injections correct the anemia and stop nerve damage from progressing. Untreated deficiency that lasts more than a few months can cause permanent damage to the spinal cord. Deficiency is normally confirmed by a blood test before injections start. The label describes no benefit for energy, metabolism or weight in people whose B12 is normal, and after an injection of 100 or 1,000 micrograms, 50% to 98% of the dose may appear in the urine within 48 hours. ## Legal status - FDA-approved for B12 deficiency caused by poor absorption, including pernicious anemia, bowel disease or surgery, and certain other conditions. - Prescription only as an injection. B12 by mouth is sold as a supplement. - It is not a controlled substance. ## Label dosing For pernicious anemia the label starts at 100 micrograms a day for six or seven days by injection, reduces the frequency in steps as the blood count recovers, and ends at 100 micrograms once a month for life. The label says to avoid giving it into a vein, because almost all of it is then lost in the urine. Vials are commonly 1,000 micrograms per mL. The schedules clinics use for wellness shots are not from the label. ## Safety - Generally well tolerated. The label lists rare serious reactions, including allergic reactions and fluid in the lungs. - Folic acid can hide a B12 deficiency in blood tests while nerve damage continues, so the cause of an anemia should be established first. - Multi-ingredient "lipo" shots that include B12 are compounded products with their own ingredients and no label of their own. ## Common questions ### Is vitamin B12 a peptide? No. It is a vitamin. Peptide and weight-loss clinics sell it as an injection. ### What are B12 injections approved for? Vitamin B12 deficiency caused by poor absorption, including pernicious anemia. ### Do B12 shots help with energy or weight loss? The label describes no such benefit for people whose B12 level is normal. Much of an injected dose leaves in the urine within two days. ### What is the label dose? For pernicious anemia, 100 micrograms a day for six or seven days, stepping down to 100 micrograms a month for life. ## Sources - [Cyanocobalamin injection prescribing information](https://www.drugs.com/pro/cyanocobalamin.html) - [DrugCentral: cyanocobalamin label, absorption, excretion and dosing](https://drugcentral.org/label/07575b34-4ec4-4467-88c8-5dab9dbfc03e/view) - [PrescriberPoint: cyanocobalamin indications and administration](https://prescriberpoint.com/therapies/cyanocobalamin-db84d0e) - [Drugs.com: who needs B12 injections and how deficiency is confirmed](https://www.drugs.com/vitamin-b12.html) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Wolverine blend (BPC-157 + TB-500) Source: https://aminodesk.com/library/wolverine-blend Publisher: Amino Desk Updated: 2026-11-17 Clinical review: pending "Wolverine" is a seller's name for BPC-157 and TB-500 mixed in one vial. Each ingredient can now be compounded on its own under the 2026 federal policy. The mixed vial cannot, and nobody has tested the combination in people. - **Legal lane:** outside the October 2026 policy, which allows one active ingredient per product. Not FDA-approved. - **Evidence grade:** D for the combination - **What is in it:** BPC-157 and TB-500, commonly 10 mg of each - **Established human dose:** none ## What it is A premixed vial of two repair peptides, [BPC-157](https://aminodesk.com/library/bpc-157) and [TB-500](https://aminodesk.com/library/tb-500), also sold as "BPC/TB". It is marketed for injury recovery, tendons and ligaments. The name is taken from the Marvel character. It is a marketing term and does not describe a tested product. ## What the evidence shows There is no trial of this blend. Not a small one, and not a negative one. The evidence that exists applies to each ingredient studied separately, and for both it is almost entirely animal work with no completed controlled human trials. The case for mixing them is that each is said to handle a different stage of repair. That is a hypothesis. Nobody has measured whether the pair works better than either alone. The concern reached the FDA's advisory committee in July 2026. One member who voted against adding TB-500 to the compounding list cited the lack of basic data and the fact that it is being used in combination with other drugs. ## Legal status In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it. - A vial of BPC-157 alone, from a licensed pharmacy, on a patient-specific prescription: within the policy. - A vial of BPC-157 and TB-500 together: outside it. - A clinician prescribing both separately, to be injected separately: back within it. The practical consequence is supply. A seller offering this blend is either working outside the policy or is not a licensed compounding pharmacy at all. ## Reported dosing **No dose has been established for this blend.** No human trial has tested it, so there is no label, no study and no documented prescriber consensus to report. The mixing tables and week-by-week schedules published by sellers are their own arithmetic applied to a product nobody has studied. Where we can report dosing for the individual ingredients, it is on each compound's own page, with the source shown. ## Safety - **You cannot tell what worked.** If you improve, you have learned nothing about which ingredient to keep. - **You cannot tell what went wrong.** A reaction means stopping everything, with no way to find the cause except starting over one at a time. - **The mixture itself is unstudied.** Reviews of compounded multi-peptide preparations note that no safety or absorption work exists on the combinations. - **Quality is a separate risk.** A pharmacy following the policy closely will not make a blend, so the product comes from outside that system. ## Common questions ### Is the Wolverine blend legal? Not as a mixed vial. The October 2026 policy allows pharmacies to compound BPC-157 and TB-500 one at a time on prescription. A vial holding both falls outside it. ### Has the Wolverine blend been tested in people? No. There is no human trial of the combination, and the two ingredients have no completed controlled human trials of their own. ### What dose of the Wolverine blend is used? No dose has been established. Seller schedules are not based on any study of the blend. ## Sources - [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/) - [Buchanan Ingersoll & Rooney: single-active-ingredient formulations under the policy](https://www.bipc.com/compounding-peptides-what-compounding-pharmacies-need-to-know-about-the-hhs-interim-enforcement-discretion-policy-for-six-peptides) - [Nutritional Outlook: legal analysis that a BPC-157 and TB-500 blend falls outside the policy](https://www.nutritionaloutlook.com/view/hhs-peptide-compounding-policy-supplement-industry-implications) - [Healio: advisory committee discussion, including the combination-use concern raised on TB-500](https://www.healio.com/news/primary-care/20260724/fda-committee-recommends-looser-restrictions-for-several-peptides) - [Healthy Male: the Wolverine stack as a marketing term](https://healthymale.org.au/health-article/what-you-need-to-know-about-the-wolverine-stack) All three repair blends are compared on [blends and stacks](https://aminodesk.com/stacks). To keep a private record of what you take, use the [dose and progress log](https://aminodesk.com/glp1-log). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # How to vet a provider Source: https://aminodesk.com/providers Publisher: Amino Desk Updated: 2026-11-17 Clinical review: completed 2026-11-14 Dozens of companies will sell you a GLP-1 or a peptide online. Some are run by licensed clinicians working with named pharmacies. Others are storefronts. The difference is checkable in about ten minutes, and this page is how. ## The five checks Run all five. A provider that passes four and fails one is still a provider that fails. | Check | What good looks like | How to verify | | --- | --- | --- | | **1. A real clinical evaluation** | A licensed clinician reviews your history and can decline to prescribe. You can reach them with a question afterward. | Look for a named clinician and a path to follow-up. A questionnaire where every answer leads to the same prescription is not an evaluation. | | **2. A named, licensed pharmacy** | The provider tells you which 503A or 503B pharmacy makes the medication, by name, before you pay. | Ask directly. Check the pharmacy's license with that state's board of pharmacy. Evasion is the answer. | | **3. Licensed in your state** | The prescribing clinician holds a license where you live. | Your state medical board's license lookup, which is free and public. | | **4. LegitScript certification** | Active certification, verifiable on LegitScript's own site rather than a badge on the seller's page. | Search the provider at legitscript.com. A badge image proves nothing; the entry in their database does. | | **5. No open FDA warning letter** | Nothing outstanding against the company or its compounding pharmacy. | Search the FDA's warning letter database by company name. | Two more worth doing if the provider dispenses compounded medication: NABP digital pharmacy accreditation, searchable at nabp.pharmacy, and whether the company will send you a certificate of analysis for the batch. ## Why the FDA checks matter right now This is not a hypothetical concern. The agency has run a sustained enforcement campaign against this market: - More than 100 letters went to telehealth and compounding providers over false or misleading GLP-1 claims during 2025. - 30 telehealth companies received warning letters on 20 February 2026. - 25 more followed on 16 June 2026. The violations named in the June letters are worth knowing, because they describe exactly what to watch for. Companies claimed their compounded products had been FDA-approved or evaluated for safety and effectiveness when they had not. Companies described the pharmacy they source from as "FDA-approved" or "FDA-licensed," which is not something the agency grants to compounders. And in some cases the product label pictured on the site implied the company compounded the drug itself when it did not. If you see any of those three claims on a provider's website, you have learned something useful about that provider. ## Red flags - "Same as brand name" or "FDA-approved pharmacy." Neither phrase can be true of a compounded product. - No pharmacy named anywhere on the site. - No way to speak to a clinician after you have paid. - A price that only appears after you have completed an intake quiz. - A large annual prepayment required to get the advertised rate. - Pressure to increase your dose faster than the approved label's schedule. - Selling peptides that have no legal route at all. If a site offers BPC-157 injections alongside things with no lawful pathway, its compliance standards are telling you something. ## Questions to ask before you pay 1. Which pharmacy compounds this, and in what state? 2. Is this the base form or a salt form, and which one? 3. What will I pay per month at a maintenance dose, six months from now? 4. What happens if I have a side effect at 9pm on a Saturday? 5. Can I cancel monthly, and what happens to a prepaid balance? 6. Will you send me the certificate of analysis for my batch? **On this page and money.** Amino Desk earns commissions from two telehealth companies, HealthRX and Strut Health. Any page with a paid link says so at the top. The checks above stay exactly as they are written here, and we apply them to our own partners in public on the [affiliate disclosure page](https://aminodesk.com/affiliate-disclosure), including where a partner falls short. ## Sources - [FDA: Concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) - [FDA: Alert on dosing errors with compounded injectable semaglutide](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded) - [HHS: 503A peptide enforcement discretion policy (PDF)](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [McDermott Will & Emery: FDA's June 2026 warning letters and the violations cited](https://www.mcdermottlaw.com/?p=50368640) - [Bloomberg Law: FDA warns companies over misleading claims, June 2026](https://news.bloomberglaw.com/health-law-and-business/fda-warns-companies-over-misleading-claims-of-glp-1-copycats) - [Telehealth.org: the February 2026 letters and the 2025 wave](https://telehealth.org/news/fda-warns-telehealth-companies-over-marketing-of-compounded-glp-1-weight-loss-drugs/) - [Klarity: verification checklist for GLP-1 telehealth](https://www.helloklarity.com/post/how-to-verify-a-glp-1-telehealth-provider-is-legitimate-a-safety-checklist-for-2026/) - [RAPS: FDA citations of telehealth firms, June 2026](https://www.raps.org/resource/fda-cites-companies-for-cgmp-violations-telehealth-firms-for-illegally-marketing-glp-1-drugs.html) --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL. ===== # Blends and stacks Source: https://aminodesk.com/stacks Publisher: Amino Desk Updated: 2026-11-15 Clinical review: completed 2026-11-14 Two kinds of stack dominate the market. Repair blends sold in one vial under names like Wolverine, Glow and KLOW. And weight-loss stacks built around a GLP-1 with other compounds layered on to protect muscle. Both have the same problem: nobody has tested the combination. **The thing most sellers leave out.** The HHS enforcement policy requires that a compounded product contain only a single active ingredient from its list. A vial holding BPC-157 and TB-500 together has two. Lawyers reading the policy have concluded that combination products fall outside it, which leaves common mixed formulations exposed to regulatory action even though each ingredient on its own is now permitted. ## Repair blends: what is in each one | Name | Contents | Sold for | | --- | --- | --- | | **Wolverine** also BPC/TB | [BPC-157](https://aminodesk.com/library/bpc-157) + [TB-500](https://aminodesk.com/library/tb-500), commonly 10 mg of each | Injury recovery, tendons and ligaments | | **Glow** | [GHK-Cu](https://aminodesk.com/library/ghk-cu) + BPC-157 + TB-500 | Skin, hair and recovery together | | **KLOW** | GHK-Cu + BPC-157 + TB-500 + [KPV](https://aminodesk.com/library/kpv) | The Glow formula with an anti-inflammatory fourth peptide | The most common KLOW presentation is an 80 mg vial in a fixed 50/10/10/10 split: 50 mg GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV. Some compounders add larazotide, a fifth peptide studied in intestinal permeability. Because the ratio is fixed in the vial, you cannot adjust one component without moving all four. "Wolverine" is a marketing name taken from the Marvel character, not a scientific one. None of these three names describes a tested product. ## The legal problem, in detail In October 2026, HHS issued an interim enforcement policy allowing licensed pharmacies to compound six peptides: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. Three of those appear in the blends above, which is why 2026 looked like the year blends became legitimate. The policy sets conditions, and one of them is that the compounded product contains only a single active pharmaceutical ingredient from the list. Law firms analyzing the policy have been direct about what that means: the conditions exclude multiple-API compounded products, which puts common mixed formulations outside the scope of the enforcement discretion and potentially subject to regulatory oversight. So the position as it stands: - A vial of BPC-157 alone, from a licensed pharmacy, under a patient-specific prescription: within the policy. - A vial of BPC-157 and TB-500 together: outside it. - A clinician prescribing both separately, to be injected separately: back within it. The practical consequence for you is supply. A pharmacy following the policy closely will not make a blend, so a seller offering one is either working outside the policy or is not a 503A pharmacy at all. ## What the evidence says about combining them There is no trial of any of these blends. Not a small one, not a negative one. The evidence that exists applies to each ingredient studied separately, and for BPC-157 and TB-500 that evidence is almost entirely animal work with no completed controlled human trials. The argument for blending is mechanistic: each peptide is said to handle a different stage of repair, so running them together should cover more of the process. That is a reasonable hypothesis. It is not a result. "Synergy" in blend marketing means the seller expects the combination to work better, not that anyone measured whether it does. This concern reached the FDA's own advisory committee. One member who voted against adding TB-500 to the compounding list cited the lack of fundamental data, and added a specific concern that the drug is being used in combination with other drugs. ## What a blend costs you beyond the price - **You cannot tell what worked.** If you improve on a four-peptide blend, you have learned nothing about which peptide to keep. - **You cannot tell what went wrong.** A reaction on a blend means stopping everything, and no way to identify the cause without starting over one at a time. - **The ratio is someone else's choice.** KLOW is 62.5% GHK-Cu by weight. If the component you actually want is BPC-157, you are buying mostly something else. - **Copper accumulates.** Anything GHK-Cu-based delivers copper with every dose. Long courses are a reason to pay attention to copper and zinc balance, which is a conversation for a clinician rather than a forum. - **No safety characterization exists for the mixture.** Reviews of compounded multi-peptide preparations note the absence of any safety or pharmacokinetic work on the combinations themselves. ## Dosing **No dose has been established for any of these blends.** No human trial has tested one, so there is no label, no study and no documented prescriber consensus to report. The reconstitution tables and week-by-week ladders published by vendors are their own arithmetic applied to a product nobody has studied. Where we can report dosing for the individual ingredients, it is on each compound's own page, with the source shown. ## If you are considering one anyway 1. Ask the seller which pharmacy compounded it and whether that pharmacy is operating under the HHS policy. A blend cannot be, and a straight answer tells you what you are dealing with. 2. Ask for the certificate of analysis showing each component's identity and purity separately, not a single figure for the vial. 3. Consider running one compound at a time instead. It is slower and it is the only way to learn anything about how you respond. 4. If a clinician is prescribing, ask why a blend rather than separate vials, and whether the ratio can be adjusted for you. If it cannot, you are buying a product, not a prescription tailored to you. ## Weight-loss stacks The most promoted version right now is **retatrutide plus tesamorelin plus MOTS-c**, often with NAD+, L-carnitine or 5-amino-1MQ added. Unlike the repair blends, these are separate vials injected on separate schedules rather than one mixed product, so the single-ingredient compounding rule above does not apply in the same way. The legal problems are different and, for this particular stack, larger. ### The problem it claims to solve is real This is the part worth taking seriously. Weight lost on a GLP-1 is not all fat. Reviews put lean body mass at roughly 25% to 40% of total weight lost, and that matters most for older people and anyone already low on muscle, because it accelerates sarcopenia. Two analyses presented at the European Congress on Obesity in 2026 sharpened the picture: muscle loss is small relative to fat loss, but larger than the muscle loss seen with diet and exercise alone at the same amount of weight lost. So the concern is legitimate, and it is not a reason to avoid GLP-1s. ### What actually addresses it The evidence-based answer is unglamorous. Reviews converge on resistance training as the single most effective way to limit lean mass loss, combined with protein intake higher than most people on a GLP-1 are managing. Two resistance sessions a week is the floor where retention improves meaningfully. A clinician quoted on this in 2026 put the limit of the peptide approach plainly: if a patient is undereating because of the GLP-1, the body may still prioritise survival over muscle, even with growth hormone elevated. You cannot inject your way out of insufficient protein and no training. ### What the stack's evidence actually is **No clinical trial has examined muscle preservation strategies during GLP-1 therapy.** Not for this stack, not for any other. That gap sits directly underneath the most-promoted protocols in the market. Taking the three compounds one at a time: - **Retatrutide** has strong Phase 3 weight-loss results and is the reason people want the stack. It is also [investigational](https://aminodesk.com/library/retatrutide): the only lawful way to take it is in a clinical trial. Every protocol you will read online is built on a drug its authors cannot legally obtain. - **Tesamorelin** is [FDA-approved](https://aminodesk.com/library/tesamorelin), which makes it the most defensible component. Its approval is for reducing excess abdominal fat in people with HIV and lipodystrophy. Use for general body recomposition is off-label and was not what the trials tested. - **MOTS-c** is [newly compoundable](https://aminodesk.com/library/mots-c) under the 2026 policy. Its lean-mass claims come from animal work. Each has its own page here with its own grade. None of that is evidence for the three of them together. ### How to read these protocols The published versions of this stack share a few features worth noticing: - **They end in a link to a seller.** Several of the most detailed protocols we read close with a referral link to a research-chemical vendor. The protocol is the marketing. - **They present mechanism as outcome.** "Retatrutide mobilises fat, MOTS-c programs mitochondria, NAD+ completes combustion" is a story about biology, not a measurement of what happened to anyone. - **They stack up quickly.** The same sources go on to add SS-31, SLU-PP-332, BAM15, IGF-1 LR3, melanotan II and growth hormone. At that point nobody, including the author, can attribute any result to anything. - **They are confident about numbers no study produced.** Week-by-week titration ladders for a drug with no approved dose are invention, however precise they look. ### If muscle loss is your actual worry 1. Get a body composition measurement before you start, not just a scale weight. Without a baseline you cannot know what you lost. 2. Resistance train twice a week minimum. This is the intervention with evidence behind it. 3. Raise protein deliberately. Appetite suppression makes this harder exactly when it matters more. 4. Talk to the prescriber about dose and pace. Slower weight loss protects muscle better than any peptide added on top. 5. If you still want to add a compound, add one, and measure. Adding four at once guarantees you learn nothing. **No dose is published here for this stack either.** There is no trial of the combination, and retatrutide has no approved dose in any country. Our rule is the same for weight-loss stacks as for repair blends: figures come from a label, a published human study or documented prescriber practice, or they do not appear. ## Sources - [FDA: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (agenda and briefing documents)](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) - [FDA: Certain bulk drug substances for use in compounding that may present significant safety risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) - [HHS: 503A peptide enforcement discretion policy, including the single-API condition and Appendix A](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) - [McDermott Will & Emery: the conditions exclude multiple-API compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/) - [Buchanan Ingersoll & Rooney: single-active-ingredient formulations under the policy](https://www.bipc.com/compounding-peptides-what-compounding-pharmacies-need-to-know-about-the-hhs-interim-enforcement-discretion-policy-for-six-peptides) - [Nutritional Outlook: legal analysis that a BPC-157 and TB-500 blend falls outside the policy](https://www.nutritionaloutlook.com/view/hhs-peptide-compounding-policy-supplement-industry-implications) - [Healio: advisory committee discussion, including the combination-use concern raised on TB-500](https://www.healio.com/news/primary-care/20260724/fda-committee-recommends-looser-restrictions-for-several-peptides) - [Healthy Male: the Wolverine stack as a marketing term](https://healthymale.org.au/health-article/what-you-need-to-know-about-the-wolverine-stack) - [Quality in Sport, 2026: lean mass loss as 25 to 40% of weight lost on GLP-1s, and resistance training as the most effective response](https://apcz.umk.pl/QS/article/download/72375/46558/240437) - [Epocrates: two ECO 2026 analyses on GLP-1s and muscle](https://www.epocrates.com/online/article/glp-1s-spare-muscle-but-less-so-than-diet-exercise) - [MDLinx: clinicians on GLP-1 peptide stacks and the limits of the approach](https://www.mdlinx.com/article/glp-1-plus-peptide-stacks-the-muscle-loss-trap-doctors-need-to-flag/4aYGSPWOKEQByJm1CTB9KC) - [Pharmacy Times: muscle mass changes with incretin-based therapies](https://www.pharmacytimes.com/view/muscle-mass-changes-with-incretin-based-therapies-for-weight-loss) Each blend also has its own page: [Wolverine](https://aminodesk.com/library/wolverine-blend), [GLOW](https://aminodesk.com/library/glow-blend), [KLOW](https://aminodesk.com/library/klow-blend) and [CJC-1295 with ipamorelin](https://aminodesk.com/library/cjc-1295-ipamorelin). --- Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.